1
|
Hildenbrand T, Kuhn S, Everad F, Hassepaß F, Neudert M, Offergeld C. [Views of assistant professors on digital transformation in otorhinolaryngology education : Current status and perspectives in undergraduate and advanced training]. HNO 2024; 72:303-309. [PMID: 38587662 PMCID: PMC11045641 DOI: 10.1007/s00106-024-01468-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/12/2024] [Indexed: 04/09/2024]
Abstract
BACKGROUND Digital transformation in curricular teaching in medicine comprises the use of digital teaching and learning formats as well as the transfer of digital skills for medical staff. Concepts of knowledge transfer and competency profiles also have to be adapted and transferred in advanced training due to necessary changes. OBJECTIVE The aim of this study was an evaluation of the current state of digital transformation in otorhinolaryngology teaching in undergraduate and advanced training at otorhinolaryngology departments of university medical centers in Germany. MATERIALS AND METHODS A questionnaire with nine questions on digital transformation was sent to the assistant professors of 37 national university ENT departments. The anonymous survey was conducted online via the online platform SurveyMonkey®. RESULTS Of the contacted assistant professors, 86.5% participated in the survey. Teaching sessions on digital skills for medical students are part of the curriculum in only 25% of ENT departments. Digital teaching formats are used by half of the departments in undergraduate training. Only 56.25% of the assistant professors receive support to realize the changes required by digital transformation. In 40.62% of departments, the issue of digital transformation is broached during advanced training, but only 28.12% use digital teaching methods to train junior doctors. CONCLUSION Aspects of digital transformation are implemented mainly in undergraduate education, partly driven by the COVID 19 pandemic. Overall, there is still considerable backlog in undergraduate and advanced training in ENT.
Collapse
Affiliation(s)
- T Hildenbrand
- Klinik für Hals‑, Nasen- und Ohrenheilkunde, Universitätsklinikum Freiburg, Killianstr. 5, 79106, Freiburg, Deutschland.
| | - S Kuhn
- Institut für Digitale Medizin, Universitätsklinikum Gießen-Marburg & Philipps-Universität Marburg, Marburg, Deutschland
| | - F Everad
- Klinik für Hals‑, Nasen- und Ohrenheilkunde, Universitätsklinikum Freiburg, Killianstr. 5, 79106, Freiburg, Deutschland
| | - F Hassepaß
- Klinik für Hals‑, Nasen- und Ohrenheilkunde, Universitätsklinikum Freiburg, Killianstr. 5, 79106, Freiburg, Deutschland
| | - M Neudert
- Klinik für Hals-Nasen- und Ohrenheilkunde, Universitätsklinikum Carl-Gustav-Carus, Dresden, Deutschland
| | - C Offergeld
- Klinik für Hals‑, Nasen- und Ohrenheilkunde, Universitätsklinikum Freiburg, Killianstr. 5, 79106, Freiburg, Deutschland
| |
Collapse
|
2
|
Offergeld C, Kuhn S, Kromeier J, Heermann S, Widder A, Flayyih O, Everad F, Knopf A, Albrecht T, Burkhardt V, Hildenbrand T, Ramackers W. [Is the use of virtual reality in otorhinolaryngology teaching automatically positively rated by students? : A questionnaire-based evaluation among students]. HNO 2024; 72:367-374. [PMID: 38578464 PMCID: PMC11045625 DOI: 10.1007/s00106-024-01453-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/29/2024] [Indexed: 04/06/2024]
Abstract
BACKGROUND Analogous to the situation in other disciplines, digital ENT teaching made significant progress during the pandemic. Most ENT clinics nationwide were able to offer a complete virtual teaching program in time. Innovative teaching methods were also used early on. This was recognized in student teaching evaluations. Due to the expansion of virtual reality (VR) in medical teaching, even greater satisfaction should be expected through improved teaching quality. MATERIALS AND METHODS Surveys were performed with students (n = 180) of the ENT block internship in the summer semester of 2023. The aim of the evaluation was to determine the students' satisfaction with and subjective effectiveness of the newly implemented VR digital teaching method for teaching ear anatomy and coniotomy. A survey was also carried out among resident physicians. RESULTS The ENT teaching was perceived favorably by the students, with an average rating of 11.7 out of 15. The learning effectiveness and the value of VR in the ENT learning portfolio was evaluated varyingly by the students. The physicians' assessment was different, with a more positive perception. CONCLUSION Virtual reality represents an innovative component in the teaching portfolio of otolaryngology. This new teaching method is viewed and accepted as a future-oriented tool. Remarkably, the physicians involved voted consistently positively, while the students gave more critical assessments and pointed out limitations in the individual and subjective areas. These findings are in contrast to the further development of innovative teaching methods demanded by student interest groups.
Collapse
Affiliation(s)
- C Offergeld
- Univ.-HNO-Klinik, Medizinische Fakultät, Universitätsklinikum Freiburg, Freiburg, Deutschland
| | - S Kuhn
- Institut für Digitalisierung in der Medizin, Universitätsklinikum Gießen-Marburg, Marburg, Deutschland
| | - J Kromeier
- Klinik für Radiologie, St. Josef-Krankenhaus Freiburg, Freiburg, Deutschland
| | - S Heermann
- Institut für Anatomie und Zellbiologie, Medizinische Fakultät, Universitätsklinikum Freiburg, Freiburg, Deutschland
| | - A Widder
- Studiendekanat der Med. Fak., Universitätsklinikum Freiburg, Freiburg, Deutschland
| | - O Flayyih
- Studiendekanat der Med. Fak., Universitätsklinikum Freiburg, Freiburg, Deutschland
| | - F Everad
- Univ.-HNO-Klinik, Medizinische Fakultät, Universitätsklinikum Freiburg, Freiburg, Deutschland
| | - A Knopf
- Univ.-HNO-Klinik, Medizinische Fakultät, Universitätsklinikum Freiburg, Freiburg, Deutschland
| | - T Albrecht
- Univ.-HNO-Klinik, Medizinische Fakultät, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - V Burkhardt
- Univ.-HNO-Klinik, Medizinische Fakultät, Universitätsklinikum Freiburg, Freiburg, Deutschland
| | - T Hildenbrand
- Univ.-HNO-Klinik, Medizinische Fakultät, Universitätsklinikum Freiburg, Freiburg, Deutschland
| | - W Ramackers
- Klinik für Allgemein‑, Viszeral- und Transplantationschirurgie, Medizinische Hochschule Hannover (MHH), Carl-Neuberg-Straße 1, 30625, Hannover, Deutschland.
| |
Collapse
|
3
|
Githumbi R, Kuhn S, Osiowy C, Day J, deBruyn JCC, Fritzler MJ, Johnson NA, Vanderkooi O, Schmeling H. A randomized controlled trial of two hepatitis a vaccine doses among adolescents with juvenile idiopathic arthritis and Crohn's disease on immunosuppressive therapy: a pilot study. J Travel Med 2024:taae065. [PMID: 38652172 DOI: 10.1093/jtm/taae065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/07/2023] [Revised: 04/12/2024] [Indexed: 04/25/2024]
Abstract
This pilot randomized controlled trial assessed the immunogenicity of paediatric versus adult Hepatitis A vaccine doses in immunosuppressed adolescents (12-15 years) with Juvenile Idiopathic Arthritis and Crohn's Disease. The study aimed to assess if a single, higher dose provides better immunogenicity, particularly beneficial before travel.
Collapse
Affiliation(s)
- Racheal Githumbi
- Department of Pediatrics, Cumming School of Medicine, University of Calgary
| | - Susan Kuhn
- Department of Pediatrics, Cumming School of Medicine, University of Calgary
| | - Carla Osiowy
- National Microbiology Laboratory, Public Health Agency of Canada
| | - Jacqueline Day
- National Microbiology Laboratory, Public Health Agency of Canada
| | | | - Marvin J Fritzler
- Department of Medicine, Cumming School of Medicine, University of Calgary
| | - Nicole A Johnson
- Department of Pediatrics, Cumming School of Medicine, University of Calgary
| | - Otto Vanderkooi
- Department of Pediatrics, Cumming School of Medicine, University of Calgary
| | - Heinrike Schmeling
- Department of Pediatrics, Cumming School of Medicine, University of Calgary
| |
Collapse
|
4
|
Staplin N, Haynes R, Judge PK, Wanner C, Green JB, Emberson J, Preiss D, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu WJ, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Seidi S, Landray MJ, Baigent C, Herrington WG, Abat S, Abd Rahman R, Abdul Cader R, Abdul Hafidz MI, Abdul Wahab MZ, Abdullah NK, Abdul-Samad T, Abe M, Abraham N, Acheampong S, Achiri P, Acosta JA, Adeleke A, Adell V, Adewuyi-Dalton R, Adnan N, Africano A, Agharazii M, Aguilar F, Aguilera A, Ahmad M, Ahmad MK, Ahmad NA, Ahmad NH, Ahmad NI, Ahmad Miswan N, Ahmad Rosdi H, Ahmed I, Ahmed S, Ahmed S, Aiello J, Aitken A, AitSadi R, Aker S, Akimoto S, Akinfolarin A, Akram S, Alberici F, Albert C, Aldrich L, Alegata M, Alexander L, Alfaress S, Alhadj Ali M, Ali A, Ali A, Alicic R, Aliu A, Almaraz R, Almasarwah R, Almeida J, Aloisi A, Al-Rabadi L, Alscher D, Alvarez P, Al-Zeer B, Amat M, Ambrose C, Ammar H, An Y, Andriaccio L, Ansu K, Apostolidi A, Arai N, Araki H, Araki S, Arbi A, Arechiga O, Armstrong S, Arnold T, Aronoff S, Arriaga W, Arroyo J, Arteaga D, Asahara S, Asai A, Asai N, Asano S, Asawa M, Asmee MF, Aucella F, Augustin M, Avery A, Awad A, Awang IY, Awazawa M, Axler A, Ayub W, Azhari Z, Baccaro R, Badin C, Bagwell B, Bahlmann-Kroll E, Bahtar AZ, Baigent C, Bains D, Bajaj H, Baker R, Baldini E, Banas B, Banerjee D, Banno S, Bansal S, Barberi S, Barnes S, Barnini C, Barot C, Barrett K, Barrios R, Bartolomei Mecatti B, Barton I, Barton J, Basily W, Bavanandan S, Baxter A, Becker L, Beddhu S, Beige J, Beigh S, Bell S, Benck U, Beneat A, Bennett A, Bennett D, Benyon S, Berdeprado J, Bergler T, Bergner A, Berry M, Bevilacqua M, Bhairoo J, Bhandari S, Bhandary N, Bhatt A, Bhattarai M, Bhavsar M, Bian W, Bianchini F, Bianco S, Bilous R, Bilton J, Bilucaglia D, Bird C, Birudaraju D, Biscoveanu M, Blake C, Bleakley N, Bocchicchia K, Bodine S, Bodington R, Boedecker S, Bolduc M, Bolton S, Bond C, Boreky F, Boren K, Bouchi R, Bough L, Bovan D, Bowler C, Bowman L, Brar N, Braun C, Breach A, Breitenfeldt M, Brenner S, Brettschneider B, Brewer A, Brewer G, Brindle V, Brioni E, Brown C, Brown H, Brown L, Brown R, Brown S, Browne D, Bruce K, Brueckmann M, Brunskill N, Bryant M, Brzoska M, Bu Y, Buckman C, Budoff M, Bullen M, Burke A, Burnette S, Burston C, Busch M, Bushnell J, Butler S, Büttner C, Byrne C, Caamano A, Cadorna J, Cafiero C, Cagle M, Cai J, Calabrese K, Calvi C, Camilleri B, Camp S, Campbell D, Campbell R, Cao H, Capelli I, Caple M, Caplin B, Cardone A, Carle J, Carnall V, Caroppo M, Carr S, Carraro G, Carson M, Casares P, Castillo C, Castro C, Caudill B, Cejka V, Ceseri M, Cham L, Chamberlain A, Chambers J, Chan CBT, Chan JYM, Chan YC, Chang E, Chang E, Chant T, Chavagnon T, Chellamuthu P, Chen F, Chen J, Chen P, Chen TM, Chen Y, Chen Y, Cheng C, Cheng H, Cheng MC, Cherney D, Cheung AK, Ching CH, Chitalia N, Choksi R, Chukwu C, Chung K, Cianciolo G, Cipressa L, Clark S, Clarke H, Clarke R, Clarke S, Cleveland B, Cole E, Coles H, Condurache L, Connor A, Convery K, Cooper A, Cooper N, Cooper Z, Cooperman L, Cosgrove L, Coutts P, Cowley A, Craik R, Cui G, Cummins T, Dahl N, Dai H, Dajani L, D'Amelio A, Damian E, Damianik K, Danel L, Daniels C, Daniels T, Darbeau S, Darius H, Dasgupta T, Davies J, Davies L, Davis A, Davis J, Davis L, Dayanandan R, Dayi S, Dayrell R, De Nicola L, Debnath S, Deeb W, Degenhardt S, DeGoursey K, Delaney M, Deo R, DeRaad R, Derebail V, Dev D, Devaux M, Dhall P, Dhillon G, Dienes J, Dobre M, Doctolero E, Dodds V, Domingo D, Donaldson D, Donaldson P, Donhauser C, Donley V, Dorestin S, Dorey S, Doulton T, Draganova D, Draxlbauer K, Driver F, Du H, Dube F, Duck T, Dugal T, Dugas J, Dukka H, Dumann H, Durham W, Dursch M, Dykas R, Easow R, Eckrich E, Eden G, Edmerson E, Edwards H, Ee LW, Eguchi J, Ehrl Y, Eichstadt K, Eid W, Eilerman B, Ejima Y, Eldon H, Ellam T, Elliott L, Ellison R, Emberson J, Epp R, Er A, Espino-Obrero M, Estcourt S, Estienne L, Evans G, Evans J, Evans S, Fabbri G, Fajardo-Moser M, Falcone C, Fani F, Faria-Shayler P, Farnia F, Farrugia D, Fechter M, Fellowes D, Feng F, Fernandez J, Ferraro P, Field A, Fikry S, Finch J, Finn H, Fioretto P, Fish R, Fleischer A, Fleming-Brown D, Fletcher L, Flora R, Foellinger C, Foligno N, Forest S, Forghani Z, Forsyth K, Fottrell-Gould D, Fox P, Frankel A, Fraser D, Frazier R, Frederick K, Freking N, French H, Froment A, Fuchs B, Fuessl L, Fujii H, Fujimoto A, Fujita A, Fujita K, Fujita Y, Fukagawa M, Fukao Y, Fukasawa A, Fuller T, Funayama T, Fung E, Furukawa M, Furukawa Y, Furusho M, Gabel S, Gaidu J, Gaiser S, Gallo K, Galloway C, Gambaro G, Gan CC, Gangemi C, Gao M, Garcia K, Garcia M, Garofalo C, Garrity M, Garza A, Gasko S, Gavrila M, Gebeyehu B, Geddes A, Gentile G, George A, George J, Gesualdo L, Ghalli F, Ghanem A, Ghate T, Ghavampour S, Ghazi A, Gherman A, Giebeln-Hudnell U, Gill B, Gillham S, Girakossyan I, Girndt M, Giuffrida A, Glenwright M, Glider T, Gloria R, Glowski D, Goh BL, Goh CB, Gohda T, Goldenberg R, Goldfaden R, Goldsmith C, Golson B, Gonce V, Gong Q, Goodenough B, Goodwin N, Goonasekera M, Gordon A, Gordon J, Gore A, Goto H, Goto S, Goto S, Gowen D, Grace A, Graham J, Grandaliano G, Gray M, Green JB, Greene T, Greenwood G, Grewal B, Grifa R, Griffin D, Griffin S, Grimmer P, Grobovaite E, Grotjahn S, Guerini A, Guest C, Gunda S, Guo B, Guo Q, Haack S, Haase M, Haaser K, Habuki K, Hadley A, Hagan S, Hagge S, Haller H, Ham S, Hamal S, Hamamoto Y, Hamano N, Hamm M, Hanburry A, Haneda M, Hanf C, Hanif W, Hansen J, Hanson L, Hantel S, Haraguchi T, Harding E, Harding T, Hardy C, Hartner C, Harun Z, Harvill L, Hasan A, Hase H, Hasegawa F, Hasegawa T, Hashimoto A, Hashimoto C, Hashimoto M, Hashimoto S, Haskett S, Hauske SJ, Hawfield A, Hayami T, Hayashi M, Hayashi S, Haynes R, Hazara A, Healy C, Hecktman J, Heine G, Henderson H, Henschel R, Hepditch A, Herfurth K, Hernandez G, Hernandez Pena A, Hernandez-Cassis C, Herrington WG, Herzog C, Hewins S, Hewitt D, Hichkad L, Higashi S, Higuchi C, Hill C, Hill L, Hill M, Himeno T, Hing A, Hirakawa Y, Hirata K, Hirota Y, Hisatake T, Hitchcock S, Hodakowski A, Hodge W, Hogan R, Hohenstatt U, Hohenstein B, Hooi L, Hope S, Hopley M, Horikawa S, Hosein D, Hosooka T, Hou L, Hou W, Howie L, Howson A, Hozak M, Htet Z, Hu X, Hu Y, Huang J, Huda N, Hudig L, Hudson A, Hugo C, Hull R, Hume L, Hundei W, Hunt N, Hunter A, Hurley S, Hurst A, Hutchinson C, Hyo T, Ibrahim FH, Ibrahim S, Ihana N, Ikeda T, Imai A, Imamine R, Inamori A, Inazawa H, Ingell J, Inomata K, Inukai Y, Ioka M, Irtiza-Ali A, Isakova T, Isari W, Iselt M, Ishiguro A, Ishihara K, Ishikawa T, Ishimoto T, Ishizuka K, Ismail R, Itano S, Ito H, Ito K, Ito M, Ito Y, Iwagaitsu S, Iwaita Y, Iwakura T, Iwamoto M, Iwasa M, Iwasaki H, Iwasaki S, Izumi K, Izumi K, Izumi T, Jaafar SM, Jackson C, Jackson Y, Jafari G, Jahangiriesmaili M, Jain N, Jansson K, Jasim H, Jeffers L, Jenkins A, Jesky M, Jesus-Silva J, Jeyarajah D, Jiang Y, Jiao X, Jimenez G, Jin B, Jin Q, Jochims J, Johns B, Johnson C, Johnson T, Jolly S, Jones L, Jones L, Jones S, Jones T, Jones V, Joseph M, Joshi S, Judge P, Junejo N, Junus S, Kachele M, Kadowaki T, Kadoya H, Kaga H, Kai H, Kajio H, Kaluza-Schilling W, Kamaruzaman L, Kamarzarian A, Kamimura Y, Kamiya H, Kamundi C, Kan T, Kanaguchi Y, Kanazawa A, Kanda E, Kanegae S, Kaneko K, Kaneko K, Kang HY, Kano T, Karim M, Karounos D, Karsan W, Kasagi R, Kashihara N, Katagiri H, Katanosaka A, Katayama A, Katayama M, Katiman E, Kato K, Kato M, Kato N, Kato S, Kato T, Kato Y, Katsuda Y, Katsuno T, Kaufeld J, Kavak Y, Kawai I, Kawai M, Kawai M, Kawase A, Kawashima S, Kazory A, Kearney J, Keith B, Kellett J, Kelley S, Kershaw M, Ketteler M, Khai Q, Khairullah Q, Khandwala H, Khoo KKL, Khwaja A, Kidokoro K, Kielstein J, Kihara M, Kimber C, Kimura S, Kinashi H, Kingston H, Kinomura M, Kinsella-Perks E, Kitagawa M, Kitajima M, Kitamura S, Kiyosue A, Kiyota M, Klauser F, Klausmann G, Kmietschak W, Knapp K, Knight C, Knoppe A, Knott C, Kobayashi M, Kobayashi R, Kobayashi T, Koch M, Kodama S, Kodani N, Kogure E, Koizumi M, Kojima H, Kojo T, Kolhe N, Komaba H, Komiya T, Komori H, Kon SP, Kondo M, Kondo M, Kong W, Konishi M, Kono K, Koshino M, Kosugi T, Kothapalli B, Kozlowski T, Kraemer B, Kraemer-Guth A, Krappe J, Kraus D, Kriatselis C, Krieger C, Krish P, Kruger B, Ku Md Razi KR, Kuan Y, Kubota S, Kuhn S, Kumar P, Kume S, Kummer I, Kumuji R, Küpper A, Kuramae T, Kurian L, Kuribayashi C, Kurien R, Kuroda E, Kurose T, Kutschat A, Kuwabara N, Kuwata H, La Manna G, Lacey M, Lafferty K, LaFleur P, Lai V, Laity E, Lambert A, Landray MJ, Langlois M, Latif F, Latore E, Laundy E, Laurienti D, Lawson A, Lay M, Leal I, Leal I, Lee AK, Lee J, Lee KQ, Lee R, Lee SA, Lee YY, Lee-Barkey Y, Leonard N, Leoncini G, Leong CM, Lerario S, Leslie A, Levin A, Lewington A, Li J, Li N, Li X, Li Y, Liberti L, Liberti ME, Liew A, Liew YF, Lilavivat U, Lim SK, Lim YS, Limon E, Lin H, Lioudaki E, Liu H, Liu J, Liu L, Liu Q, Liu WJ, Liu X, Liu Z, Loader D, Lochhead H, Loh CL, Lorimer A, Loudermilk L, Loutan J, Low CK, Low CL, Low YM, Lozon Z, Lu Y, Lucci D, Ludwig U, Luker N, Lund D, Lustig R, Lyle S, Macdonald C, MacDougall I, Machicado R, MacLean D, Macleod P, Madera A, Madore F, Maeda K, Maegawa H, Maeno S, Mafham M, Magee J, Maggioni AP, Mah DY, Mahabadi V, Maiguma M, Makita Y, Makos G, Manco L, Mangiacapra R, Manley J, Mann P, Mano S, Marcotte G, Maris J, Mark P, Markau S, Markovic M, Marshall C, Martin M, Martinez C, Martinez S, Martins G, Maruyama K, Maruyama S, Marx K, Maselli A, Masengu A, Maskill A, Masumoto S, Masutani K, Matsumoto M, Matsunaga T, Matsuoka N, Matsushita M, Matthews M, Matthias S, Matvienko E, Maurer M, Maxwell P, Mayne KJ, Mazlan N, Mazlan SA, Mbuyisa A, McCafferty K, McCarroll F, McCarthy T, McClary-Wright C, McCray K, McDermott P, McDonald C, McDougall R, McHaffie E, McIntosh K, McKinley T, McLaughlin S, McLean N, McNeil L, Measor A, Meek J, Mehta A, Mehta R, Melandri M, Mené P, Meng T, Menne J, Merritt K, Merscher S, Meshykhi C, Messa P, Messinger L, Miftari N, Miller R, Miller Y, Miller-Hodges E, Minatoguchi M, Miners M, Minutolo R, Mita T, Miura Y, Miyaji M, Miyamoto S, Miyatsuka T, Miyazaki M, Miyazawa I, Mizumachi R, Mizuno M, Moffat S, Mohamad Nor FS, Mohamad Zaini SN, Mohamed Affandi FA, Mohandas C, Mohd R, Mohd Fauzi NA, Mohd Sharif NH, Mohd Yusoff Y, Moist L, Moncada A, Montasser M, Moon A, Moran C, Morgan N, Moriarty J, Morig G, Morinaga H, Morino K, Morisaki T, Morishita Y, Morlok S, Morris A, Morris F, Mostafa S, Mostefai Y, Motegi M, Motherwell N, Motta D, Mottl A, Moys R, Mozaffari S, Muir J, Mulhern J, Mulligan S, Munakata Y, Murakami C, Murakoshi M, Murawska A, Murphy K, Murphy L, Murray S, Murtagh H, Musa MA, Mushahar L, Mustafa R, Mustafar R, Muto M, Nadar E, Nagano R, Nagasawa T, Nagashima E, Nagasu H, Nagelberg S, Nair H, Nakagawa Y, Nakahara M, Nakamura J, Nakamura R, Nakamura T, Nakaoka M, Nakashima E, Nakata J, Nakata M, Nakatani S, Nakatsuka A, Nakayama Y, Nakhoul G, Nangaku M, Naverrete G, Navivala A, Nazeer I, Negrea L, Nethaji C, Newman E, Ng SYA, Ng TJ, Ngu LLS, Nimbkar T, Nishi H, Nishi M, Nishi S, Nishida Y, Nishiyama A, Niu J, Niu P, Nobili G, Nohara N, Nojima I, Nolan J, Nosseir H, Nozawa M, Nunn M, Nunokawa S, Oda M, Oe M, Oe Y, Ogane K, Ogawa W, Ogihara T, Oguchi G, Ohsugi M, Oishi K, Okada Y, Okajyo J, Okamoto S, Okamura K, Olufuwa O, Oluyombo R, Omata A, Omori Y, Ong LM, Ong YC, Onyema J, Oomatia A, Oommen A, Oremus R, Orimo Y, Ortalda V, Osaki Y, Osawa Y, Osmond Foster J, O'Sullivan A, Otani T, Othman N, Otomo S, O'Toole J, Owen L, Ozawa T, Padiyar A, Page N, Pajak S, Paliege A, Pandey A, Pandey R, Pariani H, Park J, Parrigon M, Passauer J, Patecki M, Patel M, Patel R, Patel T, Patel Z, Paul R, Paul R, Paulsen L, Pavone L, Peixoto A, Peji J, Peng BC, Peng K, Pennino L, Pereira E, Perez E, Pergola P, Pesce F, Pessolano G, Petchey W, Petr EJ, Pfab T, Phelan P, Phillips R, Phillips T, Phipps M, Piccinni G, Pickett T, Pickworth S, Piemontese M, Pinto D, Piper J, Plummer-Morgan J, Poehler D, Polese L, Poma V, Pontremoli R, Postal A, Pötz C, Power A, Pradhan N, Pradhan R, Preiss D, Preiss E, Preston K, Prib N, Price L, Provenzano C, Pugay C, Pulido R, Putz F, Qiao Y, Quartagno R, Quashie-Akponeware M, Rabara R, Rabasa-Lhoret R, Radhakrishnan D, Radley M, Raff R, Raguwaran S, Rahbari-Oskoui F, Rahman M, Rahmat K, Ramadoss S, Ramanaidu S, Ramasamy S, Ramli R, Ramli S, Ramsey T, Rankin A, Rashidi A, Raymond L, Razali WAFA, Read K, Reiner H, Reisler A, Reith C, Renner J, Rettenmaier B, Richmond L, Rijos D, Rivera R, Rivers V, Robinson H, Rocco M, Rodriguez-Bachiller I, Rodriquez R, Roesch C, Roesch J, Rogers J, Rohnstock M, Rolfsmeier S, Roman M, Romo A, Rosati A, Rosenberg S, Ross T, Rossello X, Roura M, Roussel M, Rovner S, Roy S, Rucker S, Rump L, Ruocco M, Ruse S, Russo F, Russo M, Ryder M, Sabarai A, Saccà C, Sachson R, Sadler E, Safiee NS, Sahani M, Saillant A, Saini J, Saito C, Saito S, Sakaguchi K, Sakai M, Salim H, Salviani C, Sammons E, Sampson A, Samson F, Sandercock P, Sanguila S, Santorelli G, Santoro D, Sarabu N, Saram T, Sardell R, Sasajima H, Sasaki T, Satko S, Sato A, Sato D, Sato H, Sato H, Sato J, Sato T, Sato Y, Satoh M, Sawada K, Schanz M, Scheidemantel F, Schemmelmann M, Schettler E, Schettler V, Schlieper GR, Schmidt C, Schmidt G, Schmidt U, Schmidt-Gurtler H, Schmude M, Schneider A, Schneider I, Schneider-Danwitz C, Schomig M, Schramm T, Schreiber A, Schricker S, Schroppel B, Schulte-Kemna L, Schulz E, Schumacher B, Schuster A, Schwab A, Scolari F, Scott A, Seeger W, Seeger W, Segal M, Seifert L, Seifert M, Sekiya M, Sellars R, Seman MR, Shah S, Shah S, Shainberg L, Shanmuganathan M, Shao F, Sharma K, Sharpe C, Sheikh-Ali M, Sheldon J, Shenton C, Shepherd A, Shepperd M, Sheridan R, Sheriff Z, Shibata Y, Shigehara T, Shikata K, Shimamura K, Shimano H, Shimizu Y, Shimoda H, Shin K, Shivashankar G, Shojima N, Silva R, Sim CSB, Simmons K, Sinha S, Sitter T, Sivanandam S, Skipper M, Sloan K, Sloan L, Smith R, Smyth J, Sobande T, Sobata M, Somalanka S, Song X, Sonntag F, Sood B, Sor SY, Soufer J, Sparks H, Spatoliatore G, Spinola T, Squyres S, Srivastava A, Stanfield J, Staplin N, Staylor K, Steele A, Steen O, Steffl D, Stegbauer J, Stellbrink C, Stellbrink E, Stevens W, Stevenson A, Stewart-Ray V, Stickley J, Stoffler D, Stratmann B, Streitenberger S, Strutz F, Stubbs J, Stumpf J, Suazo N, Suchinda P, Suckling R, Sudin A, Sugamori K, Sugawara H, Sugawara K, Sugimoto D, Sugiyama H, Sugiyama H, Sugiyama T, Sullivan M, Sumi M, Suresh N, Sutton D, Suzuki H, Suzuki R, Suzuki Y, Suzuki Y, Suzuki Y, Swanson E, Swift P, Syed S, Szerlip H, Taal M, Taddeo M, Tailor C, Tajima K, Takagi M, Takahashi K, Takahashi K, Takahashi M, Takahashi T, Takahira E, Takai T, Takaoka M, Takeoka J, Takesada A, Takezawa M, Talbot M, Taliercio J, Talsania T, Tamori Y, Tamura R, Tamura Y, Tan CHH, Tan EZZ, Tanabe A, Tanabe K, Tanaka A, Tanaka A, Tanaka N, Tang S, Tang Z, Tanigaki K, Tarlac M, Tatsuzawa A, Tay JF, Tay LL, Taylor J, Taylor K, Taylor K, Te A, Tenbusch L, Teng KS, Terakawa A, Terry J, Tham ZD, Tholl S, Thomas G, Thong KM, Tietjen D, Timadjer A, Tindall H, Tipper S, Tobin K, Toda N, Tokuyama A, Tolibas M, Tomita A, Tomita T, Tomlinson J, Tonks L, Topf J, Topping S, Torp A, Torres A, Totaro F, Toth P, Toyonaga Y, Tripodi F, Trivedi K, Tropman E, Tschope D, Tse J, Tsuji K, Tsunekawa S, Tsunoda R, Tucky B, Tufail S, Tuffaha A, Turan E, Turner H, Turner J, Turner M, Tuttle KR, Tye YL, Tyler A, Tyler J, Uchi H, Uchida H, Uchida T, Uchida T, Udagawa T, Ueda S, Ueda Y, Ueki K, Ugni S, Ugwu E, Umeno R, Unekawa C, Uozumi K, Urquia K, Valleteau A, Valletta C, van Erp R, Vanhoy C, Varad V, Varma R, Varughese A, Vasquez P, Vasseur A, Veelken R, Velagapudi C, Verdel K, Vettoretti S, Vezzoli G, Vielhauer V, Viera R, Vilar E, Villaruel S, Vinall L, Vinathan J, Visnjic M, Voigt E, von-Eynatten M, Vourvou M, Wada J, Wada J, Wada T, Wada Y, Wakayama K, Wakita Y, Wallendszus K, Walters T, Wan Mohamad WH, Wang L, Wang W, Wang X, Wang X, Wang Y, Wanner C, Wanninayake S, Watada H, Watanabe K, Watanabe K, Watanabe M, Waterfall H, Watkins D, Watson S, Weaving L, Weber B, Webley Y, Webster A, Webster M, Weetman M, Wei W, Weihprecht H, Weiland L, Weinmann-Menke J, Weinreich T, Wendt R, Weng Y, Whalen M, Whalley G, Wheatley R, Wheeler A, Wheeler J, Whelton P, White K, Whitmore B, Whittaker S, Wiebel J, Wiley J, Wilkinson L, Willett M, Williams A, Williams E, Williams K, Williams T, Wilson A, Wilson P, Wincott L, Wines E, Winkelmann B, Winkler M, Winter-Goodwin B, Witczak J, Wittes J, Wittmann M, Wolf G, Wolf L, Wolfling R, Wong C, Wong E, Wong HS, Wong LW, Wong YH, Wonnacott A, Wood A, Wood L, Woodhouse H, Wooding N, Woodman A, Wren K, Wu J, Wu P, Xia S, Xiao H, Xiao X, Xie Y, Xu C, Xu Y, Xue H, Yahaya H, Yalamanchili H, Yamada A, Yamada N, Yamagata K, Yamaguchi M, Yamaji Y, Yamamoto A, Yamamoto S, Yamamoto S, Yamamoto T, Yamanaka A, Yamano T, Yamanouchi Y, Yamasaki N, Yamasaki Y, Yamasaki Y, Yamashita C, Yamauchi T, Yan Q, Yanagisawa E, Yang F, Yang L, Yano S, Yao S, Yao Y, Yarlagadda S, Yasuda Y, Yiu V, Yokoyama T, Yoshida S, Yoshidome E, Yoshikawa H, Young A, Young T, Yousif V, Yu H, Yu Y, Yuasa K, Yusof N, Zalunardo N, Zander B, Zani R, Zappulo F, Zayed M, Zemann B, Zettergren P, Zhang H, Zhang L, Zhang L, Zhang N, Zhang X, Zhao J, Zhao L, Zhao S, Zhao Z, Zhong H, Zhou N, Zhou S, Zhu D, Zhu L, Zhu S, Zietz M, Zippo M, Zirino F, Zulkipli FH. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabetes Endocrinol 2024; 12:39-50. [PMID: 38061371 PMCID: PMC7615591 DOI: 10.1016/s2213-8587(23)00321-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 10/24/2023] [Accepted: 10/25/2023] [Indexed: 12/23/2023]
Abstract
BACKGROUND Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce progression of chronic kidney disease and the risk of cardiovascular morbidity and mortality in a wide range of patients. However, their effects on kidney disease progression in some patients with chronic kidney disease are unclear because few clinical kidney outcomes occurred among such patients in the completed trials. In particular, some guidelines stratify their level of recommendation about who should be treated with SGLT2 inhibitors based on diabetes status and albuminuria. We aimed to assess the effects of empagliflozin on progression of chronic kidney disease both overall and among specific types of participants in the EMPA-KIDNEY trial. METHODS EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA), and included individuals aged 18 years or older with an estimated glomerular filtration rate (eGFR) of 20 to less than 45 mL/min per 1·73 m2, or with an eGFR of 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher. We explored the effects of 10 mg oral empagliflozin once daily versus placebo on the annualised rate of change in estimated glomerular filtration rate (eGFR slope), a tertiary outcome. We studied the acute slope (from randomisation to 2 months) and chronic slope (from 2 months onwards) separately, using shared parameter models to estimate the latter. Analyses were done in all randomly assigned participants by intention to treat. EMPA-KIDNEY is registered at ClinicalTrials.gov, NCT03594110. FINDINGS Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and then followed up for a median of 2·0 years (IQR 1·5-2·4). Prespecified subgroups of eGFR included 2282 (34·5%) participants with an eGFR of less than 30 mL/min per 1·73 m2, 2928 (44·3%) with an eGFR of 30 to less than 45 mL/min per 1·73 m2, and 1399 (21·2%) with an eGFR 45 mL/min per 1·73 m2 or higher. Prespecified subgroups of uACR included 1328 (20·1%) with a uACR of less than 30 mg/g, 1864 (28·2%) with a uACR of 30 to 300 mg/g, and 3417 (51·7%) with a uACR of more than 300 mg/g. Overall, allocation to empagliflozin caused an acute 2·12 mL/min per 1·73 m2 (95% CI 1·83-2·41) reduction in eGFR, equivalent to a 6% (5-6) dip in the first 2 months. After this, it halved the chronic slope from -2·75 to -1·37 mL/min per 1·73 m2 per year (relative difference 50%, 95% CI 42-58). The absolute and relative benefits of empagliflozin on the magnitude of the chronic slope varied significantly depending on diabetes status and baseline levels of eGFR and uACR. In particular, the absolute difference in chronic slopes was lower in patients with lower baseline uACR, but because this group progressed more slowly than those with higher uACR, this translated to a larger relative difference in chronic slopes in this group (86% [36-136] reduction in the chronic slope among those with baseline uACR <30 mg/g compared with a 29% [19-38] reduction for those with baseline uACR ≥2000 mg/g; ptrend<0·0001). INTERPRETATION Empagliflozin slowed the rate of progression of chronic kidney disease among all types of participant in the EMPA-KIDNEY trial, including those with little albuminuria. Albuminuria alone should not be used to determine whether to treat with an SGLT2 inhibitor. FUNDING Boehringer Ingelheim and Eli Lilly.
Collapse
|
5
|
Judge PK, Staplin N, Mayne KJ, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Ng SYA, Roddick AJ, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu WJ, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Massey D, Landray MJ, Baigent C, Haynes R, Herrington WG, Abat S, Abd Rahman R, Abdul Cader R, Abdul Hafidz MI, Abdul Wahab MZ, Abdullah NK, Abdul-Samad T, Abe M, Abraham N, Acheampong S, Achiri P, Acosta JA, Adeleke A, Adell V, Adewuyi-Dalton R, Adnan N, Africano A, Agharazii M, Aguilar F, Aguilera A, Ahmad M, Ahmad MK, Ahmad NA, Ahmad NH, Ahmad NI, Ahmad Miswan N, Ahmad Rosdi H, Ahmed I, Ahmed S, Ahmed S, Aiello J, Aitken A, AitSadi R, Aker S, Akimoto S, Akinfolarin A, Akram S, Alberici F, Albert C, Aldrich L, Alegata M, Alexander L, Alfaress S, Alhadj Ali M, Ali A, Ali A, Alicic R, Aliu A, Almaraz R, Almasarwah R, Almeida J, Aloisi A, Al-Rabadi L, Alscher D, Alvarez P, Al-Zeer B, Amat M, Ambrose C, Ammar H, An Y, Andriaccio L, Ansu K, Apostolidi A, Arai N, Araki H, Araki S, Arbi A, Arechiga O, Armstrong S, Arnold T, Aronoff S, Arriaga W, Arroyo J, Arteaga D, Asahara S, Asai A, Asai N, Asano S, Asawa M, Asmee MF, Aucella F, Augustin M, Avery A, Awad A, Awang IY, Awazawa M, Axler A, Ayub W, Azhari Z, Baccaro R, Badin C, Bagwell B, Bahlmann-Kroll E, Bahtar AZ, Baigent C, Bains D, Bajaj H, Baker R, Baldini E, Banas B, Banerjee D, Banno S, Bansal S, Barberi S, Barnes S, Barnini C, Barot C, Barrett K, Barrios R, Bartolomei Mecatti B, Barton I, Barton J, Basily W, Bavanandan S, Baxter A, Becker L, Beddhu S, Beige J, Beigh S, Bell S, Benck U, Beneat A, Bennett A, Bennett D, Benyon S, Berdeprado J, Bergler T, Bergner A, Berry M, Bevilacqua M, Bhairoo J, Bhandari S, Bhandary N, Bhatt A, Bhattarai M, Bhavsar M, Bian W, Bianchini F, Bianco S, Bilous R, Bilton J, Bilucaglia D, Bird C, Birudaraju D, Biscoveanu M, Blake C, Bleakley N, Bocchicchia K, Bodine S, Bodington R, Boedecker S, Bolduc M, Bolton S, Bond C, Boreky F, Boren K, Bouchi R, Bough L, Bovan D, Bowler C, Bowman L, Brar N, Braun C, Breach A, Breitenfeldt M, Brenner S, Brettschneider B, Brewer A, Brewer G, Brindle V, Brioni E, Brown C, Brown H, Brown L, Brown R, Brown S, Browne D, Bruce K, Brueckmann M, Brunskill N, Bryant M, Brzoska M, Bu Y, Buckman C, Budoff M, Bullen M, Burke A, Burnette S, Burston C, Busch M, Bushnell J, Butler S, Büttner C, Byrne C, Caamano A, Cadorna J, Cafiero C, Cagle M, Cai J, Calabrese K, Calvi C, Camilleri B, Camp S, Campbell D, Campbell R, Cao H, Capelli I, Caple M, Caplin B, Cardone A, Carle J, Carnall V, Caroppo M, Carr S, Carraro G, Carson M, Casares P, Castillo C, Castro C, Caudill B, Cejka V, Ceseri M, Cham L, Chamberlain A, Chambers J, Chan CBT, Chan JYM, Chan YC, Chang E, Chang E, Chant T, Chavagnon T, Chellamuthu P, Chen F, Chen J, Chen P, Chen TM, Chen Y, Chen Y, Cheng C, Cheng H, Cheng MC, Cherney D, Cheung AK, Ching CH, Chitalia N, Choksi R, Chukwu C, Chung K, Cianciolo G, Cipressa L, Clark S, Clarke H, Clarke R, Clarke S, Cleveland B, Cole E, Coles H, Condurache L, Connor A, Convery K, Cooper A, Cooper N, Cooper Z, Cooperman L, Cosgrove L, Coutts P, Cowley A, Craik R, Cui G, Cummins T, Dahl N, Dai H, Dajani L, D'Amelio A, Damian E, Damianik K, Danel L, Daniels C, Daniels T, Darbeau S, Darius H, Dasgupta T, Davies J, Davies L, Davis A, Davis J, Davis L, Dayanandan R, Dayi S, Dayrell R, De Nicola L, Debnath S, Deeb W, Degenhardt S, DeGoursey K, Delaney M, Deo R, DeRaad R, Derebail V, Dev D, Devaux M, Dhall P, Dhillon G, Dienes J, Dobre M, Doctolero E, Dodds V, Domingo D, Donaldson D, Donaldson P, Donhauser C, Donley V, Dorestin S, Dorey S, Doulton T, Draganova D, Draxlbauer K, Driver F, Du H, Dube F, Duck T, Dugal T, Dugas J, Dukka H, Dumann H, Durham W, Dursch M, Dykas R, Easow R, Eckrich E, Eden G, Edmerson E, Edwards H, Ee LW, Eguchi J, Ehrl Y, Eichstadt K, Eid W, Eilerman B, Ejima Y, Eldon H, Ellam T, Elliott L, Ellison R, Emberson J, Epp R, Er A, Espino-Obrero M, Estcourt S, Estienne L, Evans G, Evans J, Evans S, Fabbri G, Fajardo-Moser M, Falcone C, Fani F, Faria-Shayler P, Farnia F, Farrugia D, Fechter M, Fellowes D, Feng F, Fernandez J, Ferraro P, Field A, Fikry S, Finch J, Finn H, Fioretto P, Fish R, Fleischer A, Fleming-Brown D, Fletcher L, Flora R, Foellinger C, Foligno N, Forest S, Forghani Z, Forsyth K, Fottrell-Gould D, Fox P, Frankel A, Fraser D, Frazier R, Frederick K, Freking N, French H, Froment A, Fuchs B, Fuessl L, Fujii H, Fujimoto A, Fujita A, Fujita K, Fujita Y, Fukagawa M, Fukao Y, Fukasawa A, Fuller T, Funayama T, Fung E, Furukawa M, Furukawa Y, Furusho M, Gabel S, Gaidu J, Gaiser S, Gallo K, Galloway C, Gambaro G, Gan CC, Gangemi C, Gao M, Garcia K, Garcia M, Garofalo C, Garrity M, Garza A, Gasko S, Gavrila M, Gebeyehu B, Geddes A, Gentile G, George A, George J, Gesualdo L, Ghalli F, Ghanem A, Ghate T, Ghavampour S, Ghazi A, Gherman A, Giebeln-Hudnell U, Gill B, Gillham S, Girakossyan I, Girndt M, Giuffrida A, Glenwright M, Glider T, Gloria R, Glowski D, Goh BL, Goh CB, Gohda T, Goldenberg R, Goldfaden R, Goldsmith C, Golson B, Gonce V, Gong Q, Goodenough B, Goodwin N, Goonasekera M, Gordon A, Gordon J, Gore A, Goto H, Goto S, Goto S, Gowen D, Grace A, Graham J, Grandaliano G, Gray M, Green JB, Greene T, Greenwood G, Grewal B, Grifa R, Griffin D, Griffin S, Grimmer P, Grobovaite E, Grotjahn S, Guerini A, Guest C, Gunda S, Guo B, Guo Q, Haack S, Haase M, Haaser K, Habuki K, Hadley A, Hagan S, Hagge S, Haller H, Ham S, Hamal S, Hamamoto Y, Hamano N, Hamm M, Hanburry A, Haneda M, Hanf C, Hanif W, Hansen J, Hanson L, Hantel S, Haraguchi T, Harding E, Harding T, Hardy C, Hartner C, Harun Z, Harvill L, Hasan A, Hase H, Hasegawa F, Hasegawa T, Hashimoto A, Hashimoto C, Hashimoto M, Hashimoto S, Haskett S, Hauske SJ, Hawfield A, Hayami T, Hayashi M, Hayashi S, Haynes R, Hazara A, Healy C, Hecktman J, Heine G, Henderson H, Henschel R, Hepditch A, Herfurth K, Hernandez G, Hernandez Pena A, Hernandez-Cassis C, Herrington WG, Herzog C, Hewins S, Hewitt D, Hichkad L, Higashi S, Higuchi C, Hill C, Hill L, Hill M, Himeno T, Hing A, Hirakawa Y, Hirata K, Hirota Y, Hisatake T, Hitchcock S, Hodakowski A, Hodge W, Hogan R, Hohenstatt U, Hohenstein B, Hooi L, Hope S, Hopley M, Horikawa S, Hosein D, Hosooka T, Hou L, Hou W, Howie L, Howson A, Hozak M, Htet Z, Hu X, Hu Y, Huang J, Huda N, Hudig L, Hudson A, Hugo C, Hull R, Hume L, Hundei W, Hunt N, Hunter A, Hurley S, Hurst A, Hutchinson C, Hyo T, Ibrahim FH, Ibrahim S, Ihana N, Ikeda T, Imai A, Imamine R, Inamori A, Inazawa H, Ingell J, Inomata K, Inukai Y, Ioka M, Irtiza-Ali A, Isakova T, Isari W, Iselt M, Ishiguro A, Ishihara K, Ishikawa T, Ishimoto T, Ishizuka K, Ismail R, Itano S, Ito H, Ito K, Ito M, Ito Y, Iwagaitsu S, Iwaita Y, Iwakura T, Iwamoto M, Iwasa M, Iwasaki H, Iwasaki S, Izumi K, Izumi K, Izumi T, Jaafar SM, Jackson C, Jackson Y, Jafari G, Jahangiriesmaili M, Jain N, Jansson K, Jasim H, Jeffers L, Jenkins A, Jesky M, Jesus-Silva J, Jeyarajah D, Jiang Y, Jiao X, Jimenez G, Jin B, Jin Q, Jochims J, Johns B, Johnson C, Johnson T, Jolly S, Jones L, Jones L, Jones S, Jones T, Jones V, Joseph M, Joshi S, Judge P, Junejo N, Junus S, Kachele M, Kadowaki T, Kadoya H, Kaga H, Kai H, Kajio H, Kaluza-Schilling W, Kamaruzaman L, Kamarzarian A, Kamimura Y, Kamiya H, Kamundi C, Kan T, Kanaguchi Y, Kanazawa A, Kanda E, Kanegae S, Kaneko K, Kaneko K, Kang HY, Kano T, Karim M, Karounos D, Karsan W, Kasagi R, Kashihara N, Katagiri H, Katanosaka A, Katayama A, Katayama M, Katiman E, Kato K, Kato M, Kato N, Kato S, Kato T, Kato Y, Katsuda Y, Katsuno T, Kaufeld J, Kavak Y, Kawai I, Kawai M, Kawai M, Kawase A, Kawashima S, Kazory A, Kearney J, Keith B, Kellett J, Kelley S, Kershaw M, Ketteler M, Khai Q, Khairullah Q, Khandwala H, Khoo KKL, Khwaja A, Kidokoro K, Kielstein J, Kihara M, Kimber C, Kimura S, Kinashi H, Kingston H, Kinomura M, Kinsella-Perks E, Kitagawa M, Kitajima M, Kitamura S, Kiyosue A, Kiyota M, Klauser F, Klausmann G, Kmietschak W, Knapp K, Knight C, Knoppe A, Knott C, Kobayashi M, Kobayashi R, Kobayashi T, Koch M, Kodama S, Kodani N, Kogure E, Koizumi M, Kojima H, Kojo T, Kolhe N, Komaba H, Komiya T, Komori H, Kon SP, Kondo M, Kondo M, Kong W, Konishi M, Kono K, Koshino M, Kosugi T, Kothapalli B, Kozlowski T, Kraemer B, Kraemer-Guth A, Krappe J, Kraus D, Kriatselis C, Krieger C, Krish P, Kruger B, Ku Md Razi KR, Kuan Y, Kubota S, Kuhn S, Kumar P, Kume S, Kummer I, Kumuji R, Küpper A, Kuramae T, Kurian L, Kuribayashi C, Kurien R, Kuroda E, Kurose T, Kutschat A, Kuwabara N, Kuwata H, La Manna G, Lacey M, Lafferty K, LaFleur P, Lai V, Laity E, Lambert A, Landray MJ, Langlois M, Latif F, Latore E, Laundy E, Laurienti D, Lawson A, Lay M, Leal I, Leal I, Lee AK, Lee J, Lee KQ, Lee R, Lee SA, Lee YY, Lee-Barkey Y, Leonard N, Leoncini G, Leong CM, Lerario S, Leslie A, Levin A, Lewington A, Li J, Li N, Li X, Li Y, Liberti L, Liberti ME, Liew A, Liew YF, Lilavivat U, Lim SK, Lim YS, Limon E, Lin H, Lioudaki E, Liu H, Liu J, Liu L, Liu Q, Liu WJ, Liu X, Liu Z, Loader D, Lochhead H, Loh CL, Lorimer A, Loudermilk L, Loutan J, Low CK, Low CL, Low YM, Lozon Z, Lu Y, Lucci D, Ludwig U, Luker N, Lund D, Lustig R, Lyle S, Macdonald C, MacDougall I, Machicado R, MacLean D, Macleod P, Madera A, Madore F, Maeda K, Maegawa H, Maeno S, Mafham M, Magee J, Maggioni AP, Mah DY, Mahabadi V, Maiguma M, Makita Y, Makos G, Manco L, Mangiacapra R, Manley J, Mann P, Mano S, Marcotte G, Maris J, Mark P, Markau S, Markovic M, Marshall C, Martin M, Martinez C, Martinez S, Martins G, Maruyama K, Maruyama S, Marx K, Maselli A, Masengu A, Maskill A, Masumoto S, Masutani K, Matsumoto M, Matsunaga T, Matsuoka N, Matsushita M, Matthews M, Matthias S, Matvienko E, Maurer M, Maxwell P, Mayne KJ, Mazlan N, Mazlan SA, Mbuyisa A, McCafferty K, McCarroll F, McCarthy T, McClary-Wright C, McCray K, McDermott P, McDonald C, McDougall R, McHaffie E, McIntosh K, McKinley T, McLaughlin S, McLean N, McNeil L, Measor A, Meek J, Mehta A, Mehta R, Melandri M, Mené P, Meng T, Menne J, Merritt K, Merscher S, Meshykhi C, Messa P, Messinger L, Miftari N, Miller R, Miller Y, Miller-Hodges E, Minatoguchi M, Miners M, Minutolo R, Mita T, Miura Y, Miyaji M, Miyamoto S, Miyatsuka T, Miyazaki M, Miyazawa I, Mizumachi R, Mizuno M, Moffat S, Mohamad Nor FS, Mohamad Zaini SN, Mohamed Affandi FA, Mohandas C, Mohd R, Mohd Fauzi NA, Mohd Sharif NH, Mohd Yusoff Y, Moist L, Moncada A, Montasser M, Moon A, Moran C, Morgan N, Moriarty J, Morig G, Morinaga H, Morino K, Morisaki T, Morishita Y, Morlok S, Morris A, Morris F, Mostafa S, Mostefai Y, Motegi M, Motherwell N, Motta D, Mottl A, Moys R, Mozaffari S, Muir J, Mulhern J, Mulligan S, Munakata Y, Murakami C, Murakoshi M, Murawska A, Murphy K, Murphy L, Murray S, Murtagh H, Musa MA, Mushahar L, Mustafa R, Mustafar R, Muto M, Nadar E, Nagano R, Nagasawa T, Nagashima E, Nagasu H, Nagelberg S, Nair H, Nakagawa Y, Nakahara M, Nakamura J, Nakamura R, Nakamura T, Nakaoka M, Nakashima E, Nakata J, Nakata M, Nakatani S, Nakatsuka A, Nakayama Y, Nakhoul G, Nangaku M, Naverrete G, Navivala A, Nazeer I, Negrea L, Nethaji C, Newman E, Ng SYA, Ng TJ, Ngu LLS, Nimbkar T, Nishi H, Nishi M, Nishi S, Nishida Y, Nishiyama A, Niu J, Niu P, Nobili G, Nohara N, Nojima I, Nolan J, Nosseir H, Nozawa M, Nunn M, Nunokawa S, Oda M, Oe M, Oe Y, Ogane K, Ogawa W, Ogihara T, Oguchi G, Ohsugi M, Oishi K, Okada Y, Okajyo J, Okamoto S, Okamura K, Olufuwa O, Oluyombo R, Omata A, Omori Y, Ong LM, Ong YC, Onyema J, Oomatia A, Oommen A, Oremus R, Orimo Y, Ortalda V, Osaki Y, Osawa Y, Osmond Foster J, O'Sullivan A, Otani T, Othman N, Otomo S, O'Toole J, Owen L, Ozawa T, Padiyar A, Page N, Pajak S, Paliege A, Pandey A, Pandey R, Pariani H, Park J, Parrigon M, Passauer J, Patecki M, Patel M, Patel R, Patel T, Patel Z, Paul R, Paul R, Paulsen L, Pavone L, Peixoto A, Peji J, Peng BC, Peng K, Pennino L, Pereira E, Perez E, Pergola P, Pesce F, Pessolano G, Petchey W, Petr EJ, Pfab T, Phelan P, Phillips R, Phillips T, Phipps M, Piccinni G, Pickett T, Pickworth S, Piemontese M, Pinto D, Piper J, Plummer-Morgan J, Poehler D, Polese L, Poma V, Pontremoli R, Postal A, Pötz C, Power A, Pradhan N, Pradhan R, Preiss D, Preiss E, Preston K, Prib N, Price L, Provenzano C, Pugay C, Pulido R, Putz F, Qiao Y, Quartagno R, Quashie-Akponeware M, Rabara R, Rabasa-Lhoret R, Radhakrishnan D, Radley M, Raff R, Raguwaran S, Rahbari-Oskoui F, Rahman M, Rahmat K, Ramadoss S, Ramanaidu S, Ramasamy S, Ramli R, Ramli S, Ramsey T, Rankin A, Rashidi A, Raymond L, Razali WAFA, Read K, Reiner H, Reisler A, Reith C, Renner J, Rettenmaier B, Richmond L, Rijos D, Rivera R, Rivers V, Robinson H, Rocco M, Rodriguez-Bachiller I, Rodriquez R, Roesch C, Roesch J, Rogers J, Rohnstock M, Rolfsmeier S, Roman M, Romo A, Rosati A, Rosenberg S, Ross T, Rossello X, Roura M, Roussel M, Rovner S, Roy S, Rucker S, Rump L, Ruocco M, Ruse S, Russo F, Russo M, Ryder M, Sabarai A, Saccà C, Sachson R, Sadler E, Safiee NS, Sahani M, Saillant A, Saini J, Saito C, Saito S, Sakaguchi K, Sakai M, Salim H, Salviani C, Sammons E, Sampson A, Samson F, Sandercock P, Sanguila S, Santorelli G, Santoro D, Sarabu N, Saram T, Sardell R, Sasajima H, Sasaki T, Satko S, Sato A, Sato D, Sato H, Sato H, Sato J, Sato T, Sato Y, Satoh M, Sawada K, Schanz M, Scheidemantel F, Schemmelmann M, Schettler E, Schettler V, Schlieper GR, Schmidt C, Schmidt G, Schmidt U, Schmidt-Gurtler H, Schmude M, Schneider A, Schneider I, Schneider-Danwitz C, Schomig M, Schramm T, Schreiber A, Schricker S, Schroppel B, Schulte-Kemna L, Schulz E, Schumacher B, Schuster A, Schwab A, Scolari F, Scott A, Seeger W, Seeger W, Segal M, Seifert L, Seifert M, Sekiya M, Sellars R, Seman MR, Shah S, Shah S, Shainberg L, Shanmuganathan M, Shao F, Sharma K, Sharpe C, Sheikh-Ali M, Sheldon J, Shenton C, Shepherd A, Shepperd M, Sheridan R, Sheriff Z, Shibata Y, Shigehara T, Shikata K, Shimamura K, Shimano H, Shimizu Y, Shimoda H, Shin K, Shivashankar G, Shojima N, Silva R, Sim CSB, Simmons K, Sinha S, Sitter T, Sivanandam S, Skipper M, Sloan K, Sloan L, Smith R, Smyth J, Sobande T, Sobata M, Somalanka S, Song X, Sonntag F, Sood B, Sor SY, Soufer J, Sparks H, Spatoliatore G, Spinola T, Squyres S, Srivastava A, Stanfield J, Staplin N, Staylor K, Steele A, Steen O, Steffl D, Stegbauer J, Stellbrink C, Stellbrink E, Stevens W, Stevenson A, Stewart-Ray V, Stickley J, Stoffler D, Stratmann B, Streitenberger S, Strutz F, Stubbs J, Stumpf J, Suazo N, Suchinda P, Suckling R, Sudin A, Sugamori K, Sugawara H, Sugawara K, Sugimoto D, Sugiyama H, Sugiyama H, Sugiyama T, Sullivan M, Sumi M, Suresh N, Sutton D, Suzuki H, Suzuki R, Suzuki Y, Suzuki Y, Suzuki Y, Swanson E, Swift P, Syed S, Szerlip H, Taal M, Taddeo M, Tailor C, Tajima K, Takagi M, Takahashi K, Takahashi K, Takahashi M, Takahashi T, Takahira E, Takai T, Takaoka M, Takeoka J, Takesada A, Takezawa M, Talbot M, Taliercio J, Talsania T, Tamori Y, Tamura R, Tamura Y, Tan CHH, Tan EZZ, Tanabe A, Tanabe K, Tanaka A, Tanaka A, Tanaka N, Tang S, Tang Z, Tanigaki K, Tarlac M, Tatsuzawa A, Tay JF, Tay LL, Taylor J, Taylor K, Taylor K, Te A, Tenbusch L, Teng KS, Terakawa A, Terry J, Tham ZD, Tholl S, Thomas G, Thong KM, Tietjen D, Timadjer A, Tindall H, Tipper S, Tobin K, Toda N, Tokuyama A, Tolibas M, Tomita A, Tomita T, Tomlinson J, Tonks L, Topf J, Topping S, Torp A, Torres A, Totaro F, Toth P, Toyonaga Y, Tripodi F, Trivedi K, Tropman E, Tschope D, Tse J, Tsuji K, Tsunekawa S, Tsunoda R, Tucky B, Tufail S, Tuffaha A, Turan E, Turner H, Turner J, Turner M, Tuttle KR, Tye YL, Tyler A, Tyler J, Uchi H, Uchida H, Uchida T, Uchida T, Udagawa T, Ueda S, Ueda Y, Ueki K, Ugni S, Ugwu E, Umeno R, Unekawa C, Uozumi K, Urquia K, Valleteau A, Valletta C, van Erp R, Vanhoy C, Varad V, Varma R, Varughese A, Vasquez P, Vasseur A, Veelken R, Velagapudi C, Verdel K, Vettoretti S, Vezzoli G, Vielhauer V, Viera R, Vilar E, Villaruel S, Vinall L, Vinathan J, Visnjic M, Voigt E, von-Eynatten M, Vourvou M, Wada J, Wada J, Wada T, Wada Y, Wakayama K, Wakita Y, Wallendszus K, Walters T, Wan Mohamad WH, Wang L, Wang W, Wang X, Wang X, Wang Y, Wanner C, Wanninayake S, Watada H, Watanabe K, Watanabe K, Watanabe M, Waterfall H, Watkins D, Watson S, Weaving L, Weber B, Webley Y, Webster A, Webster M, Weetman M, Wei W, Weihprecht H, Weiland L, Weinmann-Menke J, Weinreich T, Wendt R, Weng Y, Whalen M, Whalley G, Wheatley R, Wheeler A, Wheeler J, Whelton P, White K, Whitmore B, Whittaker S, Wiebel J, Wiley J, Wilkinson L, Willett M, Williams A, Williams E, Williams K, Williams T, Wilson A, Wilson P, Wincott L, Wines E, Winkelmann B, Winkler M, Winter-Goodwin B, Witczak J, Wittes J, Wittmann M, Wolf G, Wolf L, Wolfling R, Wong C, Wong E, Wong HS, Wong LW, Wong YH, Wonnacott A, Wood A, Wood L, Woodhouse H, Wooding N, Woodman A, Wren K, Wu J, Wu P, Xia S, Xiao H, Xiao X, Xie Y, Xu C, Xu Y, Xue H, Yahaya H, Yalamanchili H, Yamada A, Yamada N, Yamagata K, Yamaguchi M, Yamaji Y, Yamamoto A, Yamamoto S, Yamamoto S, Yamamoto T, Yamanaka A, Yamano T, Yamanouchi Y, Yamasaki N, Yamasaki Y, Yamasaki Y, Yamashita C, Yamauchi T, Yan Q, Yanagisawa E, Yang F, Yang L, Yano S, Yao S, Yao Y, Yarlagadda S, Yasuda Y, Yiu V, Yokoyama T, Yoshida S, Yoshidome E, Yoshikawa H, Young A, Young T, Yousif V, Yu H, Yu Y, Yuasa K, Yusof N, Zalunardo N, Zander B, Zani R, Zappulo F, Zayed M, Zemann B, Zettergren P, Zhang H, Zhang L, Zhang L, Zhang N, Zhang X, Zhao J, Zhao L, Zhao S, Zhao Z, Zhong H, Zhou N, Zhou S, Zhu D, Zhu L, Zhu S, Zietz M, Zippo M, Zirino F, Zulkipli FH. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol 2024; 12:51-60. [PMID: 38061372 DOI: 10.1016/s2213-8587(23)00322-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 10/24/2023] [Accepted: 10/25/2023] [Indexed: 12/23/2023]
Abstract
BACKGROUND The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. METHODS EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. FINDINGS Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5-2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62-0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16-1·59), representing a 50% (42-58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). INTERPRETATION In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. FUNDING Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council.
Collapse
|
6
|
Barnett ED, Wheelock AB, MacLeod WB, McCarthy AE, Walker PF, Coyle CM, Greenaway CA, Castelli F, López-Vélez R, Gobbi FG, Trigo E, Grobusch MP, Gautret P, Hamer DH, Kuhn S, Stauffer WM. Infections with long latency in international refugees, immigrants, and migrants seen at GeoSentinel sites, 2016-2018. Travel Med Infect Dis 2023; 56:102653. [PMID: 37852594 PMCID: PMC10760402 DOI: 10.1016/j.tmaid.2023.102653] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Revised: 10/06/2023] [Accepted: 10/09/2023] [Indexed: 10/20/2023]
Abstract
BACKGROUND The continued increase in global migration compels clinicians to be aware of specific health problems faced by refugees, immigrants, and migrants (RIM). This analysis aimed to characterize RIM evaluated at GeoSentinel sites, their migration history, and infectious diseases detected through screening and diagnostic workups. METHODS A case report form was used to collect data on demographics, migration route, infectious diseases screened, test results, and primary infectious disease diagnosis for RIM patients seen at GeoSentinel sites. Descriptive statistics were performed. RESULTS Between October 2016 and November 2018, 5,319 RIM patients were evaluated at GeoSentinel sites in 19 countries. Africa was the region of birth for 2,436 patients (46 %), followed by the Americas (1,644, 31 %), and Asia (1,098, 21 %). Tuberculosis (TB) was the most common infection screened and reported as positive (853/2,273, 38 % positive by any method). TB, strongyloidiasis, and hepatitis B surface antigen positivity were observed across all migration administrative categories and regions of birth. Chagas disease was reported only among RIM patients from the Americas (393/394, 100 %) and schistosomiasis predominantly in those from Africa (480/510, 94 %). TB infection (694/5,319, 13 %) and Chagas disease (524/5,319, 10 %) were the leading primary infectious disease diagnoses. CONCLUSIONS Several infections of long latency (e.g. TB, hepatitis B, and strongyloidiasis) with potential for long-term sequelae were seen among RIM patients across all migration administrative categories and regions of origin. Obtaining detailed epidemiologic information from RIM patients is critical to optimize detection of diseases of individual and public health importance, particularly those with long latency periods.
Collapse
Affiliation(s)
- Elizabeth D Barnett
- Department of Pediatrics, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA
| | - Alyse B Wheelock
- Section of Preventive Medicine and Epidemiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
| | - William B MacLeod
- Department of Global Health, Boston University School of Public Health, Boston, MA, USA
| | - Anne E McCarthy
- Department of Medicine, University of Ottawa, Ottawa, Canada
| | - Patricia F Walker
- Department of Medicine, University of Minnesota, HealthPartners Institute, Minnesota, USA
| | - Christina M Coyle
- Department of Infectious Diseases, Albert Einstein College of Medicine, Bronx, NY, USA
| | - Christina A Greenaway
- SMBD Jewish General Hospital, Division of Infectious Diseases, McGill University, Montreal, Quebec, Canada
| | - Francesco Castelli
- University Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili of Brescia, Brescia, Lombardy, Italy
| | - Rogelio López-Vélez
- Ramón y Cajal Institute for Health Research, Ramón y Cajal University Hospital, Madrid, Spain
| | - Federico G Gobbi
- Department of Infectious-Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - Elena Trigo
- Department of Internal Medicine, National Referral Unit for Imported Tropical Diseases, High Level Isolation Unit, Hospital Universitario La Paz-Carlos III, IdiPAZ, Madrid, Spain
| | - Martin P Grobusch
- Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands
| | - Philippe Gautret
- VITROME, Aix Marseille University, IRD, AP-HM, SSA, Marseille, France; Institut Méditerranée Infection, Marseille, France
| | - Davidson H Hamer
- Department of Global Health, Boston University School of Public Health, Boston, MA, USA; Section of Infectious Diseases, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA
| | - Susan Kuhn
- Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | | |
Collapse
|
7
|
Castañeda-Mogollón D, Toppings NB, Kamaliddin C, Lang R, Kuhn S, Pillai DR. Amplicon Deep Sequencing Reveals Multiple Genetic Events Lead to Treatment Failure with Atovaquone-Proguanil in Plasmodium falciparum. Antimicrob Agents Chemother 2023; 67:e0170922. [PMID: 37154745 PMCID: PMC10269153 DOI: 10.1128/aac.01709-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Accepted: 03/05/2023] [Indexed: 05/10/2023] Open
Abstract
Atovaquone-proguanil (AP) is used as treatment for uncomplicated malaria, and as a chemoprophylactic agent against Plasmodium falciparum. Imported malaria remains one of the top causes of fever in Canadian returning travelers. Twelve sequential whole-blood samples before and after AP treatment failure were obtained from a patient diagnosed with P. falciparum malaria upon their return from Uganda and Sudan. Ultradeep sequencing was performed on the cytb, dhfr, and dhps markers of treatment resistance before and during the episode of recrudescence. Haplotyping profiles were generated using three different approaches: msp2-3D7 agarose and capillary electrophoresis, and cpmp using amplicon deep sequencing (ADS). A complexity of infection (COI) analysis was conducted. De novo cytb Y268C mutants strains were observed during an episode of recrudescence 17 days and 16 h after the initial malaria diagnosis and AP treatment initiation. No Y268C mutant reads were observed in any of the samples prior to the recrudescence. SNPs in the dhfr and dhps genes were observed upon initial presentation. The haplotyping profiles suggest multiple clones mutating under AP selection pressure (COI > 3). Significant differences in COI were observed by capillary electrophoresis and ADS compared to the agarose gel results. ADS using cpmp revealed the lowest haplotype variation across the longitudinal analysis. Our findings highlight the value of ultra-deep sequencing methods in the understanding of P. falciparum haplotype infection dynamics. Longitudinal samples should be analyzed in genotyping studies to increase the analytical sensitivity.
Collapse
Affiliation(s)
- Daniel Castañeda-Mogollón
- Cumming School of Medicine, Department of Pathology & Laboratory Medicine, the University of Calgary, Calgary, Alberta, Canada
- Cumming School of Medicine, Department of Microbiology, Immunology, and Infectious Diseases, the University of Calgary, Calgary, Alberta, Canada
- Calvin, Phoebe & Joan Snyder Institute for Chronic Diseases, the University of Calgary, Calgary, Alberta, Canada
| | - Noah B. Toppings
- Cumming School of Medicine, Department of Pathology & Laboratory Medicine, the University of Calgary, Calgary, Alberta, Canada
- Cumming School of Medicine, Department of Microbiology, Immunology, and Infectious Diseases, the University of Calgary, Calgary, Alberta, Canada
- Calvin, Phoebe & Joan Snyder Institute for Chronic Diseases, the University of Calgary, Calgary, Alberta, Canada
| | - Claire Kamaliddin
- Cumming School of Medicine, Department of Pathology & Laboratory Medicine, the University of Calgary, Calgary, Alberta, Canada
- Cumming School of Medicine, Department of Microbiology, Immunology, and Infectious Diseases, the University of Calgary, Calgary, Alberta, Canada
- Calvin, Phoebe & Joan Snyder Institute for Chronic Diseases, the University of Calgary, Calgary, Alberta, Canada
| | - Raynell Lang
- Cumming School of Medicine, Department of Medicine, the University of Calgary, Calgary, Alberta, Canada
- Cumming School of Medicine, Department of Community Health Sciences, the University of Calgary, Calgary, Alberta, Canada
| | - Susan Kuhn
- Cumming School of Medicine, Department of Pediatrics, the University of Calgary, Calgary, Alberta, Canada
| | - Dylan R. Pillai
- Cumming School of Medicine, Department of Pathology & Laboratory Medicine, the University of Calgary, Calgary, Alberta, Canada
- Cumming School of Medicine, Department of Microbiology, Immunology, and Infectious Diseases, the University of Calgary, Calgary, Alberta, Canada
- Calvin, Phoebe & Joan Snyder Institute for Chronic Diseases, the University of Calgary, Calgary, Alberta, Canada
- Alberta Precision Laboratories, Diagnostic & Scientific Centre, Calgary, Alberta, Canada
| |
Collapse
|
8
|
Schade A, Bader A, Huber T, Kuhn S, Czyszanowski T, Pfenning A, Rygała M, Smołka T, Motyka M, Sęk G, Hartmann F, Höfling S. Monolithic high contrast grating on GaSb/AlAsSb based epitaxial structures for mid-infrared wavelength applications. Opt Express 2023; 31:16025-16034. [PMID: 37157690 DOI: 10.1364/oe.487119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
We demonstrate monolithic high contrast gratings (MHCG) based on GaSb/AlAs0.08Sb0.92 epitaxial structures with sub-wavelength gratings enabling high reflection of unpolarized mid-infrared radiation at the wavelength range from 2.5 to 5 µm. We study the reflectivity wavelength dependence of MHCGs with ridge widths ranging from 220 to 984 nm and fixed 2.6 µm grating period and demonstrate that peak reflectivity of above 0.7 can be shifted from 3.0 to 4.3 µm for ridge widths from 220 to 984 nm, respectively. Maximum reflectivity of up to 0.9 at 4 µm can be achieved. The experiments are in good agreement with numerical simulations, confirming high process flexibility in terms of peak reflectivity and wavelength selection. MHCGs have hitherto been regarded as mirrors enabling high reflection of selected light polarization. With this work, we show that thoughtfully designed MHCG yields high reflectivity for both orthogonal polarizations simultaneously. Our experiment demonstrates that MHCGs are promising candidates to replace conventional mirrors like distributed Bragg reflectors to realize resonator based optical and optoelectronic devices such as resonant cavity enhanced light emitting diodes and resonant cavity enhanced photodetectors in the mid-infrared spectral region, for which epitaxial growth of distributed Bragg reflectors is challenging.
Collapse
|
9
|
Doucette EJ, Gray J, Fonseca K, Charlton C, Kanji JN, Tipples G, Kuhn S, Dunn J, Sayers P, Symonds N, Wu G, Freedman SB, Kellner JD. A longitudinal seroepidemiology study to evaluate antibody response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Canada from July 2020 to April 2022: Alberta COVID-19 Childhood Cohort (AB3C) Study. PLoS One 2023; 18:e0284046. [PMID: 37023007 PMCID: PMC10079115 DOI: 10.1371/journal.pone.0284046] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2022] [Accepted: 03/22/2023] [Indexed: 04/07/2023] Open
Abstract
BACKGROUND Measurement of SARS-CoV-2 antibody seropositivity is important to accurately understand exposure to infection and/or vaccination in specific populations. This study aimed to estimate the serologic response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Alberta over a two-year period. METHODS Children with or without prior SARS-CoV-2 infections, were enrolled in Calgary, Canada in 2020. Venous blood was sampled 4 times from July 2020 to April 2022 for SARS-CoV-2 nucleocapsid and spike antibodies. Demographic and clinical information was obtained including SARS-CoV-2 testing results and vaccination records. RESULTS 1035 children were enrolled and 88.9% completed all 4 visits; median age 9 years (IQR: 5,13); 519 (50.1%) female; and 815 (78.7%) Caucasian. Before enrolment, 118 (11.4%) had confirmed or probable SARS-CoV-2. By April 2022, 39.5% of previously uninfected participants had a SARS-CoV-2 infection. Nucleocapsid antibody seropositivity declined to 16.4% of all infected children after more than 200 days post diagnosis. Spike antibodies remained elevated in 93.6% of unvaccinated infected children after more than 200 days post diagnosis. By April 2022, 408 (95.6%) children 12 years and older had received 2 or more vaccine doses, and 241 (61.6%) 5 to 11 year-old children had received 2 vaccine doses. At that time, all 685 vaccinated children had spike antibodies, compared with 94/176 (53.4%) of unvaccinated children. CONCLUSIONS In our population, after the first peak of Omicron variant infections and introduction of COVID-19 vaccines for children, all vaccinated children, but just over one-half of unvaccinated children, had SARS-CoV-2 spike antibodies indicating infection and/or vaccination, highlighting the benefit of vaccination. It is not yet known whether a high proportion of seropositivity at the present time predicts sustained population-level protection against future SARS-CoV-2 transmission, infection or severe COVID-19 outcomes in children.
Collapse
Affiliation(s)
- Emily J. Doucette
- Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Joslyn Gray
- Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Kevin Fonseca
- Department of Microbiology, Immunology & Infectious Diseases, University of Calgary, Calgary, Alberta, Canada
- Public Health Laboratory, Alberta Precision Laboratories, Alberta, Canada
| | - Carmen Charlton
- Public Health Laboratory, Alberta Precision Laboratories, Alberta, Canada
- Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
- Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada
| | - Jamil N. Kanji
- Public Health Laboratory, Alberta Precision Laboratories, Alberta, Canada
- Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
- Department of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
- Division of Infectious Diseases, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Graham Tipples
- Public Health Laboratory, Alberta Precision Laboratories, Alberta, Canada
- Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada
- Department of Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
| | - Susan Kuhn
- Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Jessica Dunn
- Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Payton Sayers
- Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Nicola Symonds
- School of Medicine, Queen’s University, Kingston, Ontario, Canada
| | - Guosong Wu
- Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
| | - Stephen B. Freedman
- Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
- Department of Emergency Medicine, University of Calgary, Calgary, Alberta, Canada
| | - James D. Kellner
- Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
- Alberta Children’s Hospital Research Institute, University of Calgary, Calgary, AB, Canada
| |
Collapse
|
10
|
Díaz-Menéndez M, Angelo KM, de Miguel Buckley R, Bottieau E, Huits R, Grobusch MP, Gobbi FG, Asgeirsson H, Duvignaud A, Norman FF, Javelle E, Epelboin L, Rothe C, Chappuis F, Martinez GE, Popescu C, Camprubí-Ferrer D, Molina I, Odolini S, Barkati S, Kuhn S, Vaughan S, McCarthy A, Lago M, Libman MD, Hamer DH. Dengue outbreak amongst travellers returning from Cuba-GeoSentinel surveillance network, January-September 2022. J Travel Med 2023; 30:taac139. [PMID: 36573483 PMCID: PMC10166199 DOI: 10.1093/jtm/taac139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/24/2022] [Revised: 10/21/2022] [Accepted: 11/14/2022] [Indexed: 12/28/2022]
Abstract
Increasing numbers of travellers returning from Cuba with dengue virus infection were reported to the GeoSentinel Network from June to September 2022, reflecting an ongoing local outbreak. This report demonstrates the importance of travellers as sentinels of arboviral outbreaks and highlights the need for early identification of travel-related dengue.
Collapse
Affiliation(s)
- Marta Díaz-Menéndez
- Tropical Medicine Department, Hospital Universitario La Paz Carlos III, CIBERINFECT, Pso de la Castellana, 261, 28046 Madrid, Spain
| | - Kristina M Angelo
- Division of Global Migration and Quarantine, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30329, USA
| | - Rosa de Miguel Buckley
- Tropical Medicine Department, Hospital Universitario La Paz Carlos III, CIBERINFECT, Pso de la Castellana, 261, 28046 Madrid, Spain
| | - Emmanuel Bottieau
- Department of Clinical Sciences, Institute of Tropical Medicine, 155 Nationalestraat, Antwerp 2000, Belgium
| | - Ralph Huits
- Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Via don A. Sempreboni, 5, 37024 Negrar, Verona, Italy
| | - Martin P Grobusch
- Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Center, AMC, Amsterdam Infection & Immunity, Amsterdam Public Health, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
| | - Federico Giovanni Gobbi
- Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Via don A. Sempreboni, 5, 37024 Negrar, Verona, Italy
| | - Hilmir Asgeirsson
- Department of Infectious Diseases, Karolinska University Hospital, 14186 Stockholm, Sweden
- Division of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, 14186 Stockholm, Sweden
| | - Alexandre Duvignaud
- Department of Infectious Diseases and Tropical Medicine, Hôpital Pellegrin, CHU Bordeaux, Place Amélie Raba Léon, 33076 Bordeaux, France
| | - Francesca F Norman
- Unidad de Medicina Tropical-Servicio de Enfermedades Infecciosas-Hospital Ramon y Cajal, C'tra de Calmenar Km. 9,1, Madrid 08001, Spain
| | - Emilie Javelle
- IHU-Méditerranée Infection, 19-21 Boulevard Jean Moulin, Marseille 13005, France
| | - Loïc Epelboin
- Centre Hospitalier Andree Rosemon, Av des flamboyants, Cayenne 97036, France
| | - Camilla Rothe
- Department of Infectious Diseases and Tropical Medicine, Ludwig-Maximilians-Universität München, Leopoldstrasse 5, 80802 Munich, Germany
| | - Francois Chappuis
- Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, 6 rue Gabrielle Perret Gentil, Geneva 1205, Switzerland
| | - Gabriela Equihua Martinez
- Institute of Tropical Medicine and International Health-Charité-Universitätsmedizin Berlin, Spandauer Damm 130, Berlin 10117, Germany
| | - Corneliu Popescu
- Carol Davila University of Medicine and Pharmacy, Dionisie Lupu St., 37, Sector 2, Bucharest 050474, Romania
- Dr Victor Babes Clinical Hospital and Infectious Diseases, Strada Gheorghe Adam 13, Timișoara 300310, Romania
| | - Daniel Camprubí-Ferrer
- ISGlobal, Hospital Clinic Universitat de Barcelona, Roselló, 132, 08036 Barcelona, Spain
| | - Israel Molina
- Hospital Universitari Vall d'Hebron, P° Vall d'Hebron 119, Barcelona 08035, Spain
| | - Silvia Odolini
- University Division of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia 25123, Italy
| | - Sapha Barkati
- J.D. MacLean Centre for Tropical Diseases, McGill University Health Centre, 1001 boul Decarie, Montreal, QC H4A 3J1, Canada
| | - Susan Kuhn
- Alberta Children's Hospital, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada
| | - Stephen Vaughan
- Alberta Children's Hospital, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada
| | - Anne McCarthy
- The Ottawa Hospital Civic Campus, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada
| | - Mar Lago
- Tropical Medicine Department, Hospital Universitario La Paz Carlos III, CIBERINFECT, Pso de la Castellana, 261, 28046 Madrid, Spain
| | - Michael D Libman
- J.D. MacLean Centre for Tropical Diseases, McGill University Health Centre, 1001 boul Decarie, Montreal, QC H4A 3J1, Canada
| | - Davidson H Hamer
- Department of Global Health, Boston University School of Public Health; Section of Infectious Diseases, Boston University School of Medicine; Center for Infectious Disease Policy and Research, Boston University; and National Emerging Infectious Disease Laboratory, Crosstown 308, 801 Massachusetts Avenue, Boston, MA 02118, USA
| |
Collapse
|
11
|
Rothweiler R, Kuhn S, Stark T, Heinemann S, Hoess A, Fuessinger MA, Brandenburg LS, Roelz R, Metzger MC, Hubbe U. Development of a new critical size defect model in the paranasal sinus and first approach for defect reconstruction-An in vivo maxillary bone defect study in sheep. J Mater Sci Mater Med 2022; 33:76. [PMID: 36264396 PMCID: PMC9584845 DOI: 10.1007/s10856-022-06698-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 04/04/2022] [Accepted: 09/22/2022] [Indexed: 06/16/2023]
Abstract
Fractures of the paranasal sinuses often require surgical intervention. Persisting bone defects lead to permanent visible deformities of the facial contours. Bone substitutes for reconstruction of defects with simultaneous induction of new bone formation are not commercially available for the paranasal sinus. New materials are urgently needed and have to be tested in their future area of application. For this purpose critical size defect models for the paranasal sinus have to be developed. A ≥2.4 cm large bilateral circular defect was created in the anterior wall of the maxillary sinus in six sheep via an extraoral approach. The defect was filled with two types of an osteoconductive titanium scaffold (empty scaffold vs. scaffold filled with a calcium phosphate bone cement paste) or covered with a titanium mesh either. Sheep were euthanized after four months. All animals performed well, no postoperative complications occured. Meshes and scaffolds were safely covered with soft tissue at the end of the study. The initial defect size of ≥2.4 cm only shrunk minimally during the investigation period confirming a critical size defect. No ingrowth of bone into any of the scaffolds was observed. The anterior wall of the maxillary sinus is a region with low complication rate for performing critical size defect experiments in sheep. We recommend this region for experiments with future scaffold materials whose intended use is not only limited to the paranasal sinus, as the defect is challenging even for bone graft substitutes with proven osteoconductivity. Graphical abstract.
Collapse
Affiliation(s)
- R Rothweiler
- Department of Oral and Maxillofacial Surgery, Faculty of Medicine, University of Freiburg, Hugstetter Straße 55, 79106, Freiburg, Germany.
| | - S Kuhn
- Stryker Leibinger GmbH & Co. KG, Bötzinger Straße 41, 79111, Freiburg, Germany
| | - T Stark
- Stryker Leibinger GmbH & Co. KG, Bötzinger Straße 41, 79111, Freiburg, Germany
| | - S Heinemann
- INNOTERE GmbH, Meissner Str. 191, 01445, Radebeul, Germany
| | - A Hoess
- INNOTERE GmbH, Meissner Str. 191, 01445, Radebeul, Germany
| | - M A Fuessinger
- Department of Oral and Maxillofacial Surgery, Faculty of Medicine, University of Freiburg, Hugstetter Straße 55, 79106, Freiburg, Germany
| | - L S Brandenburg
- Department of Oral and Maxillofacial Surgery, Faculty of Medicine, University of Freiburg, Hugstetter Straße 55, 79106, Freiburg, Germany
| | - R Roelz
- Department of Neurosurgery, Faculty of Medicine, University of Freiburg, Breisacher Str. 64, 79106, Freiburg, Germany
| | - M C Metzger
- Department of Oral and Maxillofacial Surgery, Faculty of Medicine, University of Freiburg, Hugstetter Straße 55, 79106, Freiburg, Germany
| | - U Hubbe
- Department of Neurosurgery, Faculty of Medicine, University of Freiburg, Breisacher Str. 64, 79106, Freiburg, Germany.
| |
Collapse
|
12
|
Kuhn S, Lehmann K, Verthein U. Evaluation der 3. Verordnung zur Änderung der
Betäubungsmittel-Verschreibungsverordnung (3.BtMVVÄndV):
Ergebnisse im Überblick. Suchttherapie 2022. [DOI: 10.1055/s-0042-1755972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/22/2023]
Affiliation(s)
- S Kuhn
- Universitätsklinikum Hamburg-Eppendorf, Zentrum für
Interdisziplinäre Suchtforschung der Universität Hamburg (ZIS),
Hamburg
| | - K Lehmann
- Universitätsklinikum Hamburg-Eppendorf, Zentrum für
Interdisziplinäre Suchtforschung der Universität Hamburg (ZIS),
Hamburg
| | - U Verthein
- Universitätsklinikum Hamburg-Eppendorf, Zentrum für
Interdisziplinäre Suchtforschung der Universität Hamburg (ZIS),
Hamburg
| |
Collapse
|
13
|
Lehmann K, Kuhn S, Verthein U. Substitutionsbehandlung Opioidabhängiger unter der
COVID-19-Pandemie. Suchttherapie 2022. [DOI: 10.1055/s-0042-1756101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/22/2023]
Affiliation(s)
- K Lehmann
- Zentrum für Interdisziplinäre Suchtforschung der
Universität Hamburg, Hamburg
| | - S Kuhn
- Zentrum für Interdisziplinäre Suchtforschung der
Universität Hamburg, Hamburg
| | - U Verthein
- Zentrum für Interdisziplinäre Suchtforschung der
Universität Hamburg, Hamburg
| |
Collapse
|
14
|
Yeo J, Furr Gudmundsen C, Fazel S, Corrigan A, Fullerton MM, Hu J, Jadavji T, Kuhn S, Kassam A, Constantinescu C. A Behavior Change Model to Address Caregiver Hesitancy around COVID-19 Vaccination in Pediatrics. Vaccine 2022; 40:5664-5669. [PMID: 35987872 PMCID: PMC9353609 DOI: 10.1016/j.vaccine.2022.08.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Revised: 07/30/2022] [Accepted: 08/01/2022] [Indexed: 11/16/2022]
Abstract
Introduction Many families express hesitancy around immunizing their children against COVID-19. We sought to better understand the perspectives of vaccine hesitant caregivers, and develop targeted recommendations for health care workers and policymakers to engage in more effective vaccine discussions. Methods We conducted semi-structured telephone interviews with 23 caregivers recruited from a pediatric infectious diseases clinic, including a subset of patients referred to discuss vaccine hesitancy. Thematic analysis of the interviews identified themes that were mapped using behavior change models to identify perceived barriers and facilitators towards COVID-19 immunization. Results Barriers and facilitators were mapped to the WHO (World Health Organization) 3C’s (confidence, complacency, convenience) model of vaccine hesitancy as well as the COM-B (capability, opportunity, motivation) behavior change model. Barriers included mistrust in authorities, misperception of the risk of COVID-19 in children, and perceived health contraindications and negative previous vaccine experiences. Facilitators included positive relationships with healthcare workers, the promise of a “return to normal”, and societal pressures to immunize. Conclusions Efforts to increase vaccine uptake in the pediatric population must target specific barriers and facilitators to immunization expressed by caregivers. To address these concerns, we suggest: 1. Educating hesitant caregivers by highlighting the long-term pandemic effects on children and the threat of COVID-19 to children’s health, 2. Building on the trust caregivers have in healthcare workers by involving frontline workers in public health policy, and 3. Harnessing the power of peer pressure by mobilization of societal pressures and establishing COVID-19 vaccination as the norm in children.
Collapse
Affiliation(s)
- Jordan Yeo
- Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
| | | | - Sajjad Fazel
- Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
| | - Alex Corrigan
- Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
| | | | - Jia Hu
- Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada
| | - Taj Jadavji
- Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Section of Pediatric Infectious Diseases, Alberta Children's Hospital, Calgary, AB, Canada
| | - Susan Kuhn
- Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Section of Pediatric Infectious Diseases, Alberta Children's Hospital, Calgary, AB, Canada
| | - Aliya Kassam
- Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada
| | - Cora Constantinescu
- Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Section of Pediatric Infectious Diseases, Alberta Children's Hospital, Calgary, AB, Canada.
| |
Collapse
|
15
|
Hubbe U, Beiser S, Kuhn S, Stark T, Hoess A, Cristina-Schmitz H, Vasilikos I, Metzger MC, Rothweiler R. A fully ingrowing implant for cranial reconstruction: Results in critical size defects in sheep using 3D-printed titanium scaffold. Biomater Adv 2022; 136:212754. [PMID: 35929289 DOI: 10.1016/j.bioadv.2022.212754] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Revised: 02/23/2022] [Accepted: 03/06/2022] [Indexed: 06/15/2023]
Abstract
Current alloplastic materials such as PMMA, titanium or PEEK don't show relevant bone ingrowth into the implant when used for cranioplasty, ceramic implants have the drawback being brittle. New materials and implant designs are urgently needed being biocompatible, stable enough for cranioplasty and stimulating bone formation. In an in vivo critical size sheep model circular cranial defects (>2.4 cm) were covered with three different types of a 3D-printed porous titanium scaffolds with multidirectional, stochastically distributed architecture (uncoated scaffold, hydroxyapatite-coated scaffold, uncoated scaffold filled with a calcium phosphate bone cement paste containing β-TCP granules). An empty titanium mesh served as control. Among the different investigated setups the hydroxyapatite-coated scaffolds showed a surprisingly favourable performance. Push-out tests revealed a 2.9 fold higher force needed in the hydroxyapatite-coated scaffolds compared to the mesh group. Mean CT density at five different points inside the scaffold was 2385HU in the hydroxyapatite-coated group compared to 1978HU in the uncoated scaffold at nine months. Average lateral bone ingrowth after four months in the hydroxyapatite-coated scaffold group was up to the implant center, 12.1 mm on average, compared to 2.8 mm in the control group covered with mesh only. These properties make the investigated scaffold with multidirectional, stochastically distributed structure superior to all products currently on the market. The study gives a good idea of what future materials for cranioplasty might look like.
Collapse
Affiliation(s)
- U Hubbe
- Department of Neurosurgery, Faculty of Medicine, University of Freiburg, Breisacher Str. 64, Freiburg 79106, Germany.
| | - S Beiser
- Department of Neurosurgery, Faculty of Medicine, University of Freiburg, Breisacher Str. 64, Freiburg 79106, Germany.
| | - S Kuhn
- Stryker Leibinger GmbH & Co. KG, Bötzinger Straße 41, Freiburg 79111, Germany.
| | - T Stark
- Stryker Leibinger GmbH & Co. KG, Bötzinger Straße 41, Freiburg 79111, Germany.
| | - A Hoess
- INNOTERE GmbH, Meissner Str. 191, Radebeul, 01445, Germany
| | - H Cristina-Schmitz
- Division of Experimental Surgery, Center for Experimental Models and Transgenic Services, Germany; Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany.
| | - I Vasilikos
- Department of Neurosurgery, Faculty of Medicine, University of Freiburg, Breisacher Str. 64, Freiburg 79106, Germany.
| | - M C Metzger
- Department of Oral and Maxillofacial Surgery, Faculty of Medicine, University of Freiburg, Hugstetter Straße 55, Freiburg 79106, Germany.
| | - R Rothweiler
- Department of Oral and Maxillofacial Surgery, Faculty of Medicine, University of Freiburg, Hugstetter Straße 55, Freiburg 79106, Germany.
| |
Collapse
|
16
|
Robinson PD, Vaughan S, Missaghi B, Meatherall B, Pattullo A, Kuhn S, Conly J. A case series of infectious complications in medical tourists requiring hospital admission or outpatient home parenteral therapy. J Assoc Med Microbiol Infect Dis Can 2022; 7:64-74. [PMID: 36340853 PMCID: PMC9603019 DOI: 10.3138/jammi-2021-0015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/28/2021] [Revised: 09/09/2021] [Accepted: 09/24/2021] [Indexed: 06/16/2023]
Abstract
BACKGROUND Travelling for medical care is increasing, and this medical tourism (MT) may have complications, notably infectious diseases (ID). We sought to identify MT-related infections (MTRIs) in a large Canadian health region and estimate resulting costs. METHODS Retrospective and prospective capture of post-MT cases requiring hospital admission or outpatient parenteral antimicrobial therapy was completed by canvassing ID physicians practising in Calgary, Alberta, from January 2017 to July 2019. Cost estimates for management were made with the Canadian Institute for Health Information's (CIHI's) patient cost estimator database tool applied to estimated rates of Canadians engaging in MT from a 2017 Fraser Institute report. RESULTS We identified 12 cases of MT-related infectious syndromes. Eight had microbial etiologies identified. MTs were young (mean 40.3 [SD 12.2] y) and female (n = 11) and pursued surgical treatment (n = 11). Destination countries and surgical procedures varied but were largely cosmetic (n = 5) and orthopaedic (n = 3). Duration to organism identification (mean 5.3 wk) and treatment courses (mean 19 wk) appeared lengthy. CIHI cost estimates for management of relevant infectious complications of our cases ranged from $6,288 to $20,741, with total cost for cases with matching codes (n = 8) totalling $94,290. CONCLUSIONS In our series of MTRIs, etiologic organisms often found in Canadian-performed post-procedural infections were identified, and prolonged treatment durations were noted. Young women pursuing cosmetic surgery may be a population to target with public health measures to reduce the incidence of MTRIs and burden of disease.
Collapse
Affiliation(s)
- Paul D Robinson
- Department of Medicine, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada
| | - Stephen Vaughan
- Department of Medicine, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada
- Synder Institute for Chronic Diseases, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada
| | - Bayan Missaghi
- Department of Medicine, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada
| | - Bonnie Meatherall
- Department of Medicine, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada
| | - Andrew Pattullo
- Department of Medicine, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada
| | - Susan Kuhn
- Department of Pediatrics, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada
| | - John Conly
- Department of Medicine, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada
- Department of Pediatrics, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada
- Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada
- Synder Institute for Chronic Diseases, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada
- O’Brien Institute for Public Health, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada
| |
Collapse
|
17
|
Mah J, Bakker A, Tseng C, Lafay-Cousin L, Kuhn S, Brundler MA, Lisboa LF. Isolated Pulmonary Emergomycosis in an Immunocompetent Patient in Alberta, Canada. Open Forum Infect Dis 2022; 9:ofac021. [PMID: 35174253 PMCID: PMC8843081 DOI: 10.1093/ofid/ofac021] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Accepted: 01/11/2022] [Indexed: 11/30/2022] Open
Abstract
Emergomyces canadensis pulmonary infection was incidentally diagnosed in an asymptomatic patient suspected to have metastatic osteosarcoma. Molecular diagnosis was imperative to fungal identification given overlapping histopathological features with histoplasmosis. This report documents a case of isolated pulmonary emergomycosis in an otherwise immunocompetent patient while discussing diagnostic and management pitfalls of this emerging and underdiagnosed infection.
Collapse
Affiliation(s)
- Jordan Mah
- Section of Infectious Diseases, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Andrea Bakker
- Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Calvin Tseng
- Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Lucie Lafay-Cousin
- Section of Pediatric Hematology Oncology and Bone Marrow Transplantation, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada
| | - Susan Kuhn
- Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Marie-Anne Brundler
- Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.,Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Luiz F Lisboa
- Section of Microbiology, Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| |
Collapse
|
18
|
Yeo J, Gudmundsen C, Fazel S, Corrigan A, Fullerton M, Gagneur A, Hu J, Jadavji T, Kuhn S. 80 Archetypes of vaccine hesitant caregivers towards COVID-19 immunization during a global pandemic: A qualitative study. Paediatr Child Health 2021. [PMCID: PMC8689839 DOI: 10.1093/pch/pxab061.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Primary Subject area
Public Health and Preventive Medicine
Background
As Canada embarks on its rollout of the COVID-19 vaccine, vaccine hesitancy has the potential to hamper success of the vaccination campaign. Multiple surveys show that the number of Canadians willing to take the vaccine is insufficient to achieve herd immunity. Therefore, governments and health agencies are looking for solutions to increase vaccination uptake. Obtaining a better understanding of the perspective of those who are vaccine-hesitant is critical to developing successful implementation strategies for COVID-19 vaccination.
Objectives
To explore COVID-19 vaccination determinants among hesitant caregivers and describe categories of COVID-19 vaccine hesitancy.
Design/Methods
We conducted 23 semi-structured telephone interviews with parents recruited from a tertiary pediatric care centre. Seventeen participants had previously attended a specialty clinic to discuss vaccine hesitancy; the remaining were recruited from an infectious diseases follow-up clinic. The interview guide was structured around the Theoretical Domains Framework, assessing 14 behavioural constructs to identify specific determinants that guide behaviour change. Interviews were audio-recorded, transcribed, and analyzed by two independent data coders using a pragmatic inductive approach. Recurring themes were noted among subgroups of participants, who were subsequently divided into categories based on their underlying concerns.
Results
Five archetypes of vaccine-hesitant caregivers emerged in our data (Table 1). 1). “Bubble Dwellers” perceive themselves to be safe by following public health recommendations, and distinguish themselves from higher-risk groups to whom the vaccine should first be offered. 2). “Worriers and Delayers” identify the pandemic as a threat and are generally supportive of vaccines, but are concerned about side effects and issues surrounding vaccine development and prefer to delay vaccination. 3). “Need-for-Normals” are more concerned about social isolation and the economy than the direct effects of the COVID-19 virus, but express that the idea of a “return to normal” may sway their opinions regarding the vaccine. 4). “Exceptionalists” hold personal misperceptions of vaccine contraindications due to comorbidities or previous experiences with vaccination, and are concerned that the current rollout invokes a “one size fits all” model that does not apply to their circumstances. 5. “Freedom Fighters” view the pandemic as a hoax, are anti-establishment, and believe the information they have been provided is not convincing for them to adopt the vaccine.
Conclusion
The evolving pandemic provides a unique opportunity to understand determinants of vaccination intention in the vaccine hesitant population. Our qualitative study is unique in that we were able to draw upon pre-identified vaccine hesitant individuals to explore their perspectives around COVID-19 immunization. We propose that rather than viewing these individuals as one homogenous group, policymakers and health professionals address these discrete subgroups with specific communication tools and information. We are hopeful that our results will help tailor implementation strategies that are targeted to different vaccine hesitancy archetypes, as the vaccine is made available to the general public in the coming year.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Jia Hu
- Alberta Medical Association
| | | | - Susan Kuhn
- University of Calgary Cora Constantinescu University of Calgary
| |
Collapse
|
19
|
Comtois J, Camara-Lemarroy CR, Mah JK, Kuhn S, Curtis C, Braun MH, Tellier R, Burton JM. Longitudinally extensive transverse myelitis with positive aquaporin-4 IgG associated with dengue infection: a case report and systematic review of cases. Mult Scler Relat Disord 2021; 55:103206. [PMID: 34418736 DOI: 10.1016/j.msard.2021.103206] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2021] [Revised: 07/03/2021] [Accepted: 08/06/2021] [Indexed: 10/20/2022]
Abstract
BACKGROUND Neuromyelitis Optica Spectrum Disorder can be associated with parainfectious and post-infectious triggers. Dengue virus infection is one of the most common arbovirus infections in the world, and may present with neurological manifestations. OBJECTIVES We present a case of DENV-associated with LETM and positive aquaporin-4 IgG, and a systematic review of published cases. METHODS Medline (Ovid) and PubMed were search through June 2021, for case reports, series and observational studies that described patients with DENV-associated LETM and/or NMOSD. RESULTS An adolescent girl who had recently immigrated from a Dengue-endemic region presented with a LETM with high positive AQP4-IgG titer and seropositive DENV IgM/IgG antibodies. She responded well to steroids and subsequently started maintenance rituximab for her NMOSD diagnosis. LITERATURE REVIEW 22 publications describing 27 patients met inclusion criteria. In addition to this case, three published cases met current criteria for NMOSD with serological evidence of acute DENV infection. CONCLUSIONS It is unknown whether there is a pathophysiological association between DENV infection and NMOSD. Regardless, if an immune-mediated event is suspected, particularly NMOSD, appropriate immunotherapy should be considered early. Decision regarding long term immunotherapy may depend on index of suspicion of true NMOSD, and this is where AQP4-IgG status and follow-up is helpful.
Collapse
Affiliation(s)
- Jacynthe Comtois
- Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Medicine, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada; Department of neurosciences, Faculty of medicine, University of Montreal, Montreal, Quebec, Canada
| | - Carlos R Camara-Lemarroy
- Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
| | - Jean K Mah
- Division of Pediatric Neurology, Department of Pediatrics, Cumming School of Medicine, University of Calgary, Alberta, Canada
| | - Susan Kuhn
- Division of Infectious Diseases, Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Colleen Curtis
- Division of Pediatric Neurology, Department of Pediatrics, Cumming School of Medicine, University of Calgary, Alberta, Canada
| | - Marvin H Braun
- Division of Pediatric Neurology, Department of Pediatrics, Cumming School of Medicine, University of Calgary, Alberta, Canada
| | - Raymond Tellier
- Division of Infectious diseases, Department of Medicine, McGill University, Montreal, Quebec, Canada
| | - Jodie M Burton
- Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Clinical Neurosciences and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
| |
Collapse
|
20
|
Konje ET, Hatfield J, Sauve R, Kuhn S, Magoma M, Dewey D. Late initiation and low utilization of postnatal care services among women in the rural setting in Northwest Tanzania: a community-based study using a mixed method approach. BMC Health Serv Res 2021; 21:635. [PMID: 34215254 PMCID: PMC8252323 DOI: 10.1186/s12913-021-06695-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2020] [Accepted: 06/24/2021] [Indexed: 11/15/2022] Open
Abstract
Background Maternal and newborn mortality is high immediately after childbirth and up to 42 days postnatally despite the availability of interventions. Postnatal care is crucial in preventing mortality and improving the health of women and newborns. This prospective cohort study investigated the initiation and utilization of postnatal care at health facilities and explored users’ and providers’ perspectives on utilization of postnatal care services. Methods A sequential explanatory mixed method was used involving women who were followed from the 3rd trimester of pregnancy to 3–4 months postnatally in Northwest, Tanzania. From January to December 2018, a door-to-door survey was conducted 3–4 months postnatally among 1385 of these women. A convenience sample of women and community health workers participated in focus group discussions, and traditional birth attendants and nurses participated in key informant interviews to complement quantitative data. Data analyses were conducted using STATA version 13 and NVIVO version 12. Study findings Approximately, one half of participants attended postnatal care within 42 days after delivery. Postnatal care seeking within 48 h after delivery was reported by 14.6 % of the participants. Women who attended antenatal care at least four times, delivered at health facilities or experienced delivery-related complications were more likely to seek postnatal care. Limited knowledge on the postnatal care services and obstetric complications after childbirth, and not being scheduled for postnatal care by health providers negatively influenced services uptake. Overwhelming workload and shortages of supplies were reported to hinder the provision of postnatal care services. Conclusions Utilization of postnatal care services remains low in this setting as a result of a number of disparate and complex factors that influence women’s choices. Provision of effective postnatal care is hindered by lack of supplies, staffing, and inadequate infrastructure. To ensure accessibility and availability of quality services in this setting, both demand and supply sides factors need to be addressed. Supplementary Information The online version contains supplementary material available at 10.1186/s12913-021-06695-8.
Collapse
Affiliation(s)
- Eveline T Konje
- Department of Biostatistics and Epidemiology, School of Public Health, Catholic University of Health and Allied Sciences, Mwanza, Tanzania. .,Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Alberta, Calgary, Canada.
| | - Jennifer Hatfield
- Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Alberta, Calgary, Canada
| | - Reg Sauve
- Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Alberta, Calgary, Canada
| | - Susan Kuhn
- Department of Paediatrics, University of Calgary, Alberta, Calgary, Canada
| | - Moke Magoma
- Engender Health Tanzania, Dar es Salaam, Tanzania
| | - Deborah Dewey
- Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Alberta, Calgary, Canada.,Department of Paediatrics, University of Calgary, Alberta, Calgary, Canada.,Owerko Centre, Cumming School of Medicine, Alberta Children's Hospital Research Institute, University of Calgary, Alberta, Calgary, Canada.,Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Alberta, Calgary, Canada
| |
Collapse
|
21
|
Goebel TA, Nold J, Hupel C, Kuhn S, Haarlammert N, Schreiber T, Matzdorf C, Imogore TO, Krämer RG, Richter D, Tünnermann A, Nolte S. Ultrashort pulse written fiber Bragg gratings as narrowband filters in multicore fibers. Appl Opt 2021; 60:D43-D51. [PMID: 34263827 DOI: 10.1364/ao.421089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Accepted: 04/13/2021] [Indexed: 06/13/2023]
Abstract
We present the inscription of narrow-linewidth fiber Bragg gratings (FBGs) into different types of multicore fibers (MCFs) using ultrashort laser pulses and the phase mask technique, which can act as notch filters. Such filters are required, e.g., to suppress light emitted by hydroxyl in the Earth's upper atmosphere, which disturbs ground-based observation of extraterrestrial objects in the near infrared. However, the inscription into a commercially available seven-core fiber showed a quite large core-to-core deviation of the resonance wavelength of up to 0.45 nm. Two options are presented to overcome this: first, we present the photo-treatment of the FBGs to tune the resonance wavelength, which allows for sufficient resonance shifts. Second, adapted MCFs containing 12 cores, arranged on a circle, are fabricated. For this, two different fabrication procedures were investigated, namely, the mechanical drilling of the preform for a rod-in-tube version as well as a stack-and-draw approach. Both adapted MCFs yielded significant improvements with core-to-core wavelength variations of the FBGs of only about 0.18 nm and 0.11 nm, respectively, sufficient to fulfill the requirements for astronomical filter applications as discussed above.
Collapse
|
22
|
Sinclair S, Bouchal SR, Schulte F, M T Guilcher G, Kuhn S, Rapoport A, Punnett A, Fernandez CV, Letourneau N, Chung J. Compassion in pediatric oncology: A patient, parent and healthcare provider empirical model. Psychooncology 2021; 30:1728-1738. [PMID: 34021652 PMCID: PMC8518637 DOI: 10.1002/pon.5737] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 05/12/2021] [Accepted: 05/17/2021] [Indexed: 12/30/2022]
Abstract
Objective Compassion has long been considered a cornerstone of quality pediatric healthcare by patients, parents, healthcare providers and systems leaders. However, little dedicated research on the nature, components and delivery of compassion in pediatric settings has been conducted. This study aimed to define and develop a patient, parent, and healthcare provider informed empirical model of compassion in pediatric oncology in order to begin to delineate the key qualities, skills and behaviors of compassion within pediatric healthcare. Methods Data was collected via semi‐structured interviews with pediatric oncology patients (n = 33), parents (n = 16) and healthcare providers (n = 17) from 4 Canadian academic medical centers and was analyzed in accordance with Straussian Grounded Theory. Results Four domains and 13 related themes were identified, generating the Pediatric Compassion Model, that depicts the dimensions of compassion and their relationship to one another. A collective definition of compassion was generated–a beneficent response that seeks to address the suffering and needs of a person and their family through relational understanding, shared humanity, and action. Conclusions A patient, parent, and healthcare provider informed empirical pediatric model of compassion was generated from this study providing insight into compassion from both those who experience it and those who express it. Future research on compassion in pediatric oncology and healthcare should focus on barriers and facilitators of compassion, measure development, and intervention research aimed at equipping healthcare providers and system leaders with tools and training aimed at improving it.
Collapse
Affiliation(s)
- Shane Sinclair
- Faculty of Nursing, University of Calgary, Calgary, Canada.,Department of Oncology, Division of Palliative Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada.,Compassion Research Lab, Faculty of Nursing, University of Calgary, Calgary, Canada
| | | | - Fiona Schulte
- Department of Oncology, Division of Psychosocial Oncology, Cumming School of Medicine, University of Calgary, Calgary, Canada
| | - Gregory M T Guilcher
- Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Canada.,Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Canada
| | - Susan Kuhn
- Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Canada
| | - Adam Rapoport
- Department of Paediatrics, University of Toronto, Toronto, Canada.,Department of Family & Community Medicine, University of Toronto, Toronto, Canada.,Emily's House Children Hospice, Toronto, Canada
| | - Angela Punnett
- Department of Paediatrics, University of Toronto, Toronto, Canada.,Division of Pediatric Haematology/Oncology, The Hospital for Sick Kids, Toronto, Canada
| | - Conrad V Fernandez
- Department of Pediatrics, IWK Health, Dalhousie University, Halifax, Canada
| | - Nicole Letourneau
- Faculty of Nursing, University of Calgary, Calgary, Canada.,Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Canada
| | - Joanna Chung
- Medical Psychology and Hematology/Oncology/BMT Program, British Columbia Children's Hospital, Vancouver, Canada
| |
Collapse
|
23
|
Offergeld C, Ketterer M, Neudert M, Hassepaß F, Weerda N, Richter B, Traser L, Becker C, Deeg N, Knopf A, Wesarg T, Rauch AK, Jakob T, Ferver F, Lang F, Vielsmeier V, Hackenberg S, Diensthuber M, Praetorius M, Hofauer B, Mansour N, Kuhn S, Hildenbrand T. ["Online from tomorrow on please": comparison of digital framework conditions of curricular teaching at national university ENT clinics in times of COVID-19 : Digital teaching at national university ENT clinics]. HNO 2020; 69:213-220. [PMID: 32929523 PMCID: PMC7490113 DOI: 10.1007/s00106-020-00939-5] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/07/2020] [Indexed: 11/30/2022]
Abstract
Hintergrund Die Corona-Krise beeinflusst nicht nur das professionelle Handeln, sondern auch die Lehre an den Universitäten. Schlagworte wie „E-Learning“ und „Digitalisierung“ suggerieren die Möglichkeit innovativer, ad hoc verfügbarer Lösungsansätze für die Lehre in der aktuellen COVID-19-Situation. Die aktuelle Umstellung auf digitale Lehre ist aber nicht primär durch eine didaktische Sinnhaftigkeit oder institutionelle Strategie, sondern durch äußere Notwendigkeit geprägt. Ziel der Arbeit Ziel der Arbeit war die Erfassung der Lehrsituation an nationalen Universitäts-HNO-Kliniken und akademischen Lehrkrankenhäusern zu Beginn des virtuellen Corona-Sommersemesters 2020. Material und Methode Ein eigens erstellter Fragebogen zur jeweiligen lokalen Situation, den örtlichen Rahmenbedingungen sowie zu bundesweiten Szenarien wurde an alle 39 nationalen Universitäts-HNO-Kliniken und 20 akademischen Lehrkrankenhäuser mit HNO-Hauptabteilung versandt. Ergebnisse Die ausgefüllten Fragebögen von 31 Universitätskliniken (UK) und 10 akademische Lehrkrankenhäuser (ALK) gingen in die Auswertung ein. Es zeigten sich offensichtliche Diskrepanzen zwischen verfügbaren Ressourcen und tatsächlich verfügbaren digitalisierten Lehrinhalten. Weitere Kritikpunkte offenbarten sich in Bezug auf die Kommunikation mit der Medizinischen Fakultät, die digitale Infrastruktur und insbesondere in der oftmals mangelnden Kollaboration mit den zentralen Supportstrukturen, wie Medien‑, Didaktik- und Rechenzentren. Schlussfolgerung Es gibt durchaus positive Beispiele für eine gelungene Überführung der Präsenzlehre in das ausschließlich virtuelle Sommersemester 2020 innerhalb der Universitäts-HNO-Kliniken. Mehrheitlich aber überwiegen kritische Einschätzungen der Lehrbeauftragten bzw. Ärztlichen Direktoren gegenüber der aktuellen Lehrsituation. Eine zeitkritische strategische Weiterentwicklung ist dringend erforderlich.
Collapse
Affiliation(s)
- C Offergeld
- Univ.-HNO-Klinik, Med. Fakultät, Albert-Ludwigs-Universität, Killianstraße 5, 79106, Freiburg, Deutschland.
| | - M Ketterer
- Univ.-HNO-Klinik, Med. Fakultät, Albert-Ludwigs-Universität, Killianstraße 5, 79106, Freiburg, Deutschland
| | - M Neudert
- Univ.-HNO-Klinik, Med. Fakultät, Technische Universität Dresden, Dresden, Deutschland
| | - F Hassepaß
- Univ.-HNO-Klinik, Med. Fakultät, Albert-Ludwigs-Universität, Killianstraße 5, 79106, Freiburg, Deutschland
| | - N Weerda
- Univ.-HNO-Klinik, Med. Fakultät, Albert-Ludwigs-Universität, Killianstraße 5, 79106, Freiburg, Deutschland
| | - B Richter
- Institut für Musikermedizin, Med. Fakultät, Albert-Ludwigs-Universität, Freiburg, Deutschland
| | - L Traser
- Institut für Musikermedizin, Med. Fakultät, Albert-Ludwigs-Universität, Freiburg, Deutschland
| | - C Becker
- Univ.-HNO-Klinik, Med. Fakultät, Albert-Ludwigs-Universität, Killianstraße 5, 79106, Freiburg, Deutschland
| | - N Deeg
- Univ.-HNO-Klinik, Med. Fakultät, Albert-Ludwigs-Universität, Killianstraße 5, 79106, Freiburg, Deutschland
| | - A Knopf
- Univ.-HNO-Klinik, Med. Fakultät, Albert-Ludwigs-Universität, Killianstraße 5, 79106, Freiburg, Deutschland
| | - T Wesarg
- Univ.-HNO-Klinik, Med. Fakultät, Albert-Ludwigs-Universität, Killianstraße 5, 79106, Freiburg, Deutschland
| | - A-K Rauch
- Univ.-HNO-Klinik, Med. Fakultät, Albert-Ludwigs-Universität, Killianstraße 5, 79106, Freiburg, Deutschland
| | - T Jakob
- Univ.-HNO-Klinik, Med. Fakultät, Albert-Ludwigs-Universität, Killianstraße 5, 79106, Freiburg, Deutschland
| | - F Ferver
- Univ.-HNO-Klinik, Med. Fakultät, Albert-Ludwigs-Universität, Killianstraße 5, 79106, Freiburg, Deutschland
| | - F Lang
- Univ.-HNO-Klinik, Med. Fakultät, Albert-Ludwigs-Universität, Killianstraße 5, 79106, Freiburg, Deutschland
| | - V Vielsmeier
- Univ.-HNO-Klinik, Med. Fakultät, Universität Regensburg, Regensburg, Deutschland
| | - S Hackenberg
- Univ.-HNO-Klinik, Med. Fakultät, Julius-Maximilians-Universität, Würzburg, Deutschland
| | - M Diensthuber
- Univ.-HNO-Klinik, Med. Fakultät, , Goethe Universität, Frankfurt/M, Deutschland
| | - M Praetorius
- Univ.-HNO-Klinik, Med. Fakultät, Ruprecht-Karls-Universität, Heidelberg, Deutschland
| | - B Hofauer
- Univ.-HNO-Klinik, Med. Fakultät, Albert-Ludwigs-Universität, Killianstraße 5, 79106, Freiburg, Deutschland
| | - N Mansour
- Univ.-HNO-Klinik, Med. Fakultät, Albert-Ludwigs-Universität, Killianstraße 5, 79106, Freiburg, Deutschland
| | - S Kuhn
- Zentrum für Orthopädie und Unfallchirurgie, Universitätsmedizin, Johannes Gutenberg-Universität, Mainz, Deutschland
| | - T Hildenbrand
- Univ.-HNO-Klinik, Med. Fakultät, Albert-Ludwigs-Universität, Killianstraße 5, 79106, Freiburg, Deutschland
| |
Collapse
|
24
|
Konje ET, Magoma MT, Hatfield J, Kuhn S, Sauve RS, Dewey D. No difference in perinatal mortality between home and facility delivery in rural Tanzania: a prospective community-based study. Journal of Global Health Reports 2020. [DOI: 10.29392/001c.14599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Affiliation(s)
- Eveline T Konje
- Department of Biostatistics & Epidemiology, School of Public Health, Catholic University of Health and Allied Sciences, Mwanza, Tanzania; Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Alberta, Canada
| | - Moke T Magoma
- Options Tanzania Ltd 76 Ali Hassan Mwinyi Road, Dar es Salaam Tanzania
| | - Jennifer Hatfield
- Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Alberta, Canada
| | - Susan Kuhn
- Department of Paediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Reginald S Sauve
- Department of Paediatrics, Cumming School of Medicine University of Calgary, Calgary, Alberta Canada; Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta Canada
| | - Deborah Dewey
- Department of Paediatrics, Cumming School of Medicine University of Calgary, Calgary, Alberta Canada; Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta Canada
| |
Collapse
|
25
|
Restivo L, Khaira G, Sandhu A, Kuhn S. 64 Is it enough: An Assessment of Parental Satisfaction with an International Adoption Clinic at a Pediatric Tertiary Care Center. Paediatr Child Health 2020. [DOI: 10.1093/pch/pxaa068.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The circumstance in which internationally adopted children are born and live prior to adoption put them at high risk for health issues. Nearly all adoptees have complex medical conditions, the most common being cleft lip/palate, orthopaedic problems, infectious diseases, congenital heart diseases, and/or nutritional deficiencies, as well as cognitive impairments, and/or developmental delays. Specifically, nearly all institutionalized children will have expressive language delays and most will have motor delays. Although improvement can be seen with time, most do not attain their full potential. Additionally, by nature of adoption, all children experience trauma. In some situations, this will be further compounded by neglect and/or abuse faced prior to adoption, or during institutionalization. Consequently, almost all adoptees develop attachment difficulties. Trained medical professionals are required to screen, monitor, and provide management suggestions for this complex and unique population.
Objectives
To our knowledge, parental experience of an international adoption clinic has not yet been published. This parent-based evaluation of the parental experience at a pediatric tertiary care center’s international adoption clinic, provides insights that may help guide provision of care for this high-risk population in our centre, throughout the country, and internationally.
Design/Methods
A qualitative, exploratory design was employed using telephone interviews of eighteen parents of adoptees assessed by a pediatric tertiary care center’s international adoption clinic since 2010. This approach was chosen to allow for more extensive exploration of parental experience, and to identify barriers and facilitators of care. Interviews were 30 to 90 minutes, semi-structured, and transcribed verbatim. Field notes were made during the interviews to note intonation and major concerns, and were used to supplement transcripts during data analysis. Questions covered experiences with pre-adoption counselling, arranging the first clinic visit, health and developmental assessments, life after clinic discharge, and general comments/suggestions. Thematic analysis was performed on the transcripts using Maguire’s step-by-step guide.
Results
Analysis resulted in four main themes and seven subthemes. The first theme was “difficulty of international adoption”. The second theme “utility and impact of services offered” was subdivided into “pre-adoption counselling”, “clinic visits and medical assessments”, and “post adoption seminars”. The third theme “the administrative procedures of the clinic” was subdivided into “timing and ease of organizing a first visit”, and “hours of operation”. The final theme “gaps in care” was divided into “ongoing difficulty with attachment”, and “allied healthcare services”. These results demonstrate that parents of internationally adopted children often feel overwhelmed by the medical needs of their children and feel unsupported. They recommend comprehensive and in-person pre-adoption counselling with standard referral processes to ensure timely access to care. Post-arrival medical and developmental assessments should be flexible and complete. Most importantly, clinics should incorporate support from allied healthcare professionals, including social work, psychology, occupational therapy, and physiotherapy. In particular, parents were interested in further management of attachment.
Conclusion
This first parent-based evaluation of the parental experience at a pediatric tertiary care center’s international adoption clinic provides insights that may help guide provision of care to this high-risk population in centres across Canada and internationally.
Collapse
|
26
|
Angelo KM, Stoney RJ, Brun-Cottan G, Leder K, Grobusch MP, Hochberg N, Kuhn S, Bottieau E, Schlagenhauf P, Chen L, Hynes NA, Perez CP, Mockenhaupt FP, Molina I, Crespillo-Andújar C, Malvy D, Caumes E, Plourde P, Shaw M, McCarthy AE, Piper-Jenks N, Connor BA, Hamer DH, Wilder-Smith A. Zika among international travellers presenting to GeoSentinel sites, 2012-2019: implications for clinical practice. J Travel Med 2020; 27:5824831. [PMID: 32330261 PMCID: PMC7604850 DOI: 10.1093/jtm/taaa061] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/18/2020] [Revised: 04/15/2020] [Accepted: 04/17/2020] [Indexed: 12/20/2022]
Abstract
INTRODUCTION International travellers contribute to the rapid spread of Zika virus (ZIKV) and its sentinel identification globally. We describe ZIKV infections among international travellers seen at GeoSentinel sites with a focus on ZIKV acquired in the Americas and the Caribbean, describe countries of exposure and traveller characteristics, and assess ZIKV diagnostic testing by site. METHODS Records with an international travel-related diagnosis of confirmed or probable ZIKV from January 2012 through December 2019 reported to GeoSentinel with a recorded illness onset date were included to show reported cases over time. Records from March 2016 through December 2019 with an exposure region of the Americas or the Caribbean were included in the descriptive analysis. A survey was conducted to assess the availability, accessibility and utilization of ZIKV diagnostic tests at GeoSentinel sites. RESULTS GeoSentinel sites reported 525 ZIKV cases from 2012 through 2019. Between 2012 and 2014, eight cases were reported, and all were acquired in Asia or Oceania. After 2014, most cases were acquired in the Americas or the Caribbean, a large decline in ZIKV cases occurred in 2018-19.Between March 2016 and December 2019, 423 patients acquired ZIKV in the Americas or the Caribbean, peak reporting to these regions occurred in 2016 [330 cases (78%)]. The median age was 36 years (range: 3-92); 63% were female. The most frequent region of exposure was the Caribbean (60%). Thirteen travellers were pregnant during or after travel; one had a sexually acquired ZIKV infection. There was one case of fetal anomaly and two travellers with Guillain-Barré syndrome. GeoSentinel sites reported various challenges to diagnose ZIKV effectively. CONCLUSION ZIKV should remain a consideration for travellers returning from areas with risk of ZIKV transmission. Travellers should discuss their travel plans with their healthcare providers to ensure ZIKV prevention measures are taken.
Collapse
Affiliation(s)
- Kristina M Angelo
- Division of Global Migration and Quarantine, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30329, USA
| | - Rhett J Stoney
- Division of Global Migration and Quarantine, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30329, USA
| | - Gaelle Brun-Cottan
- Department of Medicine, Boston University School of Medicine, 72 E Concord St, Boston, MA 02118, USA
| | - Karin Leder
- School of Public Health and Preventive Medicine, Victorian Infectious Disease Service, Royal Melbourne Hospital, Doherty Institute for Infection and Immunity, Monash University, 300 Grattan St, Parkville 3050, Australia
| | - Martin P Grobusch
- Center for Tropical Medicine and Travel Medicine, Amsterdam University Medical Centers, University of Amsterdam, 1012 WX Amsterdam, The Netherlands
| | - Natasha Hochberg
- Department of Pediatrics, Boston University School of Medicine, 72 E Concord St, Boston, MA 02118, USA
| | - Susan Kuhn
- Department of Pediatrics, Alberta Health Services, 10101 Southport Rd SW, Calgary AB T2W 3N2, Canada
| | - Emmanuel Bottieau
- Department of Clinical Sciences, Institute of Tropical Medicine, Kronenburgstraat 43, 2000 Antwerp, Belgium
| | - Patricia Schlagenhauf
- WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics, and Prevention Institute, University of Zurich, Rämistrasse 71, 8006 Zurich, Switzerland
| | - Lin Chen
- Division of Infectious Diseases and Travel Medicine, Mount Auburn Hospital, Cambridge and Harvard Medical School, 25 Shattuck St, Boston, MA 02115, USA
| | - Noreen A Hynes
- Johns Hopkins University School of Medicine, 733 N Broadway, Baltimore, MD 21205, USA
| | - Cecilia Perret Perez
- School of Medicine, Universidad Catolica de Chile, Av Libertador Bernardo O'Higgins 340, Santiago, Santiago Metropolitan, Chile
| | - Frank P Mockenhaupt
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Tropical Medicine and International Health, Augustenburger Pl. 1, 13353 Berlin, Germany
| | - Israel Molina
- Department of Infectious Diseases, Vall d'Hebron University Hospital, Universitat Autónoma de Barcelona, PROSICS, Campus de la UAB, Plaça Cívica, 08193, Barcelona, Spain
| | - Clara Crespillo-Andújar
- National Referral Unit for Tropical and Travel Medicine, Department of Internal Medicine, University Hospital La Paz-Carlos III, Paseo de la Castellana, 261, 28046 Madrid, Spain
| | - Denis Malvy
- Department for Infectious Diseases and Tropical Medicine, University Hospital Centre of Bordeaux, and Inserm 1219, University of Bordeaux, 146 Rue Léo Saignat, 33076 Bordeaux, France
| | - Eric Caumes
- Hôpital Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, 75013 Paris, France
| | - Pierre Plourde
- University of Manitoba, 66 Chancellors Cir, Winnipeg MB R3T 2N2, Canada
| | - Marc Shaw
- James Cook University, 1 James Cook Dr, Douglas, Townsville 4811, Australia.,Worldwise Travellers' Health Centres, 18 Saint Marks Road, Remuera, Auckland 1050, New Zealand
| | - Anne E McCarthy
- Department of Medicine, Ottawa Hospital, University of Ottawa, 75 Laurier Ave E, Ottawa K1N 6N5, Canada
| | | | - Bradley A Connor
- The New York Center for Travel and Tropical Medicine, Weill Cornell Medical College, 1300 York Ave, New York, NY 10065, USA
| | - Davidson H Hamer
- Department of Global Health, Boston University School of Public Health, 715 Albany St, Boston, MA 02118, USA.,Section of Infectious Diseases, Department of Medicine, Boston Medical Center, One Boston Medical Center Pl, Boston, MA 02118, USA
| | - Annelies Wilder-Smith
- Department of Epidemiology and Global Health, University of Umea, Petrus Laestadius Väg, 901 87, Umeå, Sweden.,Department for Disease Control, London School of Hygiene and Tropical Medicine, Keppel St, Bloomsbury, London WC1E 7HT, UK
| |
Collapse
|
27
|
Konje ET, Hatfield J, Kuhn S, Sauve RS, Magoma M, Dewey D. Is it home delivery or health facility? Community perceptions on place of childbirth in rural Northwest Tanzania using a qualitative approach. BMC Pregnancy Childbirth 2020; 20:270. [PMID: 32375691 PMCID: PMC7201655 DOI: 10.1186/s12884-020-02967-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Accepted: 04/22/2020] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND In low and middle-income countries, pregnancy and delivery complications may deprive women and their newborns of life or the realization of their full potential. Provision of quality obstetric emergency and childbirth care can reduce maternal and newborn deaths. Underutilization of maternal and childbirth services remains a public health concern in Tanzania. The aim of this study was to explore elements of the local social, cultural, economic, and health systems that influenced the use of health facilities for delivery in a rural setting in Northwest Tanzania. METHODS A qualitative approach was used to explore community perceptions of issues related to low utilization of health facilities for childbirth. Between September and December 2017, 11 focus group discussions were conducted with women (n = 33), men (n = 5) and community health workers (CHWs; n = 28); key informant interviews were conducted with traditional birth attendants (TBAs; n = 2). Coding, identification, indexing, charting, and mapping of these interviews was done using NVIVO 12 after manual familiarization of the data. Data saturation was used to determine when no further interviews or discussions were required. RESULTS Four themes emerge; self-perceived obstetric risk, socio-cultural issues, economic concerns and health facility related factors. Health facility delivery was perceived to be crucial for complicated labor. However, the idea that childbirth was a "normal" process and lack of social and cultural acceptability of facility services, made home delivery appealing to many women and their families. In addition, out of pocket payments for suboptimal quality of health care was reported to hinder facility delivery. CONCLUSION Home delivery persists in rural settings due to economic and social issues, and the cultural meanings attached to childbirth. Accessibility to and affordability of respectful and culturally acceptable childbirth services remain challenging in this setting. Addressing barriers on both the demand and supply side could result in improved maternal and child outcomes during labor and delivery.
Collapse
Affiliation(s)
- Eveline T. Konje
- Department of Biostatistics & Epidemiology, School of Public Health, Catholic University of Health and Allied Sciences, P.O. BOX 1464 BUGANDO AREA, Mwanza, Tanzania
- Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive, NW, Calgary, AB Canada
| | - Jennifer Hatfield
- Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive, NW, Calgary, AB Canada
| | - Susan Kuhn
- Department of Paediatrics, Cumming School of Medicine, University of Calgary, 28 OKE Dr. NW, Calgary, AB Canada
| | - Reginald S. Sauve
- Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive, NW, Calgary, AB Canada
- Department of Paediatrics, Cumming School of Medicine, University of Calgary, 28 OKE Dr. NW, Calgary, AB Canada
| | - Moke Magoma
- Engender Health Tanzania, Dar es Salaam, Tanzania
| | - Deborah Dewey
- Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive, NW, Calgary, AB Canada
- Department of Paediatrics, Cumming School of Medicine, University of Calgary, 28 OKE Dr. NW, Calgary, AB Canada
- Owerko Centre at the Alberta Children’s Hospital Research Institute, Cumming School of Medicine, University of Calgary, 2500 University Dr. NW, Calgary, AB Canada
| |
Collapse
|
28
|
Sinclair S, Kondejewski J, Schulte F, Letourneau N, Kuhn S, Raffin-Bouchal S, Guilcher GMT, Strother D. Compassion in Pediatric Healthcare: A Scoping Review. J Pediatr Nurs 2020; 51:57-66. [PMID: 31901770 DOI: 10.1016/j.pedn.2019.12.009] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Revised: 12/10/2019] [Accepted: 12/15/2019] [Indexed: 12/30/2022]
Abstract
PROBLEM Compassion has been described as a central construct or essential feature of quality healthcare and is as important to patients' and families' overall healthcare experience as the health interventions and treatments they receive. However, there is little shared understanding of what constitutes compassion, how it is delivered within a pediatric setting, and pediatric patients' and families perspectives and preferences for receiving it. ELIGIBILITY CRITERIA Studies that (1) described the nature of the existing literature on compassion in pediatric healthcare; (2) summarized key concepts in the existing evidence base that pertain to compassion in pediatric healthcare; and 3) identified factors that are associated with compassion in pediatric healthcare were eligible for inclusion in this review. SAMPLE Twenty-nine papers were included in the review. RESULTS Findings revealed several factors are associated with compassion in pediatric healthcare, including continuity of care, communication, and coordination of care. Most notably, identified studies treated compassion in a subsidiary fashion, and this review revealed no studies that provided a patient-informed evidence-based definition of compassion in the pediatric healthcare setting. CONCLUSION Future research is required to generate a comprehensive and accurate understanding of the terms 'compassion' and 'compassionate care' when used in the context of pediatric healthcare. IMPLICATIONS This research will inform the therapeutic processes and ultimately enable the development of strategies to improve the delivery of compassionate healthcare to pediatric patients.
Collapse
Affiliation(s)
- Shane Sinclair
- Faculty of Nursing, University of Calgary, Canada; Compassion Research Lab, University of Calgary, Canada; Department of Oncology, Division of Palliative Medicine, Cumming School of Medicine, University of Calgary, Canada.
| | - Jane Kondejewski
- Faculty of Nursing, University of Calgary, Canada; Compassion Research Lab, University of Calgary, Canada
| | - Fiona Schulte
- Department of Oncology, Division of Psychosocial Oncology, Cumming School of Medicine, University of Calgary, Canada
| | - Nicole Letourneau
- Faculty of Nursing, University of Calgary, Canada; Departments of Psychiatry & Community Health Sciences, Cumming School of Medicine, University of Calgary, Canada; Department of Pediatrics, Cumming School of Medicine, University of Calgary, Canada
| | - Susan Kuhn
- Department of Pediatrics, Cumming School of Medicine, University of Calgary, Canada
| | | | - Gregory M T Guilcher
- Department of Pediatrics, Cumming School of Medicine, University of Calgary, Canada; Department of Oncology, Cumming School of Medicine, University of Calgary, Canada
| | - Douglas Strother
- Department of Pediatrics, Cumming School of Medicine, University of Calgary, Canada; Department of Oncology, Cumming School of Medicine, University of Calgary, Canada
| |
Collapse
|
29
|
Marasinghe DH, Cheaveau J, Meatherall B, Kuhn S, Vaughan S, Zimmer R, Pillai DR. Risk of malaria associated with travel to malaria-endemic areas to visit friends and relatives: a population-based case-control study. CMAJ Open 2020; 8:E60-E68. [PMID: 31992561 PMCID: PMC6996033 DOI: 10.9778/cmajo.20190070] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
BACKGROUND Reports relying on population-based data and using epidemiologic methodologies such as case-control study designs for malaria in travellers and multivariable regression analysis of risk factors are rare. The aim of this study was to investigate the epidemiologic characteristics of travellers who tested positive for malaria after visiting friends and relatives in malaria-endemic areas to determine the risk of malaria associated with such travel. METHODS Using routinely collected data from a population-based laboratory database, we conducted a case-control study of symptomatic people returning from travel to malaria-endemic areas who presented for malaria testing in Calgary from 2013 to 2017. We used a multivariable logistic regression to analyze the association between the presence of malaria and other risk factors. RESULTS There were 251 confirmed malaria cases during the study period, of which 219 were matched to 1129 returning travellers without malaria. Based on the multivariable regression, the odds of a traveller who visited friends and relatives in malariaendemic areas being diagnosed with malaria was 2.82 (95% confidence interval [CI] 1.42-5.92) times greater than that of other travellers to these regions. Adults (odds ratio [OR] 3.62, 95% CI 1.66-8.84), males (OR 2.70, 95% CI 1.56-4.80), travellers to Africa (OR 11.52, 95% CI 6.33-22.05) and those who did not seek pretravel advice (OR 0.38, 95% CI 0.20-0.70) were more likely to be diagnosed with malaria. Although those travelling to visit friends and relatives tended to stay longer in endemic areas than other travellers, visit duration was not associated with an increased likelihood of malaria in the model. The annual incidence of malaria was highest (13.34 per 100 000) in metropolitan wards associated with lower socioeconomic status and immigrant communities. INTERPRETATION Travellers who visited friends and relatives in malaria-endemic areas were less likely than other travellers to these regions to seek pretravel advice, take prophylaxis and have a visit duration less than 2 weeks; travelling to Africa and being male increased the odds of being diagnosed with malaria, independent of other factors. These data suggest that targeted strategies to provide pretravel care to travellers who visit friends and relatives in malaria-endemic areas may aid in reducing the burden of malaria in this population.
Collapse
Affiliation(s)
- Dewdunee H Marasinghe
- Department of Epidemiology, Biostatistics and Occupational Health (Marasinghe), McGill University, Montréal, Que.; Departments of Microbiology, Immunology and Infectious Diseases (Cheaveau, Pillai), Medicine (Meatherall, Vaughan, Pillai), Pediatrics (Kuhn), Community Health Sciences (Zimmer, Pillai) and Pathology and Laboratory Medicine (Pillai), University of Calgary, Calgary, Alta
| | - James Cheaveau
- Department of Epidemiology, Biostatistics and Occupational Health (Marasinghe), McGill University, Montréal, Que.; Departments of Microbiology, Immunology and Infectious Diseases (Cheaveau, Pillai), Medicine (Meatherall, Vaughan, Pillai), Pediatrics (Kuhn), Community Health Sciences (Zimmer, Pillai) and Pathology and Laboratory Medicine (Pillai), University of Calgary, Calgary, Alta
| | - Bonnie Meatherall
- Department of Epidemiology, Biostatistics and Occupational Health (Marasinghe), McGill University, Montréal, Que.; Departments of Microbiology, Immunology and Infectious Diseases (Cheaveau, Pillai), Medicine (Meatherall, Vaughan, Pillai), Pediatrics (Kuhn), Community Health Sciences (Zimmer, Pillai) and Pathology and Laboratory Medicine (Pillai), University of Calgary, Calgary, Alta
| | - Susan Kuhn
- Department of Epidemiology, Biostatistics and Occupational Health (Marasinghe), McGill University, Montréal, Que.; Departments of Microbiology, Immunology and Infectious Diseases (Cheaveau, Pillai), Medicine (Meatherall, Vaughan, Pillai), Pediatrics (Kuhn), Community Health Sciences (Zimmer, Pillai) and Pathology and Laboratory Medicine (Pillai), University of Calgary, Calgary, Alta
| | - Stephen Vaughan
- Department of Epidemiology, Biostatistics and Occupational Health (Marasinghe), McGill University, Montréal, Que.; Departments of Microbiology, Immunology and Infectious Diseases (Cheaveau, Pillai), Medicine (Meatherall, Vaughan, Pillai), Pediatrics (Kuhn), Community Health Sciences (Zimmer, Pillai) and Pathology and Laboratory Medicine (Pillai), University of Calgary, Calgary, Alta
| | - Rudolf Zimmer
- Department of Epidemiology, Biostatistics and Occupational Health (Marasinghe), McGill University, Montréal, Que.; Departments of Microbiology, Immunology and Infectious Diseases (Cheaveau, Pillai), Medicine (Meatherall, Vaughan, Pillai), Pediatrics (Kuhn), Community Health Sciences (Zimmer, Pillai) and Pathology and Laboratory Medicine (Pillai), University of Calgary, Calgary, Alta
| | - Dylan R Pillai
- Department of Epidemiology, Biostatistics and Occupational Health (Marasinghe), McGill University, Montréal, Que.; Departments of Microbiology, Immunology and Infectious Diseases (Cheaveau, Pillai), Medicine (Meatherall, Vaughan, Pillai), Pediatrics (Kuhn), Community Health Sciences (Zimmer, Pillai) and Pathology and Laboratory Medicine (Pillai), University of Calgary, Calgary, Alta.
| |
Collapse
|
30
|
Abstract
BACKGROUND The need for application expertise in natural language processing (NLP) is increasing in radiology. This way, in a complementary fashion to structured reporting using templates, the necessary database for quality assurance and continuous process optimization can be generated. OBJECTIVE Possibilities and challenges of the application of NLP from the radiology point of view are explained. MATERIALS AND METHODS The requirements and expectations for NLP systems are identified and demonstrated using a case study. RESULTS For an effective use of this technology, NLP tasks for the interpretation of text using RadLex, an intuitive usage and feedback option as well as transparent quality of the NLP results are important. DISCUSSION Using suitable NLP systems, targeted information can be extracted from large amounts of free text with manageable manual effort and high quality.
Collapse
Affiliation(s)
- F Jungmann
- Klinik und Poliklinik für Diagnostische und Interventionelle Radiologie, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland.
| | - S Kuhn
- Zentrum für Orthopädie und Unfallchirurgie, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Deutschland
| | - I Tsaur
- Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Deutschland
| | - B Kämpgen
- Empolis Information Management GmbH, Kaiserslautern, Deutschland
| |
Collapse
|
31
|
deBruyn JCC, Soon IS, Fonseca K, Feng S, Purtzki M, Goedhart C, Kuhn S, Vanderkooi OG, Wrobel I. Serologic Status of Routine Childhood Vaccines, Cytomegalovirus, and Epstein-Barr Virus in Children With Inflammatory Bowel Disease. Inflamm Bowel Dis 2019; 25:1218-1226. [PMID: 30551205 DOI: 10.1093/ibd/izy366] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2018] [Indexed: 02/06/2023]
Abstract
BACKGROUND Data on the serologic status of childhood vaccines, cytomegalovirus (CMV) and Epstein-Barr virus (EBV), are limited in inflammatory bowel disease (IBD). Therefore, we evaluated vaccine coverage and seroprotection, along with CMV and EBV seropositivity, in pediatric IBD. METHODS In a cross-sectional study, demographic data, IBD history, vaccine records, and serum for antibodies against measles, mumps, rubella, diphtheria, tetanus, varicella, hepatitis B (HBV), CMV, and EBV were collected from children with IBD. We evaluated potential factors associated with serologic status. RESULTS Of 156 subjects, vaccine coverage was up to date for age in 93.5% for measles, mumps, rubella, 95.6% for diphtheria, tetanus, pertussis, polio, hemophilus influenza B, 75.8% for HBV, and 93.5% for varicella, including past infection and vaccination. Seroprotection was present in 65.8% for measles, 60.5% for mumps, 79.1% for rubella, 79.5% for diphtheria, 80.8% for tetanus, 70.5% for varicella, and 62.8% for HBV of subjects. Older age at diagnosis was associated with seroprotection among subjects with complete HBV (odds ratio [OR], 1.20; 95% confidence interval [CI], 1.03-1.39) and rubella series (OR, 1.18; 95% CI, 1.02-1.37). Older age at serum collection was associated with seroprotection among subjects with prior varicella vaccination or infection (OR, 1.69; 95% CI, 1.33-2.15). Only 25.2% and 37.8% demonstrated seropositivity to CMV and EBV, respectively. Among subjects on immunosuppressive medications, 75.3% and 62.4% were seronegative for CMV and EBV, respectively. CONCLUSIONS Children with IBD have low serologic protection to childhood vaccines in spite of high vaccine coverage and universal vaccinations. Children with IBD, including a large proportion on immunosuppressive medications, have low seropositivity to CMV and EBV.
Collapse
Affiliation(s)
- Jennifer C C deBruyn
- Section of Paediatric Gastroenterology, Department of Paediatrics, University of Calgary, Calgary, Alberta, Canada.,Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
| | - Ing Shian Soon
- Section of Paediatric Gastroenterology, Department of Paediatrics, University of Calgary, Calgary, Alberta, Canada
| | - Kevin Fonseca
- Virology, Provincial Laboratory for Public Health, University of Calgary, Calgary, Alberta, Canada
| | - Sharon Feng
- Section of Paediatric Gastroenterology, Department of Paediatrics, University of Calgary, Calgary, Alberta, Canada
| | - Melanie Purtzki
- Section of Paediatric Gastroenterology, Department of Paediatrics, University of Calgary, Calgary, Alberta, Canada
| | - Caitlin Goedhart
- Section of Paediatric Gastroenterology, Department of Paediatrics, University of Calgary, Calgary, Alberta, Canada
| | - Susan Kuhn
- Section of Infectious Diseases, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada
| | - Otto G Vanderkooi
- Section of Infectious Diseases, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada.,Department of Pathology & Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada.,Department of Microbiology, Immunology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada
| | - Iwona Wrobel
- Section of Paediatric Gastroenterology, Department of Paediatrics, University of Calgary, Calgary, Alberta, Canada
| |
Collapse
|
32
|
Greenfield J, Bruyère-Garnier K, Mehler D, Appelmann P, Kuhn S, Rommens P, Lafon Y. Influence of implant and screw type on local bone strain field: a preliminary study. Comput Methods Biomech Biomed Engin 2019. [DOI: 10.1080/10255842.2020.1714972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- J. Greenfield
- Université Lyon, Université Claude Bernard Lyon 1, IFSTTAR, LBMC UMR_T9406, Lyon, France
- Department of Orthopaedics and Traumatology, University Medical Centre of Johannes Gutenberg University, Mainz, Germany
| | - K. Bruyère-Garnier
- Université Lyon, Université Claude Bernard Lyon 1, IFSTTAR, LBMC UMR_T9406, Lyon, France
| | - D. Mehler
- Department of Orthopaedics and Traumatology, University Medical Centre of Johannes Gutenberg University, Mainz, Germany
| | - P. Appelmann
- Department of Orthopaedics and Traumatology, University Medical Centre of Johannes Gutenberg University, Mainz, Germany
| | - S. Kuhn
- Department of Orthopaedics and Traumatology, University Medical Centre of Johannes Gutenberg University, Mainz, Germany
| | - P.M Rommens
- Department of Orthopaedics and Traumatology, University Medical Centre of Johannes Gutenberg University, Mainz, Germany
| | - Y. Lafon
- Université Lyon, Université Claude Bernard Lyon 1, IFSTTAR, LBMC UMR_T9406, Lyon, France
| |
Collapse
|
33
|
Boggild AK, Geduld J, Libman M, Yansouni CP, McCarthy AE, Hajek J, Ghesquiere W, Mirzanejad Y, Vincelette J, Kuhn S, Plourde PJ, Chakrabarti S, Greenaway C, Hamer DH, Kain KC. Spectrum of illness in migrants to Canada: sentinel surveillance through CanTravNet. J Travel Med 2019; 26:5159662. [PMID: 30395252 DOI: 10.1093/jtm/tay117] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/11/2018] [Revised: 10/29/2018] [Accepted: 11/02/2018] [Indexed: 12/15/2022]
Abstract
BACKGROUND Due to ongoing political instability and conflict in many parts of the world, migrants are increasingly seeking asylum and refuge in Canada. METHODS We examined demographic and travel correlates of illnesses among migrants to Canada to establish a detailed epidemiologic framework of this population for Canadian practitioners. Data on ill-returned Canadian travellers presenting to a CanTravNet site between 1 January 2015 and 31 December 2015 were analyzed. RESULTS During the study period, 2415 ill travellers and migrants presented to a CanTravNet site, and of those, 519 (21.5%) travelled for the purpose of migration. Sub-Saharan Africa (n = 160, 30.8%), southeast Asia (n = 84, 16.2%) and south central Asia (n = 75, 14.5%) were the most common source regions for migrants, while the top specific source countries, of 98 represented, were the Philippines (n = 45, 8.7%), China (n = 36, 6.9%) and Vietnam (n = 31, 6.0%). Compared with non-migrant travellers, migrants were more likely to have a pre-existing immunocompromising medical condition, such as HIV or diabetes mellitus (P < 0.0001), and to require inpatient management of their illness (P < 0.0001). Diagnoses such as tuberculosis (n = 263, 50.7%), hepatitis B and C (n = 78, 15%) and HIV (n = 11, 2.1%) were over-represented in the migrant population compared with non-migrant travellers (P < 0.0001). Most cases of tuberculosis in the migrant population (n = 263) were latent (82% [n = 216]); only 18% (n = 47) were active. CONCLUSIONS Compared with non-migrant travellers, migrants were more likely to present with a communicable infectious disease, such as tuberculosis, potentially complicated by an underlying immunosuppressing condition such as HIV. These differences highlight the divergent healthcare needs in the migrant population, and underscore the importance of surveillance programmes to understand their burden of illness. Intake programming should be adequately resourced to accommodate the medical needs of this vulnerable population of new Canadians.
Collapse
Affiliation(s)
- Andrea K Boggild
- Tropical Disease Unit, Division of Infectious Diseases, Department of Medicine, University Health Network and the University of Toronto, Toronto ON, Canada.,Public Health Ontario Laboratories, Public Health Ontario, Toronto, ON, Canada
| | - Jennifer Geduld
- Office of Border and Travel Health, Public Health Agency of Canada, Ottawa, ON, Canada
| | - Michael Libman
- The J.D. MacLean Centre for Tropical Diseases, Department of Medicine, McGill University, Montreal, Quebec, Canada
| | - Cedric P Yansouni
- The J.D. MacLean Centre for Tropical Diseases, Department of Medicine, McGill University, Montreal, Quebec, Canada
| | - Anne E McCarthy
- Tropical Medicine and International Health Clinic, Division of Infectious Diseases, Ottawa Hospital and the University of Ottawa, Ottawa ON, Canada
| | - Jan Hajek
- Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver British Columbia, Canada
| | - Wayne Ghesquiere
- Infectious Diseases, Vancouver Island Health Authority, Department of Medicine, University of British Columbia, Victoria, British Columbia, Canada
| | - Yazdan Mirzanejad
- Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver British Columbia, Canada.,Fraser Health, Surrey, British Columbia, Canada
| | - Jean Vincelette
- Hôpital Saint-Luc du CHUM, Université de Montréal, Montréal, Quebec, Canada
| | - Susan Kuhn
- Section of Pediatric Infectious Diseases, Departments of Pediatrics and Medicine, Alberta Children's Hospital and the University of Calgary, Calgary, Alberta, Canada
| | - Pierre J Plourde
- Travel Health and Tropical Medicine Services, Population and Public Health Program, Winnipeg Regional Health Authority, Winnipeg, Manitoba, Canada
| | - Sumontra Chakrabarti
- Tropical Disease Unit, Division of Infectious Diseases, Department of Medicine, University Health Network and the University of Toronto, Toronto ON, Canada.,Trillium Health Partners, Mississauga, ON, Canada
| | - Christina Greenaway
- The J.D. MacLean Centre for Tropical Diseases, Department of Medicine, McGill University, Montreal, Quebec, Canada.,Division of Infectious Diseases, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
| | - Davidson H Hamer
- Department of Global Health, Boston University School of Public Health, Section of Infectious Diseases, Boston University School of Medicine, Boston, MA, USA
| | - Kevin C Kain
- Tropical Disease Unit, Division of Infectious Diseases, Department of Medicine, University Health Network and the University of Toronto, Toronto ON, Canada.,SAR Laboratories, Sandra Rotman Centre for Global Health, Toronto, ON Canada
| |
Collapse
|
34
|
Schreiber T, Kuhn S, Feldkamp G, Schwuchow A, Schuster K, Hein S, Eberhardt R, Tünnermann A. Micro-fluorescence lifetime and spectral imaging of ytterbium doped laser materials. Opt Express 2018; 26:32417-32432. [PMID: 30645409 DOI: 10.1364/oe.26.032417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/03/2018] [Accepted: 10/22/2018] [Indexed: 06/09/2023]
Abstract
We present the application of a confocal fluorescence microscope to the analysis of Yb-doped solid-state laser materials, with examples of Yb-doped crystals, photonic crystal fibers and fiber preforms made with different manufacturing processes. Beside the fluorescence lifetime image itself, a microscopic spectral fluorescence emission analysis is presented and spatially resolved emission cross sections are obtained. Doping concentration and its distributions and other laser optical parameters are measured, which help to analyze manufacturing steps. Further properties like photodarkening and saturation are addressed.
Collapse
|
35
|
Fransen S, Fransaer J, Kuhn S. Current and concentration distributions in electrochemical microreactors: Numerical calculations and asymptotic approximations for self-supported paired synthesis. Electrochim Acta 2018. [DOI: 10.1016/j.electacta.2018.08.082] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
36
|
Ferreira J, Castro F, Rocha F, Kuhn S. Protein crystallization in a droplet-based microfluidic device: Hydrodynamic analysis and study of the phase behaviour. Chem Eng Sci 2018. [DOI: 10.1016/j.ces.2018.06.066] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
37
|
Dreyer T, Kuhn S, Jelsma J, Heithorst N, Schilling D, Sievert W, Multhoff G, Wege AK, Kiechle M, Bronger H. Das Chemokin CX3CL1 erhöht die Immuninfiltration, reduziert Tumorwachstum und -metastasierung und verbessert die Trastuzumab-Therapie in vitro und in vivo. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- T Dreyer
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| | - S Kuhn
- Klinikum rechts der Isar, TU München, Institut für Klinische Chemie und Pathobiochemie, München, Deutschland
| | - J Jelsma
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| | - N Heithorst
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| | - D Schilling
- Klinikum rechts der Isar, TU München, Klinik für Strahlentherapie, München, Deutschland
| | - W Sievert
- Klinikum rechts der Isar, TU München, Klinik für Strahlentherapie, München, Deutschland
| | - G Multhoff
- Klinikum rechts der Isar, TU München, Klinik für Strahlentherapie, München, Deutschland
| | - AK Wege
- Universität Regensburg, Frauenklinik, München, Deutschland
| | - M Kiechle
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| | - H Bronger
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| |
Collapse
|
38
|
Bronger H, Dreyer T, Demlehner J, Kuhn S, Kraeft S, Multhoff G, Kiechle M. CXCL9 wird durch den COX-Inhibitor Indomethacin aus Mammakarzinomzellen freigesetzt und hemmt das Tumorwachstum in vivo. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- H Bronger
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| | - T Dreyer
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| | - J Demlehner
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| | - S Kuhn
- Klinikum rechts der Isar, TU München, Institut für Klinische Chemie und Pathobiochemie, München, Deutschland
| | - S Kraeft
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| | - G Multhoff
- Klinikum rechts der Isar, TU München, Klinik für Strahlentherapie, München, Deutschland
| | - M Kiechle
- Klinikum rechts der Isar, TU München, Klinik und Poliklinik für Frauenheilkunde, München, Deutschland
| |
Collapse
|
39
|
Vogt M, Meschede S, Seitz N, Kuhn S, Lutz M. Betrieb chemischer Speichertechnologien in einem Unternehmensverbund. CHEM-ING-TECH 2018. [DOI: 10.1002/cite.201855075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Vogt
- IUTA e.V; Luftreinhaltung und Aerosole; Bliersheimer Straße 58 60 47229 Duisburg Deutschland
| | - S. Meschede
- IUTA e.V; Luftreinhaltung und Aerosole; Bliersheimer Straße 58 60 47229 Duisburg Deutschland
| | - N. Seitz
- Technische Universität München; Forschungsinstitut Unternehmensführung, Logistik und Produktion; Leopoldstraße 145 80804 München Deutschland
| | - S. Kuhn
- Technische Universität München; Forschungsinstitut Unternehmensführung, Logistik und Produktion; Leopoldstraße 145 80804 München Deutschland
| | - M. Lutz
- Technische Universität München; Forschungsinstitut Unternehmensführung, Logistik und Produktion; Leopoldstraße 145 80804 München Deutschland
| |
Collapse
|
40
|
Peirano G, Gregson DB, Kuhn S, Vanderkooi OG, Nobrega DB, Pitout JDD. Rates of colonization with extended-spectrum β-lactamase-producing Escherichia coli in Canadian travellers returning from South Asia: a cross-sectional assessment. CMAJ Open 2017; 5:E850-E855. [PMID: 29246886 PMCID: PMC5741423 DOI: 10.9778/cmajo.20170041] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND A previous study in Calgary showed that travel to India was associated with high risk of community-onset infections with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli. We performed a follow-up study to determine the rate of rectal acquisition of ESBL-producing E. coli among travellers to South Asia and to identify the behaviours putting such travellers at high risk for acquiring ESBL-producing E. coli. METHODS: The study was performed at a travel clinic in Calgary. Travellers 18 years or older who were planning to visit South Asia for a period of at least 5 days were included. Three rectal swabs were obtained, and 2 questionaires were administered (before and after travel). RESULTS A total of 149 travellers participated between January 2012 and July 2014; of these, 116 (78%) provided rectal swabs upon return to Calgary and completed both pre- and post-travel questionaires. Of the 109 travellers without colonization with ESBL-producing E. coli upon enrollment, 70 (64%) acquired ESBL-producing E. coli during travel. Of the 90 participants who visited India, 66 (73%) were positive for ESBL-producing E. coli upon their return to Calgary. Most ESBL-producing E. coli specimens were identified as producing the enzyme CTX-M-15. Behaviours associated with a statistically significant risk of acquiring ESBL-producing E. coli included visiting India (odds ratio [OR] 19.9, 95% confidence interval [CI] 4.5-88.8), consuming meals with the local population (OR 6.9, 95% CI 1.2-39.6), taking any type of antibiotic during travel (OR 4.3, 95% CI 1.3-14.3) and travelling for any purpose other than business (OR 12.4, 95% CI 2.8-55.2). INTERPRETATION In this study, travel to India was associated with the highest risk of acquiring ESBL-producing E. coli relative to travel to other countries in South Asia. Nonbusiness travel, consuming foods with the local population and the use of antibiotics while travelling were associated with an increased risk of acquiring these antibiotic-resistant organisms while in India. Trial registration: ClinicalTrials.gov, no. NCT01296165.
Collapse
Affiliation(s)
- Gisele Peirano
- Affiliations: Division of Microbiology (Peirano, Gregson, Pitout), Calgary Laboratory Services; Departments of Pathology and Laboratory Medicine (Peirano, Gregson, Vanderkooi, Pitout), of Medicine (Gregson, Kuhn), of Paediatrics (Kuhn, Vanderkooi) and of Community Health Sciences (Vanderkooi), Cummings School of Medicine, University of Calgary; Department of Production Animal Health (Nobrega), Faculty of Veterinary Medicine, University of Calgary, Calgary, Alta.; Department of Medical Microbiology (Pitout), University of Pretoria, Pretoria, South Africa
| | - Daniel B Gregson
- Affiliations: Division of Microbiology (Peirano, Gregson, Pitout), Calgary Laboratory Services; Departments of Pathology and Laboratory Medicine (Peirano, Gregson, Vanderkooi, Pitout), of Medicine (Gregson, Kuhn), of Paediatrics (Kuhn, Vanderkooi) and of Community Health Sciences (Vanderkooi), Cummings School of Medicine, University of Calgary; Department of Production Animal Health (Nobrega), Faculty of Veterinary Medicine, University of Calgary, Calgary, Alta.; Department of Medical Microbiology (Pitout), University of Pretoria, Pretoria, South Africa
| | - Susan Kuhn
- Affiliations: Division of Microbiology (Peirano, Gregson, Pitout), Calgary Laboratory Services; Departments of Pathology and Laboratory Medicine (Peirano, Gregson, Vanderkooi, Pitout), of Medicine (Gregson, Kuhn), of Paediatrics (Kuhn, Vanderkooi) and of Community Health Sciences (Vanderkooi), Cummings School of Medicine, University of Calgary; Department of Production Animal Health (Nobrega), Faculty of Veterinary Medicine, University of Calgary, Calgary, Alta.; Department of Medical Microbiology (Pitout), University of Pretoria, Pretoria, South Africa
| | - Otto G Vanderkooi
- Affiliations: Division of Microbiology (Peirano, Gregson, Pitout), Calgary Laboratory Services; Departments of Pathology and Laboratory Medicine (Peirano, Gregson, Vanderkooi, Pitout), of Medicine (Gregson, Kuhn), of Paediatrics (Kuhn, Vanderkooi) and of Community Health Sciences (Vanderkooi), Cummings School of Medicine, University of Calgary; Department of Production Animal Health (Nobrega), Faculty of Veterinary Medicine, University of Calgary, Calgary, Alta.; Department of Medical Microbiology (Pitout), University of Pretoria, Pretoria, South Africa
| | - Diego B Nobrega
- Affiliations: Division of Microbiology (Peirano, Gregson, Pitout), Calgary Laboratory Services; Departments of Pathology and Laboratory Medicine (Peirano, Gregson, Vanderkooi, Pitout), of Medicine (Gregson, Kuhn), of Paediatrics (Kuhn, Vanderkooi) and of Community Health Sciences (Vanderkooi), Cummings School of Medicine, University of Calgary; Department of Production Animal Health (Nobrega), Faculty of Veterinary Medicine, University of Calgary, Calgary, Alta.; Department of Medical Microbiology (Pitout), University of Pretoria, Pretoria, South Africa
| | - Johann D D Pitout
- Affiliations: Division of Microbiology (Peirano, Gregson, Pitout), Calgary Laboratory Services; Departments of Pathology and Laboratory Medicine (Peirano, Gregson, Vanderkooi, Pitout), of Medicine (Gregson, Kuhn), of Paediatrics (Kuhn, Vanderkooi) and of Community Health Sciences (Vanderkooi), Cummings School of Medicine, University of Calgary; Department of Production Animal Health (Nobrega), Faculty of Veterinary Medicine, University of Calgary, Calgary, Alta.; Department of Medical Microbiology (Pitout), University of Pretoria, Pretoria, South Africa
| |
Collapse
|
41
|
Ehlmann BL, Edgett KS, Sutter B, Achilles CN, Litvak ML, Lapotre MGA, Sullivan R, Fraeman AA, Arvidson RE, Blake DF, Bridges NT, Conrad PG, Cousin A, Downs RT, Gabriel TSJ, Gellert R, Hamilton VE, Hardgrove C, Johnson JR, Kuhn S, Mahaffy PR, Maurice S, McHenry M, Meslin PY, Ming DW, Minitti ME, Morookian JM, Morris RV, O'Connell-Cooper CD, Pinet PC, Rowland SK, Schröder S, Siebach KL, Stein NT, Thompson LM, Vaniman DT, Vasavada AR, Wellington DF, Wiens RC, Yen AS. Chemistry, mineralogy, and grain properties at Namib and High dunes, Bagnold dune field, Gale crater, Mars: A synthesis of Curiosity rover observations. J Geophys Res Planets 2017; 122:2510-2543. [PMID: 29497589 DOI: 10.1002/2016je005225] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/16/2017] [Revised: 05/18/2017] [Accepted: 05/19/2017] [Indexed: 05/25/2023]
Abstract
The Mars Science Laboratory Curiosity rover performed coordinated measurements to examine the textures and compositions of aeolian sands in the active Bagnold dune field. The Bagnold sands are rounded to subrounded, very fine to medium sized (~45-500 μm) with ≥6 distinct grain colors. In contrast to sands examined by Curiosity in a dust-covered, inactive bedform called Rocknest and soils at other landing sites, Bagnold sands are darker, less red, better sorted, have fewer silt-sized or smaller grains, and show no evidence for cohesion. Nevertheless, Bagnold mineralogy and Rocknest mineralogy are similar with plagioclase, olivine, and pyroxenes in similar proportions comprising >90% of crystalline phases, along with a substantial amorphous component (35% ± 15%). Yet Bagnold and Rocknest bulk chemistry differ. Bagnold sands are Si enriched relative to other soils at Gale crater, and H2O, S, and Cl are lower relative to all previously measured Martian soils and most Gale crater rocks. Mg, Ni, Fe, and Mn are enriched in the coarse-sieved fraction of Bagnold sands, corroborated by visible/near-infrared spectra that suggest enrichment of olivine. Collectively, patterns in major element chemistry and volatile release data indicate two distinctive volatile reservoirs in Martian soils: (1) amorphous components in the sand-sized fraction (represented by Bagnold) that are Si-enriched, hydroxylated alteration products and/or H2O- or OH-bearing impact or volcanic glasses and (2) amorphous components in the fine fraction (<40 μm; represented by Rocknest and other bright soils) that are Fe, S, and Cl enriched with low Si and adsorbed and structural H2O.
Collapse
|
42
|
Ehlmann BL, Edgett KS, Sutter B, Achilles CN, Litvak ML, Lapotre MGA, Sullivan R, Fraeman AA, Arvidson RE, Blake DF, Bridges NT, Conrad PG, Cousin A, Downs RT, Gabriel TSJ, Gellert R, Hamilton VE, Hardgrove C, Johnson JR, Kuhn S, Mahaffy PR, Maurice S, McHenry M, Meslin P, Ming DW, Minitti ME, Morookian JM, Morris RV, O'Connell‐Cooper CD, Pinet PC, Rowland SK, Schröder S, Siebach KL, Stein NT, Thompson LM, Vaniman DT, Vasavada AR, Wellington DF, Wiens RC, Yen AS. Chemistry, mineralogy, and grain properties at Namib and High dunes, Bagnold dune field, Gale crater, Mars: A synthesis of Curiosity rover observations. J Geophys Res Planets 2017; 122:2510-2543. [PMID: 29497589 PMCID: PMC5815393 DOI: 10.1002/2017je005267] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/16/2017] [Revised: 05/18/2017] [Accepted: 05/19/2017] [Indexed: 05/31/2023]
Abstract
The Mars Science Laboratory Curiosity rover performed coordinated measurements to examine the textures and compositions of aeolian sands in the active Bagnold dune field. The Bagnold sands are rounded to subrounded, very fine to medium sized (~45-500 μm) with ≥6 distinct grain colors. In contrast to sands examined by Curiosity in a dust-covered, inactive bedform called Rocknest and soils at other landing sites, Bagnold sands are darker, less red, better sorted, have fewer silt-sized or smaller grains, and show no evidence for cohesion. Nevertheless, Bagnold mineralogy and Rocknest mineralogy are similar with plagioclase, olivine, and pyroxenes in similar proportions comprising >90% of crystalline phases, along with a substantial amorphous component (35% ± 15%). Yet Bagnold and Rocknest bulk chemistry differ. Bagnold sands are Si enriched relative to other soils at Gale crater, and H2O, S, and Cl are lower relative to all previously measured Martian soils and most Gale crater rocks. Mg, Ni, Fe, and Mn are enriched in the coarse-sieved fraction of Bagnold sands, corroborated by visible/near-infrared spectra that suggest enrichment of olivine. Collectively, patterns in major element chemistry and volatile release data indicate two distinctive volatile reservoirs in Martian soils: (1) amorphous components in the sand-sized fraction (represented by Bagnold) that are Si-enriched, hydroxylated alteration products and/or H2O- or OH-bearing impact or volcanic glasses and (2) amorphous components in the fine fraction (<40 μm; represented by Rocknest and other bright soils) that are Fe, S, and Cl enriched with low Si and adsorbed and structural H2O.
Collapse
|
43
|
Leder K, Grobusch MP, Gautret P, Chen LH, Kuhn S, Lim PL, Yates J, McCarthy AE, Rothe C, Kato Y, Bottieau E, Huber K, Schwartz E, Stauffer W, Malvy D, Shaw MTM, Rapp C, Blumberg L, Jensenius M, van Genderen PJJ, Hamer DH. Zika beyond the Americas: Travelers as sentinels of Zika virus transmission. A GeoSentinel analysis, 2012 to 2016. PLoS One 2017; 12:e0185689. [PMID: 28973011 PMCID: PMC5626466 DOI: 10.1371/journal.pone.0185689] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2017] [Accepted: 09/18/2017] [Indexed: 11/29/2022] Open
Abstract
Background Zika virus (ZIKV) was first isolated in Africa; decades later, caused large outbreaks in the Pacific, and is considered endemic in Asia. We aim to describe ZIKV disease epidemiology outside the Americas, the importance of travelers as sentinels of disease transmission, and discrepancies in travel advisories from major international health organizations. Methods and findings This descriptive analysis using GeoSentinel Surveillance Network records involves sixty-four travel and tropical medicine clinics in 29 countries. Ill returned travelers with a confirmed or probable diagnosis of ZIKV disease acquired in Africa, Asia and the Pacific seen between 1 January 2012 and 31 December 2016 are included, and the frequencies of demographic, trip, and diagnostic characteristics described. ZIKV was acquired in Asia (18), the Pacific (10) and Africa (1). For five countries (Indonesia, Philippines, Thailand, Vietnam, Cameroon), GeoSentinel patients were sentinel markers of recent Zika activity. Additionally, the first confirmed ZIKV infection acquired in Kiribati was reported to GeoSentinel (2015), and a probable case was reported from Timor Leste (April 2016), representing the only case known to date. Review of Zika situation updates from major international health authorities for country risk classifications shows heterogeneity in ZIKV country travel advisories. Conclusions Travelers are integral to the global spread of ZIKV, serving as sentinel markers of disease activity. Although GeoSentinel data are collected by specialized clinics and do not capture all imported cases, we show that surveillance of imported infections by returned travelers augments local surveillance system data regarding ZIKV epidemiology and can assist with risk categorization by international authorities. However, travel advisories are variable due to risk uncertainties.
Collapse
Affiliation(s)
- Karin Leder
- School of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
- Victorian Infectious Disease Service, Royal Melbourne Hospital at the Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
- * E-mail:
| | - Martin P. Grobusch
- Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Philippe Gautret
- Aix Marseille Université, UM63, CNRS 7278, IRD 198, INSERM 1095, IHU Méditerranée Infection, Marseillle, France
| | - Lin H. Chen
- Travel Medicine Center, Mount Auburn Hospital, Cambridge, Massachusetts, United States of America
- Harvard Medical School, Boston, Massachusetts, United States of America
| | | | - Poh Lian Lim
- Institute of Infectious Disease & Epidemiology, Tan Tock Seng Hospital, Singapore, Singapore
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
| | - Johnnie Yates
- Hawaii Permenente Medical Group, Honolulu, Hawaii, United States of America
| | - Anne E. McCarthy
- Department of Medicine, The Ottawa Hospital, Ottawa, Canada
- University of Ottawa, Ottawa, Canada
| | - Camilla Rothe
- University of Hamburg, Division of Tropical Medicine and Infectious Diseases, Hamburg, Germany
| | - Yasuyuki Kato
- Division of Preparedness and Emerging Infections, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| | - Emmanuel Bottieau
- Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
| | - Kristina Huber
- Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Munich, Germany
| | - Eli Schwartz
- Center for Geographic Medicine and Tropical Diseases, Chaim Sheba Medical Center, Tel Hashomer, Tel Aviv, Israel
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - William Stauffer
- Department of Medicine and Pediatrics, Infectious Diseases and Internal Medicine, University of Minnesota, Minnesota, United States of America
| | - Denis Malvy
- University Hospital Center & Inserm 1219, University of Bordeaux, Bordeaux, France
| | | | - Christophe Rapp
- CMETE Travel Clinic Paris, Department of Infectious and Tropical Diseases, Begin Military Hospital, Saint-Mandé, France
| | - Lucille Blumberg
- National Institute for Communicable Diseases, Johannesburg, South Africa
| | - Mogens Jensenius
- Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway
| | | | - Davidson H. Hamer
- Department of Global Health and Center for Global Health and Development, Boston University School of Public Health, Boston, Massachusetts, United States of America
- Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America
| | | |
Collapse
|
44
|
Fitzsimmons D, Kloseck M, Kuhn S. DESIGNING AGE-INTEGRATED COMMUNITIES: LESSONS FROM A NATURALLY OCCURRING RETIREMENT COMMUNITY. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.1131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | - M. Kloseck
- Western University, London, Ontario, Canada,
| | - S. Kuhn
- University of Cambridge, Cambridge, United Kingdom
| |
Collapse
|
45
|
Beier F, Hupel C, Kuhn S, Hein S, Nold J, Proske F, Sattler B, Liem A, Jauregui C, Limpert J, Haarlammert N, Schreiber T, Eberhardt R, Tünnermann A. Single mode 4.3 kW output power from a diode-pumped Yb-doped fiber amplifier. Opt Express 2017; 25:14892-14899. [PMID: 28789071 DOI: 10.1364/oe.25.014892] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/31/2017] [Accepted: 05/22/2017] [Indexed: 06/07/2023]
Abstract
We investigate the average power scaling of two diode-pumped Yb-doped fiber amplifiers emitting a diffraction-limited beam. The first fiber under investigation with a core diameter of 30 µm was able to amplify a 10 W narrow linewidth seed laser up to 2.8 kW average output power before the onset of transverse mode instabilities (TMI). A further power scaling was achieved using a second fiber with a smaller core size (23µm), which allowed for a narrow linewidth output power of 3.5 kW limited by stimulated Brillouin scattering (SBS). We mitigated SBS using a spectral broadening mechanism, which allowed us to further increase the output power to 4.3 kW only limited by the available pump power. Up to this power level, a high slope efficiency of 90% with diffraction-limited beam quality and without any sign of TMI or stimulated Raman scattering for a spectral dynamic range of higher than -80 dB was obtained.
Collapse
|
46
|
Boggild AK, Libman M, Yansouni CP, Freedman DO, Kuhn S, Plourde P, Mirzanejad Y, Hajek J, Chakrabarti S, Geduld J, McCarthy AE, Vincelette J, Ghesquiere W, Kain KC. Response to “Selection bias”. CMAJ 2017; 189:E674. [DOI: 10.1503/cmaj.732964] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
47
|
Boggild AK, Geduld J, Libman M, Yansouni CP, McCarthy AE, Hajek J, Ghesquiere W, Mirzanejad Y, Vincelette J, Kuhn S, Plourde PJ, Chakrabarti S, Freedman DO, Kain KC. Surveillance report of Zika virus among Canadian travellers returning from the Americas. CMAJ 2017; 189:E334-E340. [PMID: 28280063 PMCID: PMC5334005 DOI: 10.1503/cmaj.161241] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/12/2017] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND Widespread transmission of Zika virus in the Americas has occurred since late 2015. We examined demographic and travel-related characteristics of returned Canadian travellers with Zika infection acquired in the Americas to illuminate risk factors for acquisition and the clinical spectrum. METHODS We analyzed demographic and travel-related data for returned Canadian travellers who presented to a CanTravNet site between October 2015 and September 2016 for care of Zika virus acquired in the Americas. Data were collected with use of the GeoSentinel Surveillance Network data platform. RESULTS During the study period, 1118 travellers presented to a CanTravNet site after returning from the Americas, 41 (3.7%) of whom had Zika infection. Zika infection from the Americas was diagnosed at CanTravNet sites as often as dengue (n = 41) over the study period. In the first half of the study period, Zika virus burden was borne by people visiting friends and relatives in South America. In the latter half, coincident with the increased spread of Zika throughout the Caribbean and Central America, Zika virus occurred more often in tourists in the Caribbean. Forty (98%) of the travellers with Zika infection acquired it through probable mosquito exposure, and 1 had confirmed sexual acquisition. Congenital transmission occurred in 2 of 3 pregnancies. Two (5%) of those with Zika had symptoms resembling those of Guillain-Barré syndrome, 1 of whom also had Zika viral meningitis. INTERPRETATION Even in this small cohort, we observed the full clinical spectrum of acute Zika virus, including adverse fetal and neurologic outcomes. Our observations suggest that complications from Zika infection are underestimated by data arising exclusively from populations where Zika is endemic. Travellers should adhere to mosquito-avoidance measures and barrier protection during sexual activity.
Collapse
Affiliation(s)
- Andrea K Boggild
- Department of Medicine (Boggild, Chakrabarti, Kain), Tropical Disease Unit, Division of Infectious Diseases, University Health Network and University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; The J.D. MacLean Centre for Tropical Diseases (Libman, Yansouni), McGill University, Montréal, Que.; Tropical Medicine and International Health Clinic (McCarthy), Division of Infectious Diseases, Ottawa Hospital and University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek, Mirzanejad), University of British Columbia, Vancouver, BC; Infectious Diseases (Ghesquiere), Vancouver Island Health Authority, Victoria, BC; Department of Medicine (Ghesquiere), University of British Columbia, Vancouver, BC; Fraser Health (Mirzanejad), Surrey, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Departments of Pediatrics and Medicine (Kuhn), Section of Pediatric Infectious Diseases, Alberta Children's Hospital and University of Calgary, Calgary, Alta.; Travel Health and Tropical Medicine Services (Plourde), Population and Public Health Program, Winnipeg Regional Health Authority, Winnipeg, Man.; Trillium Health Partners (Chakrabarti), Mississauga, Ont.; Department of Medicine (Freedman), Center for Geographic Medicine, University of Alabama Birmingham, Birmingham, Ala.; SAR Laboratories (Kain), Sandra Rotman Centre, Toronto, Ont.
| | - Jennifer Geduld
- Department of Medicine (Boggild, Chakrabarti, Kain), Tropical Disease Unit, Division of Infectious Diseases, University Health Network and University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; The J.D. MacLean Centre for Tropical Diseases (Libman, Yansouni), McGill University, Montréal, Que.; Tropical Medicine and International Health Clinic (McCarthy), Division of Infectious Diseases, Ottawa Hospital and University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek, Mirzanejad), University of British Columbia, Vancouver, BC; Infectious Diseases (Ghesquiere), Vancouver Island Health Authority, Victoria, BC; Department of Medicine (Ghesquiere), University of British Columbia, Vancouver, BC; Fraser Health (Mirzanejad), Surrey, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Departments of Pediatrics and Medicine (Kuhn), Section of Pediatric Infectious Diseases, Alberta Children's Hospital and University of Calgary, Calgary, Alta.; Travel Health and Tropical Medicine Services (Plourde), Population and Public Health Program, Winnipeg Regional Health Authority, Winnipeg, Man.; Trillium Health Partners (Chakrabarti), Mississauga, Ont.; Department of Medicine (Freedman), Center for Geographic Medicine, University of Alabama Birmingham, Birmingham, Ala.; SAR Laboratories (Kain), Sandra Rotman Centre, Toronto, Ont
| | - Michael Libman
- Department of Medicine (Boggild, Chakrabarti, Kain), Tropical Disease Unit, Division of Infectious Diseases, University Health Network and University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; The J.D. MacLean Centre for Tropical Diseases (Libman, Yansouni), McGill University, Montréal, Que.; Tropical Medicine and International Health Clinic (McCarthy), Division of Infectious Diseases, Ottawa Hospital and University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek, Mirzanejad), University of British Columbia, Vancouver, BC; Infectious Diseases (Ghesquiere), Vancouver Island Health Authority, Victoria, BC; Department of Medicine (Ghesquiere), University of British Columbia, Vancouver, BC; Fraser Health (Mirzanejad), Surrey, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Departments of Pediatrics and Medicine (Kuhn), Section of Pediatric Infectious Diseases, Alberta Children's Hospital and University of Calgary, Calgary, Alta.; Travel Health and Tropical Medicine Services (Plourde), Population and Public Health Program, Winnipeg Regional Health Authority, Winnipeg, Man.; Trillium Health Partners (Chakrabarti), Mississauga, Ont.; Department of Medicine (Freedman), Center for Geographic Medicine, University of Alabama Birmingham, Birmingham, Ala.; SAR Laboratories (Kain), Sandra Rotman Centre, Toronto, Ont
| | - Cedric P Yansouni
- Department of Medicine (Boggild, Chakrabarti, Kain), Tropical Disease Unit, Division of Infectious Diseases, University Health Network and University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; The J.D. MacLean Centre for Tropical Diseases (Libman, Yansouni), McGill University, Montréal, Que.; Tropical Medicine and International Health Clinic (McCarthy), Division of Infectious Diseases, Ottawa Hospital and University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek, Mirzanejad), University of British Columbia, Vancouver, BC; Infectious Diseases (Ghesquiere), Vancouver Island Health Authority, Victoria, BC; Department of Medicine (Ghesquiere), University of British Columbia, Vancouver, BC; Fraser Health (Mirzanejad), Surrey, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Departments of Pediatrics and Medicine (Kuhn), Section of Pediatric Infectious Diseases, Alberta Children's Hospital and University of Calgary, Calgary, Alta.; Travel Health and Tropical Medicine Services (Plourde), Population and Public Health Program, Winnipeg Regional Health Authority, Winnipeg, Man.; Trillium Health Partners (Chakrabarti), Mississauga, Ont.; Department of Medicine (Freedman), Center for Geographic Medicine, University of Alabama Birmingham, Birmingham, Ala.; SAR Laboratories (Kain), Sandra Rotman Centre, Toronto, Ont
| | - Anne E McCarthy
- Department of Medicine (Boggild, Chakrabarti, Kain), Tropical Disease Unit, Division of Infectious Diseases, University Health Network and University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; The J.D. MacLean Centre for Tropical Diseases (Libman, Yansouni), McGill University, Montréal, Que.; Tropical Medicine and International Health Clinic (McCarthy), Division of Infectious Diseases, Ottawa Hospital and University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek, Mirzanejad), University of British Columbia, Vancouver, BC; Infectious Diseases (Ghesquiere), Vancouver Island Health Authority, Victoria, BC; Department of Medicine (Ghesquiere), University of British Columbia, Vancouver, BC; Fraser Health (Mirzanejad), Surrey, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Departments of Pediatrics and Medicine (Kuhn), Section of Pediatric Infectious Diseases, Alberta Children's Hospital and University of Calgary, Calgary, Alta.; Travel Health and Tropical Medicine Services (Plourde), Population and Public Health Program, Winnipeg Regional Health Authority, Winnipeg, Man.; Trillium Health Partners (Chakrabarti), Mississauga, Ont.; Department of Medicine (Freedman), Center for Geographic Medicine, University of Alabama Birmingham, Birmingham, Ala.; SAR Laboratories (Kain), Sandra Rotman Centre, Toronto, Ont
| | - Jan Hajek
- Department of Medicine (Boggild, Chakrabarti, Kain), Tropical Disease Unit, Division of Infectious Diseases, University Health Network and University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; The J.D. MacLean Centre for Tropical Diseases (Libman, Yansouni), McGill University, Montréal, Que.; Tropical Medicine and International Health Clinic (McCarthy), Division of Infectious Diseases, Ottawa Hospital and University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek, Mirzanejad), University of British Columbia, Vancouver, BC; Infectious Diseases (Ghesquiere), Vancouver Island Health Authority, Victoria, BC; Department of Medicine (Ghesquiere), University of British Columbia, Vancouver, BC; Fraser Health (Mirzanejad), Surrey, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Departments of Pediatrics and Medicine (Kuhn), Section of Pediatric Infectious Diseases, Alberta Children's Hospital and University of Calgary, Calgary, Alta.; Travel Health and Tropical Medicine Services (Plourde), Population and Public Health Program, Winnipeg Regional Health Authority, Winnipeg, Man.; Trillium Health Partners (Chakrabarti), Mississauga, Ont.; Department of Medicine (Freedman), Center for Geographic Medicine, University of Alabama Birmingham, Birmingham, Ala.; SAR Laboratories (Kain), Sandra Rotman Centre, Toronto, Ont
| | - Wayne Ghesquiere
- Department of Medicine (Boggild, Chakrabarti, Kain), Tropical Disease Unit, Division of Infectious Diseases, University Health Network and University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; The J.D. MacLean Centre for Tropical Diseases (Libman, Yansouni), McGill University, Montréal, Que.; Tropical Medicine and International Health Clinic (McCarthy), Division of Infectious Diseases, Ottawa Hospital and University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek, Mirzanejad), University of British Columbia, Vancouver, BC; Infectious Diseases (Ghesquiere), Vancouver Island Health Authority, Victoria, BC; Department of Medicine (Ghesquiere), University of British Columbia, Vancouver, BC; Fraser Health (Mirzanejad), Surrey, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Departments of Pediatrics and Medicine (Kuhn), Section of Pediatric Infectious Diseases, Alberta Children's Hospital and University of Calgary, Calgary, Alta.; Travel Health and Tropical Medicine Services (Plourde), Population and Public Health Program, Winnipeg Regional Health Authority, Winnipeg, Man.; Trillium Health Partners (Chakrabarti), Mississauga, Ont.; Department of Medicine (Freedman), Center for Geographic Medicine, University of Alabama Birmingham, Birmingham, Ala.; SAR Laboratories (Kain), Sandra Rotman Centre, Toronto, Ont
| | - Yazdan Mirzanejad
- Department of Medicine (Boggild, Chakrabarti, Kain), Tropical Disease Unit, Division of Infectious Diseases, University Health Network and University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; The J.D. MacLean Centre for Tropical Diseases (Libman, Yansouni), McGill University, Montréal, Que.; Tropical Medicine and International Health Clinic (McCarthy), Division of Infectious Diseases, Ottawa Hospital and University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek, Mirzanejad), University of British Columbia, Vancouver, BC; Infectious Diseases (Ghesquiere), Vancouver Island Health Authority, Victoria, BC; Department of Medicine (Ghesquiere), University of British Columbia, Vancouver, BC; Fraser Health (Mirzanejad), Surrey, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Departments of Pediatrics and Medicine (Kuhn), Section of Pediatric Infectious Diseases, Alberta Children's Hospital and University of Calgary, Calgary, Alta.; Travel Health and Tropical Medicine Services (Plourde), Population and Public Health Program, Winnipeg Regional Health Authority, Winnipeg, Man.; Trillium Health Partners (Chakrabarti), Mississauga, Ont.; Department of Medicine (Freedman), Center for Geographic Medicine, University of Alabama Birmingham, Birmingham, Ala.; SAR Laboratories (Kain), Sandra Rotman Centre, Toronto, Ont
| | - Jean Vincelette
- Department of Medicine (Boggild, Chakrabarti, Kain), Tropical Disease Unit, Division of Infectious Diseases, University Health Network and University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; The J.D. MacLean Centre for Tropical Diseases (Libman, Yansouni), McGill University, Montréal, Que.; Tropical Medicine and International Health Clinic (McCarthy), Division of Infectious Diseases, Ottawa Hospital and University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek, Mirzanejad), University of British Columbia, Vancouver, BC; Infectious Diseases (Ghesquiere), Vancouver Island Health Authority, Victoria, BC; Department of Medicine (Ghesquiere), University of British Columbia, Vancouver, BC; Fraser Health (Mirzanejad), Surrey, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Departments of Pediatrics and Medicine (Kuhn), Section of Pediatric Infectious Diseases, Alberta Children's Hospital and University of Calgary, Calgary, Alta.; Travel Health and Tropical Medicine Services (Plourde), Population and Public Health Program, Winnipeg Regional Health Authority, Winnipeg, Man.; Trillium Health Partners (Chakrabarti), Mississauga, Ont.; Department of Medicine (Freedman), Center for Geographic Medicine, University of Alabama Birmingham, Birmingham, Ala.; SAR Laboratories (Kain), Sandra Rotman Centre, Toronto, Ont
| | - Susan Kuhn
- Department of Medicine (Boggild, Chakrabarti, Kain), Tropical Disease Unit, Division of Infectious Diseases, University Health Network and University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; The J.D. MacLean Centre for Tropical Diseases (Libman, Yansouni), McGill University, Montréal, Que.; Tropical Medicine and International Health Clinic (McCarthy), Division of Infectious Diseases, Ottawa Hospital and University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek, Mirzanejad), University of British Columbia, Vancouver, BC; Infectious Diseases (Ghesquiere), Vancouver Island Health Authority, Victoria, BC; Department of Medicine (Ghesquiere), University of British Columbia, Vancouver, BC; Fraser Health (Mirzanejad), Surrey, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Departments of Pediatrics and Medicine (Kuhn), Section of Pediatric Infectious Diseases, Alberta Children's Hospital and University of Calgary, Calgary, Alta.; Travel Health and Tropical Medicine Services (Plourde), Population and Public Health Program, Winnipeg Regional Health Authority, Winnipeg, Man.; Trillium Health Partners (Chakrabarti), Mississauga, Ont.; Department of Medicine (Freedman), Center for Geographic Medicine, University of Alabama Birmingham, Birmingham, Ala.; SAR Laboratories (Kain), Sandra Rotman Centre, Toronto, Ont
| | - Pierre J Plourde
- Department of Medicine (Boggild, Chakrabarti, Kain), Tropical Disease Unit, Division of Infectious Diseases, University Health Network and University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; The J.D. MacLean Centre for Tropical Diseases (Libman, Yansouni), McGill University, Montréal, Que.; Tropical Medicine and International Health Clinic (McCarthy), Division of Infectious Diseases, Ottawa Hospital and University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek, Mirzanejad), University of British Columbia, Vancouver, BC; Infectious Diseases (Ghesquiere), Vancouver Island Health Authority, Victoria, BC; Department of Medicine (Ghesquiere), University of British Columbia, Vancouver, BC; Fraser Health (Mirzanejad), Surrey, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Departments of Pediatrics and Medicine (Kuhn), Section of Pediatric Infectious Diseases, Alberta Children's Hospital and University of Calgary, Calgary, Alta.; Travel Health and Tropical Medicine Services (Plourde), Population and Public Health Program, Winnipeg Regional Health Authority, Winnipeg, Man.; Trillium Health Partners (Chakrabarti), Mississauga, Ont.; Department of Medicine (Freedman), Center for Geographic Medicine, University of Alabama Birmingham, Birmingham, Ala.; SAR Laboratories (Kain), Sandra Rotman Centre, Toronto, Ont
| | - Sumontra Chakrabarti
- Department of Medicine (Boggild, Chakrabarti, Kain), Tropical Disease Unit, Division of Infectious Diseases, University Health Network and University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; The J.D. MacLean Centre for Tropical Diseases (Libman, Yansouni), McGill University, Montréal, Que.; Tropical Medicine and International Health Clinic (McCarthy), Division of Infectious Diseases, Ottawa Hospital and University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek, Mirzanejad), University of British Columbia, Vancouver, BC; Infectious Diseases (Ghesquiere), Vancouver Island Health Authority, Victoria, BC; Department of Medicine (Ghesquiere), University of British Columbia, Vancouver, BC; Fraser Health (Mirzanejad), Surrey, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Departments of Pediatrics and Medicine (Kuhn), Section of Pediatric Infectious Diseases, Alberta Children's Hospital and University of Calgary, Calgary, Alta.; Travel Health and Tropical Medicine Services (Plourde), Population and Public Health Program, Winnipeg Regional Health Authority, Winnipeg, Man.; Trillium Health Partners (Chakrabarti), Mississauga, Ont.; Department of Medicine (Freedman), Center for Geographic Medicine, University of Alabama Birmingham, Birmingham, Ala.; SAR Laboratories (Kain), Sandra Rotman Centre, Toronto, Ont
| | - David O Freedman
- Department of Medicine (Boggild, Chakrabarti, Kain), Tropical Disease Unit, Division of Infectious Diseases, University Health Network and University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; The J.D. MacLean Centre for Tropical Diseases (Libman, Yansouni), McGill University, Montréal, Que.; Tropical Medicine and International Health Clinic (McCarthy), Division of Infectious Diseases, Ottawa Hospital and University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek, Mirzanejad), University of British Columbia, Vancouver, BC; Infectious Diseases (Ghesquiere), Vancouver Island Health Authority, Victoria, BC; Department of Medicine (Ghesquiere), University of British Columbia, Vancouver, BC; Fraser Health (Mirzanejad), Surrey, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Departments of Pediatrics and Medicine (Kuhn), Section of Pediatric Infectious Diseases, Alberta Children's Hospital and University of Calgary, Calgary, Alta.; Travel Health and Tropical Medicine Services (Plourde), Population and Public Health Program, Winnipeg Regional Health Authority, Winnipeg, Man.; Trillium Health Partners (Chakrabarti), Mississauga, Ont.; Department of Medicine (Freedman), Center for Geographic Medicine, University of Alabama Birmingham, Birmingham, Ala.; SAR Laboratories (Kain), Sandra Rotman Centre, Toronto, Ont
| | - Kevin C Kain
- Department of Medicine (Boggild, Chakrabarti, Kain), Tropical Disease Unit, Division of Infectious Diseases, University Health Network and University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; The J.D. MacLean Centre for Tropical Diseases (Libman, Yansouni), McGill University, Montréal, Que.; Tropical Medicine and International Health Clinic (McCarthy), Division of Infectious Diseases, Ottawa Hospital and University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek, Mirzanejad), University of British Columbia, Vancouver, BC; Infectious Diseases (Ghesquiere), Vancouver Island Health Authority, Victoria, BC; Department of Medicine (Ghesquiere), University of British Columbia, Vancouver, BC; Fraser Health (Mirzanejad), Surrey, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Departments of Pediatrics and Medicine (Kuhn), Section of Pediatric Infectious Diseases, Alberta Children's Hospital and University of Calgary, Calgary, Alta.; Travel Health and Tropical Medicine Services (Plourde), Population and Public Health Program, Winnipeg Regional Health Authority, Winnipeg, Man.; Trillium Health Partners (Chakrabarti), Mississauga, Ont.; Department of Medicine (Freedman), Center for Geographic Medicine, University of Alabama Birmingham, Birmingham, Ala.; SAR Laboratories (Kain), Sandra Rotman Centre, Toronto, Ont
| |
Collapse
|
48
|
Hamer DH, Barbre KA, Chen LH, Grobusch MP, Schlagenhauf P, Goorhuis A, van Genderen PJJ, Molina I, Asgeirsson H, Kozarsky PE, Caumes E, Hagmann SH, Mockenhaupt FP, Eperon G, Barnett ED, Bottieau E, Boggild AK, Gautret P, Hynes NA, Kuhn S, Lash RR, Leder K, Libman M, Malvy DJM, Perret C, Rothe C, Schwartz E, Wilder-Smith A, Cetron MS, Esposito DH. Travel-Associated Zika Virus Disease Acquired in the Americas Through February 2016: A GeoSentinel Analysis. Ann Intern Med 2017; 166:99-108. [PMID: 27893080 DOI: 10.7326/m16-1842] [Citation(s) in RCA: 59] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Zika virus has spread rapidly in the Americas and has been imported into many nonendemic countries by travelers. OBJECTIVE To describe clinical manifestations and epidemiology of Zika virus disease in travelers exposed in the Americas. DESIGN Descriptive, using GeoSentinel records. SETTING 63 travel and tropical medicine clinics in 30 countries. PATIENTS Ill returned travelers with a confirmed, probable, or clinically suspected diagnosis of Zika virus disease seen between January 2013 and 29 February 2016. MEASUREMENTS Frequencies of demographic, trip, and clinical characteristics and complications. RESULTS Starting in May 2015, 93 cases of Zika virus disease were reported. Common symptoms included exanthema (88%), fever (76%), and arthralgia (72%). Fifty-nine percent of patients were exposed in South America; 71% were diagnosed in Europe. Case status was established most commonly by polymerase chain reaction (PCR) testing of blood and less often by PCR testing of other body fluids or serology and plaque-reduction neutralization testing. Two patients developed Guillain-Barré syndrome, and 3 of 4 pregnancies had adverse outcomes (microcephaly, major fetal neurologic abnormalities, and intrauterine fetal death). LIMITATION Surveillance data collected by specialized clinics may not be representative of all ill returned travelers, and denominator data are unavailable. CONCLUSION These surveillance data help characterize the clinical manifestations and adverse outcomes of Zika virus disease among travelers infected in the Americas and show a need for global standardization of diagnostic testing. The serious fetal complications observed in this study highlight the importance of travel advisories and prevention measures for pregnant women and their partners. Travelers are sentinels for global Zika virus circulation and may facilitate further transmission. PRIMARY FUNDING SOURCE Centers for Disease Control and Prevention, International Society of Travel Medicine, and Public Health Agency of Canada.
Collapse
Affiliation(s)
- Davidson H Hamer
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Kira A Barbre
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Lin H Chen
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Martin P Grobusch
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Patricia Schlagenhauf
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Abraham Goorhuis
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Perry J J van Genderen
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Israel Molina
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Hilmir Asgeirsson
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Phyllis E Kozarsky
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Eric Caumes
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Stefan H Hagmann
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Frank P Mockenhaupt
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Gilles Eperon
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Elizabeth D Barnett
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Emmanuel Bottieau
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Andrea K Boggild
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Philippe Gautret
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Noreen A Hynes
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Susan Kuhn
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - R Ryan Lash
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Karin Leder
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Michael Libman
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Denis J M Malvy
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Cecilia Perret
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Camilla Rothe
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Eli Schwartz
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Annelies Wilder-Smith
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Martin S Cetron
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | - Douglas H Esposito
- From Boston University School of Public Health, Boston Medical Center, Boston University School of Medicine, and Harvard Medical School, Boston, Massachusetts; Centers for Disease Control and Prevention and Emory University, Atlanta, Georgia; Mount Auburn Hospital, Cambridge, Massachusetts; University of Amsterdam, Amsterdam, the Netherlands; University of Zürich Centre for Travel Medicine, WHO Collaborating Centre for Travellers' Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland; Harbor Hospital, Rotterdam, the Netherlands; Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, PROSICS Barcelona, Barcelona, Spain; Karolinska University Hospital, Stockholm, Sweden; Groupe Hospitalier Pitié-Salpêtrière, UPMC University, Paris, France; Bronx-Lebanon Hospital Center and Icahn School of Medicine at Mount Sinai, Bronx, New York; Charité-Universitätsmedizin Berlin, Berlin, Germany; Geneva University Hospitals, Geneva, Switzerland; Institute of Tropical Medicine, Antwerp, Belgium; Toronto General Hospital, University of Toronto, and Public Health Ontario Laboratories, Toronto, Ontario, Canada; Aix-Marseille University, Marseille, France; Johns Hopkins School of Medicine, Baltimore, Maryland; Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada; Monash University, Melbourne, Victoria, Australia; McGill University, Montreal, Quebec, Canada; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Pontificia Universidad Católica de Chile, Santiago, Chile; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Sheba Medical Center, Tel Hashomer, and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Heidelberg University, Heidelberg, Germany; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; and Umeå University, Umea, Sweden
| | | |
Collapse
|
49
|
Boggild AK, Geduld J, Libman M, Yansouni CP, McCarthy AE, Hajek J, Ghesquiere W, Vincelette J, Kuhn S, Freedman DO, Kain KC. Malaria in travellers returning or migrating to Canada: surveillance report from CanTravNet surveillance data, 2004-2014. CMAJ Open 2016; 4:E352-E358. [PMID: 27730099 PMCID: PMC5047843 DOI: 10.9778/cmajo.20150115] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Malaria remains the most common specific cause of fever in returned travellers and can be life-threatening. We examined demographic and travel correlates of malaria among Canadian travellers and immigrants to identify groups for targeted pretravel intervention. METHODS Descriptive data on ill returned Canadian travellers and immigrants presenting to a CanTravNet site between 2004 and 2014 with a diagnosis of malaria were analyzed. Data were collected using the GeoSentinel data platform. This network comprises 63 specialized travel and tropical medicine clinics, including 7 Canadian sites (Vancouver, Calgary, Toronto, Ottawa, Winnipeg and Montréal), that contribute anonymous, delinked, clinician- and questionnaire-based travel surveillance data on all ill travellers examined to a centralized Structure Query Language database. RESULTS During the study period, 20 345 travellers and immigrants were evaluated, and 93% had a travel-related diagnosis. Of these, 437 (2.1%) patients received 456 malaria diagnoses, the most common species being Plasmodium falciparum (n = 282, 61.8%). People travelling to visit friends and relatives were most well-represented (n = 169, 38.7%), followed by business travellers (n = 71, 16.2%). Sub-Saharan Africa was the most common source region, accounting for 341 (74.8%) malaria diagnoses, followed by South Central Asia (n = 55, 12%). Nigeria was the most well-represented source country, accounting for 41 cases (9.0%). India, a high-volume destination for Canadians, accounted for 40 cases (8.8%), 36 of which were caused by Plasmodium vivax. Of 456 malaria diagnoses, 26 (5.7%) were severe. Of 377 nonimmigrant travellers with malaria, 19.9% (n = 75) travelled for less than 2 weeks, and 7.2% (n = 27) travelled for less than 1 week. INTERPRETATION This analysis provides an epidemiologic framework for Canadian practitioners encountering prospective and returned travellers. It confirms the importance of preventive measures and surveillance associated with travel to sub-Saharan Africa and India, particularly by travellers visiting friends or relatives. Short-duration travel confers important malaria risk.
Collapse
Affiliation(s)
- Andrea K Boggild
- Tropical Disease Unit, Division of Infectious Diseases, Department of Medicine (Boggild, Kain), University Health Network and the University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; JD MacLean Centre for Tropical Diseases and Division of Infectious Diseases, Department of Microbiology (Libman, Yansouni), McGill University Health Centre, Montréal, Que.; Tropical Medicine and International Health Clinic, Division of Infectious Diseases (McCarthy), Ottawa Hospital and the University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek), Vancouver General Hospital, University of British Columbia, Vancouver, BC; Infectious Diseases, Vancouver Island Health Authority, Department of Medicine (Ghesquiere), University of British Columbia, Victoria, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Section of Pediatric Infectious Diseases, Departments of Pediatrics and Medicine (Kuhn), Alberta Children's Hospital and the University of Calgary, Calgary, Alta.; Center for Geographic Medicine, Department of Medicine (Freedman), University of Alabama Birmingham, Birmingham, Ala. SAR Laboratories (Kain), Sandra Rotman Centre for Global Health, Toronto, Ont
| | - Jennifer Geduld
- Tropical Disease Unit, Division of Infectious Diseases, Department of Medicine (Boggild, Kain), University Health Network and the University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; JD MacLean Centre for Tropical Diseases and Division of Infectious Diseases, Department of Microbiology (Libman, Yansouni), McGill University Health Centre, Montréal, Que.; Tropical Medicine and International Health Clinic, Division of Infectious Diseases (McCarthy), Ottawa Hospital and the University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek), Vancouver General Hospital, University of British Columbia, Vancouver, BC; Infectious Diseases, Vancouver Island Health Authority, Department of Medicine (Ghesquiere), University of British Columbia, Victoria, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Section of Pediatric Infectious Diseases, Departments of Pediatrics and Medicine (Kuhn), Alberta Children's Hospital and the University of Calgary, Calgary, Alta.; Center for Geographic Medicine, Department of Medicine (Freedman), University of Alabama Birmingham, Birmingham, Ala. SAR Laboratories (Kain), Sandra Rotman Centre for Global Health, Toronto, Ont
| | - Michael Libman
- Tropical Disease Unit, Division of Infectious Diseases, Department of Medicine (Boggild, Kain), University Health Network and the University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; JD MacLean Centre for Tropical Diseases and Division of Infectious Diseases, Department of Microbiology (Libman, Yansouni), McGill University Health Centre, Montréal, Que.; Tropical Medicine and International Health Clinic, Division of Infectious Diseases (McCarthy), Ottawa Hospital and the University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek), Vancouver General Hospital, University of British Columbia, Vancouver, BC; Infectious Diseases, Vancouver Island Health Authority, Department of Medicine (Ghesquiere), University of British Columbia, Victoria, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Section of Pediatric Infectious Diseases, Departments of Pediatrics and Medicine (Kuhn), Alberta Children's Hospital and the University of Calgary, Calgary, Alta.; Center for Geographic Medicine, Department of Medicine (Freedman), University of Alabama Birmingham, Birmingham, Ala. SAR Laboratories (Kain), Sandra Rotman Centre for Global Health, Toronto, Ont
| | - Cedric P Yansouni
- Tropical Disease Unit, Division of Infectious Diseases, Department of Medicine (Boggild, Kain), University Health Network and the University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; JD MacLean Centre for Tropical Diseases and Division of Infectious Diseases, Department of Microbiology (Libman, Yansouni), McGill University Health Centre, Montréal, Que.; Tropical Medicine and International Health Clinic, Division of Infectious Diseases (McCarthy), Ottawa Hospital and the University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek), Vancouver General Hospital, University of British Columbia, Vancouver, BC; Infectious Diseases, Vancouver Island Health Authority, Department of Medicine (Ghesquiere), University of British Columbia, Victoria, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Section of Pediatric Infectious Diseases, Departments of Pediatrics and Medicine (Kuhn), Alberta Children's Hospital and the University of Calgary, Calgary, Alta.; Center for Geographic Medicine, Department of Medicine (Freedman), University of Alabama Birmingham, Birmingham, Ala. SAR Laboratories (Kain), Sandra Rotman Centre for Global Health, Toronto, Ont
| | - Anne E McCarthy
- Tropical Disease Unit, Division of Infectious Diseases, Department of Medicine (Boggild, Kain), University Health Network and the University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; JD MacLean Centre for Tropical Diseases and Division of Infectious Diseases, Department of Microbiology (Libman, Yansouni), McGill University Health Centre, Montréal, Que.; Tropical Medicine and International Health Clinic, Division of Infectious Diseases (McCarthy), Ottawa Hospital and the University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek), Vancouver General Hospital, University of British Columbia, Vancouver, BC; Infectious Diseases, Vancouver Island Health Authority, Department of Medicine (Ghesquiere), University of British Columbia, Victoria, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Section of Pediatric Infectious Diseases, Departments of Pediatrics and Medicine (Kuhn), Alberta Children's Hospital and the University of Calgary, Calgary, Alta.; Center for Geographic Medicine, Department of Medicine (Freedman), University of Alabama Birmingham, Birmingham, Ala. SAR Laboratories (Kain), Sandra Rotman Centre for Global Health, Toronto, Ont
| | - Jan Hajek
- Tropical Disease Unit, Division of Infectious Diseases, Department of Medicine (Boggild, Kain), University Health Network and the University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; JD MacLean Centre for Tropical Diseases and Division of Infectious Diseases, Department of Microbiology (Libman, Yansouni), McGill University Health Centre, Montréal, Que.; Tropical Medicine and International Health Clinic, Division of Infectious Diseases (McCarthy), Ottawa Hospital and the University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek), Vancouver General Hospital, University of British Columbia, Vancouver, BC; Infectious Diseases, Vancouver Island Health Authority, Department of Medicine (Ghesquiere), University of British Columbia, Victoria, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Section of Pediatric Infectious Diseases, Departments of Pediatrics and Medicine (Kuhn), Alberta Children's Hospital and the University of Calgary, Calgary, Alta.; Center for Geographic Medicine, Department of Medicine (Freedman), University of Alabama Birmingham, Birmingham, Ala. SAR Laboratories (Kain), Sandra Rotman Centre for Global Health, Toronto, Ont
| | - Wayne Ghesquiere
- Tropical Disease Unit, Division of Infectious Diseases, Department of Medicine (Boggild, Kain), University Health Network and the University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; JD MacLean Centre for Tropical Diseases and Division of Infectious Diseases, Department of Microbiology (Libman, Yansouni), McGill University Health Centre, Montréal, Que.; Tropical Medicine and International Health Clinic, Division of Infectious Diseases (McCarthy), Ottawa Hospital and the University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek), Vancouver General Hospital, University of British Columbia, Vancouver, BC; Infectious Diseases, Vancouver Island Health Authority, Department of Medicine (Ghesquiere), University of British Columbia, Victoria, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Section of Pediatric Infectious Diseases, Departments of Pediatrics and Medicine (Kuhn), Alberta Children's Hospital and the University of Calgary, Calgary, Alta.; Center for Geographic Medicine, Department of Medicine (Freedman), University of Alabama Birmingham, Birmingham, Ala. SAR Laboratories (Kain), Sandra Rotman Centre for Global Health, Toronto, Ont
| | - Jean Vincelette
- Tropical Disease Unit, Division of Infectious Diseases, Department of Medicine (Boggild, Kain), University Health Network and the University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; JD MacLean Centre for Tropical Diseases and Division of Infectious Diseases, Department of Microbiology (Libman, Yansouni), McGill University Health Centre, Montréal, Que.; Tropical Medicine and International Health Clinic, Division of Infectious Diseases (McCarthy), Ottawa Hospital and the University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek), Vancouver General Hospital, University of British Columbia, Vancouver, BC; Infectious Diseases, Vancouver Island Health Authority, Department of Medicine (Ghesquiere), University of British Columbia, Victoria, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Section of Pediatric Infectious Diseases, Departments of Pediatrics and Medicine (Kuhn), Alberta Children's Hospital and the University of Calgary, Calgary, Alta.; Center for Geographic Medicine, Department of Medicine (Freedman), University of Alabama Birmingham, Birmingham, Ala. SAR Laboratories (Kain), Sandra Rotman Centre for Global Health, Toronto, Ont
| | - Susan Kuhn
- Tropical Disease Unit, Division of Infectious Diseases, Department of Medicine (Boggild, Kain), University Health Network and the University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; JD MacLean Centre for Tropical Diseases and Division of Infectious Diseases, Department of Microbiology (Libman, Yansouni), McGill University Health Centre, Montréal, Que.; Tropical Medicine and International Health Clinic, Division of Infectious Diseases (McCarthy), Ottawa Hospital and the University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek), Vancouver General Hospital, University of British Columbia, Vancouver, BC; Infectious Diseases, Vancouver Island Health Authority, Department of Medicine (Ghesquiere), University of British Columbia, Victoria, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Section of Pediatric Infectious Diseases, Departments of Pediatrics and Medicine (Kuhn), Alberta Children's Hospital and the University of Calgary, Calgary, Alta.; Center for Geographic Medicine, Department of Medicine (Freedman), University of Alabama Birmingham, Birmingham, Ala. SAR Laboratories (Kain), Sandra Rotman Centre for Global Health, Toronto, Ont
| | - David O Freedman
- Tropical Disease Unit, Division of Infectious Diseases, Department of Medicine (Boggild, Kain), University Health Network and the University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; JD MacLean Centre for Tropical Diseases and Division of Infectious Diseases, Department of Microbiology (Libman, Yansouni), McGill University Health Centre, Montréal, Que.; Tropical Medicine and International Health Clinic, Division of Infectious Diseases (McCarthy), Ottawa Hospital and the University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek), Vancouver General Hospital, University of British Columbia, Vancouver, BC; Infectious Diseases, Vancouver Island Health Authority, Department of Medicine (Ghesquiere), University of British Columbia, Victoria, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Section of Pediatric Infectious Diseases, Departments of Pediatrics and Medicine (Kuhn), Alberta Children's Hospital and the University of Calgary, Calgary, Alta.; Center for Geographic Medicine, Department of Medicine (Freedman), University of Alabama Birmingham, Birmingham, Ala. SAR Laboratories (Kain), Sandra Rotman Centre for Global Health, Toronto, Ont
| | - Kevin C Kain
- Tropical Disease Unit, Division of Infectious Diseases, Department of Medicine (Boggild, Kain), University Health Network and the University of Toronto; Public Health Ontario Laboratories (Boggild), Public Health Ontario, Toronto, Ont.; Office of Border and Travel Health (Geduld), Public Health Agency of Canada, Ottawa, Ont.; JD MacLean Centre for Tropical Diseases and Division of Infectious Diseases, Department of Microbiology (Libman, Yansouni), McGill University Health Centre, Montréal, Que.; Tropical Medicine and International Health Clinic, Division of Infectious Diseases (McCarthy), Ottawa Hospital and the University of Ottawa, Ottawa, Ont.; Division of Infectious Diseases (Hajek), Vancouver General Hospital, University of British Columbia, Vancouver, BC; Infectious Diseases, Vancouver Island Health Authority, Department of Medicine (Ghesquiere), University of British Columbia, Victoria, BC; Hôpital Saint-Luc du CHUM (Vincelette), Université de Montréal, Montréal, Que.; Section of Pediatric Infectious Diseases, Departments of Pediatrics and Medicine (Kuhn), Alberta Children's Hospital and the University of Calgary, Calgary, Alta.; Center for Geographic Medicine, Department of Medicine (Freedman), University of Alabama Birmingham, Birmingham, Ala. SAR Laboratories (Kain), Sandra Rotman Centre for Global Health, Toronto, Ont
| |
Collapse
|
50
|
Kreitner KF, Kuhn S. Muss das CT immer im Schockraum integriert sein? Das Mainzer Modell. ROFO-FORTSCHR RONTG 2016. [DOI: 10.1055/s-0036-1581753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|